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INTRODUCTION 
Aging is a well-known fact of life, yet a poorly understood aspect of biology. It is this 
ongoing process that we will all be confronted with, first by observing it in others, and 
then by experiencing it ourselves. Aging is generally described as the accumulation of 
changes in an organism over time. In humans, aging is a multidimensional process of 
physical, psychological and social changes, with each dimension having it’s specific 
fitness over time (Figure 1.1). Biological aging, or senescence (from senex, meaning old 
age), normally only refers to the physical aspects of aging. Biological aging is 
commonly characterized as a progressive, generalized impairment of function, resulting 
in an increased vulnerability to environmental challenges, a grown risk of disease, and 
ultimately death. The length of an individual’s life, or the average length of life in a 
population or species, is referred to as lifespan. 
 
FIGURE 1.1. Development and decline of fitness in three domains during human aging. Physical or biological 
fitness rapidly declines after the reproductive age has been reached. Psychological or mental fitness however 
tend to grow with age.  
 
Biological aging is highly complex and involves multiple regulatory 
mechanisms at different levels. Scientific theories of biological aging attempt to answer 
two major questions: “How do we age?” and “Why do we age?” As for the first question, 
there are many theories about the specific biological mechanisms that cause aging 
(Box 1). At present no single theory sufficiently explains aging, and all probably 
describe some fundamental aspects of its complex nature. There is, however, wide 
agreement that deteriorative processes at the molecular level are at the basis of 
biological aging. As for the second question, it is interesting to note the rate of aging is 
very different among organisms, and that there are several organisms that show 
negligible senescence 
1,2
. Negligible senescence refers to the lack of aging symptoms, 
the absence of any observable age-related increase in mortality or decrease in 
reproduction after maturity, and no apparent decline in physiological capacity or 
disease resistance 
3
, resulting in a relatively long lifespan. Examples of such organisms 
are the rockfish (140 years), the sturgeon (150 years) and the ocean quahog (220 
years). It is thus apparent that rate of aging and average lifespan are species-specific 
characteristics that are not necessarily limited by general biological principles. Several 
evolutionary theories have been proposed to explain why different species have 
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different aging characteristics, and why we age 
4. Darwin’s theory on natural selection 
originally proposed that the force of evolution was towards achieving immortality or the 
absence of internal limitations to lifespan or reproductive capability, in addition to 
adapting to external conditions that imposed on lifespan and reproduction 
5
.  
BOX 1. THEORIES OF AGING 
 
The Somatic Mutation Theory states that an age-related increase in somatic mutations and 
other forms of DNA damage plays an important role in determining the rate of aging. There is a 
general relationship between longevity and DNA repair 
6
. In animal models, higher expression 
levels of PARP-1, a key player in the cellular response to stress-induced DNA damage, are 
associated with longer life spans 
7
. In addition, many human and mouse mutations in DNA 
repair enzymes result in accelerated aging phenotypes. 
 
The Telomere Loss Theory states that all cells have a limited capacity to replicate (the Hayflick 
limit 
8
) due to the progressive shortening of their chromosomal telomeres. Telomeres protect the 
end of chromosomes, and have been shown to shorten with each cell division. Shortened 
telomeres activate mechanisms that prevent further cell division. However, mice lacking 
telomerase do not shown a dramatically reduced life span, and telomere length is unrelated to 
lifespan, indicating that this theory can only partly explain aging. 
  
The Mitochondrial Theory states that an important connection between molecular stress and 
aging is caused by the accumulation of mitochondrial DNA (mtDNA) mutations with age 
9
. 
There is an age-related increase in cytochrome c oxidase (COX)-deficient cells, which is 
associated with mtDNA mutations. Since mitochondria are the principle source of ATP, cells 
with high levels of mtDNA mutations are likely to suffer from impaired ATP production, resulting 
in a decline in tissue bioenergetics. In addition, functionally impaired mitochondria produce 
reactive oxygen species (ROS) that in turn can damage DNA, proteins and lipids. 
 
The Altered Proteins and Waste Accumulation Theories state that age-related impairment of 
protein turnover causes accumulation over time of damaged proteins. Accumulation of altered 
proteins can cause several age-related disorders, including Alzheimer’s and Parkinson’s 
disease. Normal protein turnover involves the functions of chaperones and of the proteasome. 
There is evidence that with aging a decline occurs in the activity of both proteasomes 
10
 and 
chaperones 
11,12, which may be part of a more general failure of cellular “waste disposal” 
processes 
13,14
. 
 
Network Theories of Aging state that aging is a result of the combined effects of various cellular 
mechanisms. These network models offer the opportunity to differentiate between “early” 
mechanisms that set a process in motion and “late” mechanisms that dominate the cellular 
phenotype at the end of an organisms life 
15
. In addition, a further advantage of the network 
approach is that, although the various mechanisms comprising the network are likely to share 
common components in all cell types and in all species, there may be important differences 
concerning their relative contribution, which may explain organ- or tissue-specific vulnerability 
and species-specific lifespan.  
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In that respect it has been suggested that organisms must optimize their use of 
metabolic resources to maximize their fitness by production of descendants. To achieve 
this, resources must be allocated between competing processes such as growth, 
storage, reproduction, and maintenance and repair.  It is the compromise in allocating 
energy to the repair function that causes the body gradually to deteriorate with age 
16
. 
Since Darwin, theorists have formally proposed a number of general adjustments to the 
natural selection theory which all suggest that diffuse benefits in addition to individual 
survival or reproductive benefit can influence the process of evolution. A (self-)limited 
lifespan could for instance have benefitted evolution by increasing resources available 
for younger, and therefore minutely more evolved, individuals 
12,14,17,18
. 
In humans, social and cultural developments over the past centuries have 
imposed new perspectives on the process of aging. By and large, older people are 
healthier than just a few generations ago, with age-related diseases occurring much 
later in life 
19
 and rates of disability rapidly declining 
20
. At the same time there has been 
a shift in the past 100 years in the cause of mortality from infectious disease to age-
related disorders, and aging itself has become the number one public health issue 
faced by the developed world 
21
. This has led to several efforts to identify the 
characteristics, determinants, and interventions that promote successful aging. The 
concept of successful aging critically depends on three main components: low 
probability of disease and disease-related disability, high cognitive and physical 
functional capacity, and active engagement with life 
22,23
. Nowadays, successful aging 
mainly relies on the behavioral strategies and competencies that serve to adaptively 
manage the demands of everyday life, and therefore cognitive and emotional fitness 
have become relatively more and more important in the process of human aging. One 
of the main concerns of getting older is the experience of impairments in memory 
function, which is a key component of human cognition 
24
.  
Most elderly people experience a decline in cognitive abilities, which can 
eventually interfere with daily living and seriously affect quality of life by diminishing 
health-span and decreasing independence. As the quality and availability of healthcare 
in developed countries continues to improve, the life expectancy of our population 
continues to increase, and the prevalence of age-related cognitive decline is expected 
to rise concomitantly with our increasing lifespan. Moreover, the prevalence of 
neurodegenerative disorders such as Alzheimer’s disease (AD), which is the most 
common form of dementia and is characterized by loss of memory and associated 
cognitive decline, will also increase tremendously. Age-related cognitive decline will 
thus become the most prominent burden in health care in the coming decades, with 
close to 50% of adults over the age of 85 in the United States affected with AD 
25
.  
Understanding the cellular and molecular processes underlying normal and AD-
associated aging of the brain is of crucial importance to define therapeutic targets and 
develop therapeutic treatment for age-related cognitive decline.  
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COGNITIVE DECLINE AND AGING 
Cognitive decline is a gradual deterioration in cognitive function that impacts various 
brain functions, including perceptual speed, inductive reasoning, verbal ability, and 
importantly, hippocampus-dependent learning and memory 
24
. Cognitive decline is a 
general phenomenon of human aging. Behavioral research showed distinct patterns of 
decline and stability in cognition over the adult lifespan. Several brain functions that are 
essential for cognitive information processing, such as processing speed, working 
memory, short-term recall and the encoding of episodic memories, gradually decline 
over adult life 
26,27
. Notably, processing speed was found already affected in individuals 
between the ages of 20 to 60 years, which might explain why normal aging individuals 
take longer to learn new information 
28,29
. In addition, impairments in spatial memory 
during normal aging are highly conserved across species 
30-33
. In contrast, there are 
also domains of cognition that do not decline until later in life, including well-practiced 
tasks or tasks that involve knowledge. Vocabulary and semantic knowledge, for 
instance, are stable until late in life 
34
. Finally, there are cognitive abilities that do not 
decline at all during normal aging. Autobiographical memory, emotional processing and 
automatic memory processes seem not to decline throughout life, and long-term 
memory and implicit memory, defined as the unconscious influence of previously 
encountered information on following information, are well-preserved in aged humans 
35-
38
. 
 
The hippocampus 
The hippocampus is the most important brain structure for learning and memory 
24
. This 
has been beautifully documented in the case of Henry Gustav Molaison, also known as 
H.M., whose hippocampus was surgically removed in an attempt to cure his epilepsy 
39,40
. After the surgery, H.M. suffered from severe anterograde amnesia, which 
manifested itself as a loss of the ability to create new memories after the surgery, as 
well as moderate retrograde amnesia, resulting in loss of memories of events from 
before the surgery. These observations led to the believe that the hippocampus is 
crucial for long-term declarative memory, including both the acquisition of new 
memories and the recall of old ones 
41
. Several age-related anatomical and 
physiological changes have been observed in the hippocampus that may contribute to 
cognitive decline, including a decrease in hippocampal volume without gross neuronal 
loss 
42
, vascular rarefaction 
43,44
, decreased trophic support 
45,46
, increased oxidative 
stress 
47-49
 and inflammation 
50
, decreased metabolism and glucose utilization 
46
, 
dysregulation of protein synthesis, folding and accumulation 
51
, and impaired 
neurotransmitter synthesis and release 
52
. Progressive dysfunction of either of these 
processes with age could affect hippocampal learning and memory.  
 In terms of cellular processes, it has been reported that there is age-related 
synapse loss in the hippocampal dentate gyrus in aged rats 
53
, which correlates with a 
reduction in excitatory postsynaptic potentials (EPSPs) 
54
 and with a decline in spatial  
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memory performance 
55
. Underlying this, the decline in cognitive function might also 
result from changes in the expression of synaptic plasticity, or from molecular and 
cellular changes that directly or indirectly affect mechanisms of plasticity. In that 
respect it is interesting to note that age-related changes in cognitive function also 
correlate with changes in long-term potentiation (LTP) and long-term depression (LTD), 
the physiological substrates of plasticity, and learning and memory (Box 2). Several 
studies have demonstrated that there is an impaired induction and maintenance of LTP 
in the aged rat hippocampus 
54-57
. In particular, LTP decays more rapidly in older 
animals, which correlates with a decline in performance in the Barnes circular platform 
task 
54,55,58
. Aged rats also show increased susceptibility to the induction of LTD and 
enhanced depotentiation of previously strengthened synapses 
57
. Long-term synaptic 
plasticity in the hippocampus is dependent on the activation of glutamate receptors and 
subsequent activation of calcium-mediated signaling pathways. Thus, changes in 
calcium regulation in the aged brain may contribute to age-related alterations in 
synaptic plasticity. Indeed, voltage-activated calcium influx is increased in hippocampal 
CA1 neurons from aged rats, due to an increased expression in L-type calcium 
channels 
59
. In addition, alterations in the expression of calcium-buffering proteins and 
calcium signaling proteins occur 
60,61
, resulting in age-related plasticity deficits 
62,63
. 
BOX 2. SYNAPTIC PLASTICITY IN THE HIPPOCAMPUS. 
 
The hippocampus is part of to the limbic system and plays an important role in the acquisition, 
the consolidation and the recall of memories. Hippocampal synaptic plasticity is the 
experience-dependent change in connectivity between hippocampal neurons that is believed 
to underlie important aspects of learning and memory. The hippocampus contains three 
sequential synaptic pathways, each of which is able to undergo experience-dependent plastic 
changes. Perforant path (PP) axons from the entorhinal cortex project to form synapses on 
dendrites of dentate gyrus (DG) granule cells; in the mossy fiber pathway (MF), dentate 
granule axons synapse onto CA3 pyramidal neuron dendrites; and in the Schaffer collateral 
pathway (SC), CA3 axons synapse onto CA1 dendrites. Hippocampal electrophysiological 
examination has shown that distinct stimuli bring forth two types of change in synaptic efficacy: 
high-frequency stimuli produce synaptic strengthening, called long-term potentiation (LTP), 
and low-frequency stimulation produced synaptic weakening, called long-term depression 
 
 
(LTD). LTP is widely believed to be one of 
the main neural mechanisms by which 
memory is stored in the brain. Because of 
its critical role in memory in general, and in 
particular in spatial memory, the 
hippocampus has been the focus of 
numerous studies into the mechanisms of 
aging and age-related cognitive decline. 
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Reduced expression of calcium-binding proteins may additionally render neurons more 
vulnerable to a variety of toxic insults mediated by calcium, such as excitotoxicity, 
which may contribute to neuronal loss in AD and many other neurodegenerative 
disorders 
60,64,65
. Taken together, the hippocampus is an important system that becomes 
affected with age, and age-dependent changes in hippocampal synaptic plasticity may 
underlie the earliest cognitive signs of normal and pathological aging. In the following 
sections, I will briefly introduce the molecular and cellular mechanisms that may be 
responsible for age-related hippocampal synaptic dysfunction in health and disease. 
 
MITOCHONDRIA AND AGING 
Mitochondria play a central role in aging and in age-related neurodegenerative 
disorders. Several studies showed a decline in mitochondrial gene expression during 
aging in a wide range of organisms 
66,67
. In addition, severe reduction of mitochondrial 
function in worms shortens lifespan significantly 
68
. Transgenic mice that have elevated 
levels of accumulated mitochondrial DNA mutations show signs of accelerated aging 
and shortened lifespan 
69,70
. Conversely, a modest reduction in mitochondrial function 
extends lifespan 
71
, which could imply that the early decline in mitochondrial gene 
expression observed during normal aging could be part of a compensatory mechanism 
to increase stress resistance. This compensatory mechanism might be effective in 
resisting temporary stress, but it may fail to resist persistent stress associated with 
aging. 
Mitochondria are membrane-enclosed organelles found in most eukaryotic 
cells, including neurons, and they generate most of the cell’s ATP as a source of 
energy. ATP is generated by a process named oxidative phosphorylation, which 
involves a series of redox reactions in which electrons are transported through the 
electron transport chain at the inner mitochondrial membrane. As a negative side effect, 
oxidative phosphorylation leads to the generation of reactive oxygen species (ROS), 
which are free radicals derived from oxygen that can damage macromolecules such as 
lipids, DNA and proteins by introducing unpaired electrons. Normally, mitochondria are 
protected against ROS by multiple antioxidant defense systems, including manganese 
superoxide dismutases, periredoxins, and redox reactions mediated by cytochrome C 
and cytochrome oxidase 
66
. However, these defense systems are not always sufficient, 
and there is evidence that they increasingly fail during aging. This causes oxidative 
damage to mitochondrial proteins and DNA that requires repair. In addition, hydrogen 
peroxide is generated by the action of superoxide dismutase on superoxide radicals in 
mitochondria, and can be converted into highly reactive and damaging hydroxyl 
radicals. High levels of hydroxyl radicals are very destructive for the cell. Finally, the 
accessibility of redox-active iron is a major determinant of ROS-mediated cellular 
damage (Figure 1.2). Elevated levels of redox-active iron, derived in part from 
degenerating mitochondria, accumulates and causes ROS-mediated cellular damage in 
the normal aging brain and in several neurodegenerative diseases 
72
.  
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FIGURE 1.2. Global impact of mitochondria on brain aging. In the aging brain, reduced autophagic clearance of 
damaged mitochondria and increased mitochondrial DNA damage may reduce ATP production and elevate the 
level of reactive oxygen species. Reactive oxygen species can further damage nuclear and mitochondrial DNA, 
resulting in reduced transcription, and damage to RNA and proteins, giving rise to protein misfolding and 
aggregation. Aggregated proteins may accumulate in the aging brain as a result of inefficient clearance by the 
ubiquitin-proteasome pathway. Toxic protein aggregates may also induce apoptosis. Adapted from Yankner et 
al. 
66
 
 
One of the key mechanisms of ROS-induced mitochondrial damage is the 
introduction of mutations in mitochondrial DNA (mtDNA). Generation of large amounts of 
ROS unavoidably exposes the mtDNA to high levels of oxidative stress, and mtDNA 
damage subsequently leads to mitochondrial dysfunction and apoptosis 
73
. 
Mitochondrial dysfunction in turn promotes the production of ROS, which increases the 
level of mtDNA damage. This self-reinforcing cycle of mitochondrial dysfunction 
ultimately results in cellular apoptosis. Inherited mtDNA mutations give rise to disorders 
that predominantly affect brain and muscle, and the severity of the clinical symptoms 
depends on the number of mitochondria affected per cell 
74,75
. The brain is particularly 
vulnerable to mitochondrial dysfunction since it requires large amounts of energy and 
therefore consumes large amounts of oxygen for mitochondrial ATP production. 
Mitochondrial densities are particularly high at neuronal synapses, where large amounts 
of mitochondria are required to power energy-demanding synaptic activities 
76
. The high 
vulnerability of the brain to mitochondrial dysfunction with age is probably due to a 
combination of (i) high energy demand, (ii) an age-dependent increase in ROS 
production, (iii) an age-dependent decline of antioxidant defensive mechanisms, and 
(iv) the inability to replace lost neurons 
66,77
. Mitochondrial DNA mutations appear in the 
normal aging brain, but are enhanced in AD brains, together with an increase oxidative 
DNA damage 
61,74,75,78,79
. Different levels of mtDNA damage in the different brain regions 
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even correlates with AD pathology, with the most affected regions having the highest 
level of mtDNA damage 
80
. 
 
DNA DAMAGE AND AGING 
DNA damage was found to contribute substantially to mechanisms of aging and 
disease 
81
.  Spontaneous DNA damage is frequent and unavoidable during life. DNA is 
constantly attacked by exogenous (e.g. mutagens and radiation) and endogenous 
(e.g., ROS) genotoxic agents. To protect themselves against genotoxic damage, all 
cells use multiple DNA repair pathways. The four major DNA repair systems are 
nucleotide excision repair (NER), base excision repair (BER), mismatch repair (MMR) 
and double-strand break repair (DSBR) (Box 3). The consequences of unrepaired DNA 
damage are twofold. On one hand, unrepaired DNA damage triggers a complex DNA 
damage response and may give rise to epigenetic changes 
82
, gene silencing, and 
specific alterations in gene expression 
61,83
, which together may increase the risk of 
cancer. On the other hand, persistent DNA injury may interfere with transcription and/or 
replication, triggering cell dysfunction, cell death or permanent cell cycle arrest, which 
ultimately contributes to the process of cellular senescence and aging. Thus, at the 
level of DNA integrity, aging and cancer are two sides of the same coin, and normal 
aging may be necessary to prevent cancer 
84
. 
Deficiencies in DNA repair, and the consequential accumulation of DNA 
damage, have been associated with rare inherited human syndromes of accelerated 
aging 
85-87
. These syndromes, known as segmental progeroid syndromes, are 
characterized by the acceleration of some, but not all, features of aging, often including 
aspects of neurodegeneration 
85-88
. In addition, accumulation of DNA damage is also 
associated with the normal age-dependent decline in vital functions 
4,84,89
. Thus, DNA is 
an important target of aging, and maintenance of genome integrity is a major anti-aging 
mechanism. The brain consists mainly of non-proliferating cells and is therefore 
particularly vulnerable to defective DNA repair and the accumulation of unrepaired DNA 
lesions 
90-92
. It has been suggested that deficiencies in the repair of oxidative DNA 
damage with aging correlates with cognitive decline and with the severity of age-related 
neurodegenerative diseases 
93-97
. The major type of oxidative DNA lesions in the brain 
are single base modifications, which are found to increase with age in rodents and 
humans 
61,90
. In addition, oxidative base damage to DNA and RNA is further increased 
in AD brains 
78,98
. The involvement of DNA damage in the transcriptional alteration of 
genes in the aging brain was suggested by a study showing that oxidative DNA 
damage accumulates in the promoters of a specific subset of age-downregulated 
genes 
61
. Reduced transcription of genes involved in synaptic function, vesicular 
transport, and mitochondrial function occurred in correlation with DNA damage to these 
genes starting at middle age. DNA damage appeared in many genes after the age of 
40, and was most pronounced after the age of 70 
61
. Transcriptional repression could 
be a mechanism by which aged neurons silence damaged regions of the genome,  
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BOX 3. DNA REPAIR MECHANISMS 
  
 
 
 
 
 
 
 
 
 
The four major DNA repair systems are nucleotide excision repair (NER), base excision repair 
(BER), mismatch repair (MMR) and double-strand break repair (DSBR). Damage from 
ultraviolet (UV) radiation and reactive oxygen species (ROS) can generate large helix-
distorting DNA lesions that interfere with base pairing and block transcription and replication. 
These lesions are repaired by the NER system. BER is the major pathway responsible for 
eliminating spontaneous hydrolytic, alkylation and oxidative DNA damage, thus restoring 
genomic integrity. BER repairs damage to single nucleotide bases, and such lesions may 
interfere with normal transcription and translation. Most NER lesions arise from exogenous 
genotoxic sources, whereas BER lesions are mainly, but not exclusively, due to endogenous 
sources. These lesions only affect one of the two strands. MMR corrects mispaired base 
pairs that arise from mistakes made by DNA polymerases, as well as insertion/deletion loops. 
Breakage of the DNA backbone can also occur, either as a single-strand break (SSB) or as a 
double-strand break (DSB). SSBs are the most common lesions found in chromosomal DNA 
and are repaired by the BER pathway. One of the most toxic and mutagenic lesions are the 
DSBs, and these lesions in the nervous system results in the initiation of a defined signaling 
process leading to cell cycle arrest which allows either repair, or elimination of the damaged 
cell by apoptosis. The repair of DSBs is more problematic since both strands are affected. 
DSBs can be repaired by either one of two mechanisms: homologous recombination (HR), or 
less accurately by non-homologous end-joining (NHEJ). NHEJ directly joins the broken ends, 
whereas HR uses the intact sister chromatid as a template for repair 
77,99,100
. Figure adapted 
from Hoeijmakers 
99
. 
  
C
h
a
p
t
e
r
 
1
 
17 
 
 
FIGURE 1.3. DNA damage and brain aging. Oxidative damage to DNA may be mediated by reactive oxygen 
species (ROS) derived from aging mitochondria. DNA damage is repaired efficiently in young and early-adult 
brains, but persists in the aging brain. During normal aging, this may result in the silencing of genes involved in 
synaptic plasticity. Epigenetic gene silencing may be an effective anti-apoptotic mechanism for post-mitotic 
neurons to prevent major cognitive dysfunction, but at the same time it may also induce mild age-related 
cognitive decline through synaptic dysfunction. Adapted from Yakner et al. 
66
. 
 
enabling them to survive in the presence of unrepaired DNA damage, rather than 
undergoing apoptosis (Figure 1.3). The mechanisms of repression may be epigenetic 
58,79
, and might be advantageous for the brain because it saves irreplaceable neurons. 
Paradoxically, this survival-promoting defense mechanism of transcriptional repression, 
in particular of genes involved in synaptic functions, most likely also results in functional 
impairments at the level of the synapse. This could be one of the contributing factors to 
the gradual cognitive decline seen with age. 
 
ALZHEIMER’S DISEASE AND AGING 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, and the most 
common form of dementia in older people. AD is different from other neurodegenerative 
disorders, since it usually starts with a remarkably pure cognitive decline, and thus may 
share brain mechanisms with normal aging. Patients with AD lose their ability to form 
new memories, and when the disease progresses, also old, previously stored memories 
are lost. Over time, both declarative and non-declarative memory become strongly 
impaired, and the abilities for reasoning, abstraction, and language become 
diminished. The disease is characterized by two distinct neuropathological hallmarks: 
diffuse and neuritic plaques, which are mainly composed of the amyloid β (Aβ) peptide, 
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and neurofibrillary tangles which are composed of aggregates of hyperphosphorylated 
tau protein 
101
. The role of these lesions in the pathology of AD is strongly debated. Early 
studies suggested a correlation of amyloid plaques with cognitive decline 
102
, however, 
this was later contradicted by studies suggesting that plaques were not the closest 
correlate, and that numbers of neurofibrillary tangles and synapse loss were correlated 
more closely with cognitive test scores in patients with AD 
103
. Synapse loss contributes 
to the onset and progression of AD in humans 
101,104
, and also occurs in patients with 
mild cognitive impairment, an indication for future AD 
105
. It has been postulated that 
early synaptic dysfunction is indeed an important mechanism leading to cognitive 
decline and neuronal pathology 
101
. 
Major progress in the understanding of the etiology of AD arose from the 
identification of inherited disease-causing mutations. The first genetic cause of AD 
identified was the occurrence of a missense mutation in the amyloid precursor protein 
(APP), associated with familial AD 
106
. This mutation was located proximal to the C-
terminal end of the Aβ peptide, and it changes the proteolytic generation of Aβ, such 
that the relative amount of a slightly longer form of Aβ (Aβ42) is increased 107. This 
longer form has a greater tendency to aggregate, and could thereby potentially account 
for the pathogenicity of such APP mutations 
108
. Another mutation in APP was identified 
proximal to the N-terminus of the Aβ peptide that increased Aβ generation by 
enhancing the β-secretase cleavage 109,110. Individuals from families who carry these 
APP missense mutations generally have the onset of the disorder before the age of 65, 
often already in their 50s. Another important disease-causing mutation was identified in 
the presenilin-1 gene 
111
. Mutations in presenilin-1 are the most common known cause 
of early-onset autosomal dominant AD. Families with missense mutations have a clinical 
onset of the disease in their 40s and 50s, sometimes even in their 30s. Mutations in 
presenilin-2 account for familiar AD cases, although much less frequent. Presenilin-1 
and -2 are both part of the γ-secretase complex that mediates the intramembrane 
proteolysis of APP that releases the C-terminus of the Aβ peptide 112,113. Mutations in 
presenilin-1 or -2 increase the levels of the longer Aβ42 peptide relative to the shorter 
Aβ40 114. Whereas the autosomal dominant mutations in APP or in the presenilins are 
quite infrequent causes of AD, the only gene that has been indisputably linked to the 
prevalent late-onset form of AD is the ε4 allele of the apolipoprotein E (apoE) 115. The ε4 
allele of apoE is a significant risk for the development of AD, and increases the risk with 
10-12-fold when present in the homozygous state 
116
. In contrast, there is also evidence 
that inheritance of the ε2 allele protects against the development of AD 117,118. ApoE4 
seems to enhance the steady-state levels of Aβ peptides, Aβ40 in particular 119, 
presumably by decreasing its clearance from brain tissue. The presence of an apoE-ε4 
allele correlates with increased Aβ deposition in the human brain, and apoE-ε4 also 
induces Aβ fibrillization in APP transgenic mice 120. In a recent study it was shown that 
increasing apoeE expression in mouse models of AD results in enhanced apoE-
mediated clearance of soluble Aβ, an almost complete removal of plaques, and a rapid 
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reversal of cognitive, social and olfactory deficits 
121
. Thus, increased proteolytic 
cleavage of Aβ and reduced clearance of extracellular Aβ both lead to elevated levels 
of soluble Aβ, which seems to be a necessary condition for developing AD. Soluble Aβ 
is known to be toxic to synapses 
122,123
, which may further link the principal genetic risk 
factors for AD and the synaptic and cognitive impairments that characterize the 
disease. 
 As already mentioned earlier, the tau protein is the major component in 
neurofibrillary tangles. These are also present in normal human aging brains. 
Phosphorylation of tau at multiple sites leads to its apparent dissociation from 
microtubules and intracellular accumulation into oligomeric and fibrillar aggregates. 
This in turn could destabilize microtubules and impair anterograde axonal transport of 
essential macromolecules and organelles to distant synaptic sites. It has been 
hypothesized that mutations in the MAPT gene encoding for tau might be associated 
with AD. Indeed, there are studies relating MAPT polymorphisms with AD 
124,125
, but 
these findings could not be replicated by others 
126
. The role of tau in 
neurodegeneration was firmly established in frontotemporal dementia with Parkinsonism 
linked to chromosome 17 (FTDP-17). Frontotemporal dementias are a wide range of 
clinical disorders characterized by the onset of dementing illness in which language 
and behavioral deficits are the presenting symptoms rather than the deficits in episodic 
memory that are characteristic of AD. Furthermore, these disorders are characterized 
by neuronal cell death in the frontal and temporal lobes, and have multiple forms of 
aggregated tau 
127
. Importantly, these findings demonstrate the importance of 
neurofibrillary pathology in some neurodegenerative disorders, but its role in AD 
remains unclear.  
 More and more evidence suggests that AD begins with subtle changes of 
hippocampal synaptic function prior to frank neuronal degeneration 
128,129
, and this is 
probably mediated by soluble oligomeric forms of β-amyloid that are toxic to synapses 
130,131
 and may reduce synaptic long-term potentiation (LTP) 
132
, the physiological 
correlate of learning and memory. This suggests that synaptic dysfunction is an 
important factor contributing to the early stages of cognitive decline in AD 
103,133-136
. The 
memory deficits and cognitive decline observed in AD patients correlate better with the 
synaptic pathology than with either the plaques or the tangles. Therefore, it is of critical 
importance to study early synaptic dysfunction in AD, and to identify synaptic molecular 
pathways that may be targeted to treat the early cognitive decline in AD. 
 
ANIMAL MODELS OF AGING 
Normative aging 
Most individuals will exhibit deficits in memory during normal, healthy aging, and in the 
absence of any neuropathology. This age-associated decline in normal memory 
function is subtle compared to the severe alterations observed in age-associated 
disorders, such as Alzheimer’s or Parkinson’s disease, but they are nevertheless 
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disturbing. Understanding the age-related changes in cognition during normative aging 
sets a background against which it is possible to evaluate the effects of pathological 
disease states, both qualitatively (i.e., do they comprise similar mechanisms or not) and 
quantitatively (i.e., are normal age-related changes exaggerated in disease). To 
investigate normal age-related impairments at the neuronal or synaptic level, laboratory 
mouse models are particularly useful. House mice usually live under a year in the wild, 
due to a high level of predation and exposure to harsh environments and pathogens. 
However, in protected environments, i.e., under laboratory conditions, they often live 
two to three years, which is comparable to the increased life expectancy that has been 
reached in humans in our Western society over the last centuries as a result of 
improved health care and disease treatment. Thus, monitoring behavioral and synaptic 
changes over the entire lifespan of healthy laboratory mice may reveal age-related 
changes that are relevant to understand aging of the human brain, both in health and in 
disease. 
 
Alzheimer’s disease 
Major steps towards understanding AD and developing therapies for AD were made 
through the use of transgenic mouse models of AD. Several mouse models have been 
developed to mimic the major neuropathological hallmarks of AD, namely amyloid 
plaques and neurofibrillary tangles. These animal models recapitulate many, although 
not all, features of AD, and are widely used in AD research. Most AD mouse models 
overexpress APP, presenilin and/or tau transgenes harboring known human disease-
associated mutations (see above), resulting in the overproduction of Aβ and 
hyperphosphorylation of tau. Two important mouse models were used in this study are 
the APP
swe
,PS1
dE9
 double transgenic 
137
 and APP
swe
,PS1
M146V
,tau
P301L
 triple transgenic 
138
 
models of Alzheimer’s disease. 
 APP
swe
,PS1
dE9
 mice have a human mutation in APP and an exon 9 deletion in 
the presenilin 1 gene. Co-expression of APP
swe
 and PS1
dE9 
dramatically accelerates 
amyloid pathology. These mice have a substantial amount of Aβ deposits by 6 months 
of age and plaque burden increases progressively over time 
137,139,140
. In addition, co-
expression of APP
swe
 and PS1
dE9 
increases the ratio of Aβ40:Aβ42. Furthermore, these 
animals show a decline in memory performance and a reduction in hippocampal LTP at 
9–15 months of age, comparable to that of 19–25 months old non-transgenic mice 
141,142
. However, until now, no neuronal cell loss and neurofibrillary tangles have been 
demonstrated in this mouse 
143
. 
 The triple-transgenic mouse model (3xTg-AD) harbors APP
swe
, PS1
M146V
 and 
tau
P301L
 transgenes, and displays both Aβ and tau pathology 138. 3xTg-AD mice show 
intracellular Aβ immunoreactivity in the neocortex between 3 and 4 months of age, and 
by 6 months of age also in the CA1 region of the hippocampus. Extracellular Aβ 
deposits first appear in the frontal cortex by 6 months of age, but no tau pathology is 
observed at this age. It is not until 12 months of age that extensive human tau 
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immunoreactivity is first evident in CA1 neurons. Plaques and tangles appear to be 
mainly restricted to the hippocampus, amygdala and cerebral cortex, which are also the 
main brain structures affected in AD. In addition, 3xTg-AD mice also exhibit deficits in 
synaptic plasticity, and synaptic dysfunction at an early age (6 months), that precedes 
any pathological features. The changes in synaptic function include reduced 
transmission and impairments in LTP that occur prior to extracellular Aβ depositions and 
tangles, but is associated with intracellular Aβ immunoreactivity 138,144. Finally, 3xTG-AD 
mice also exhibit cholinergic alterations and cortex-specific neuronal cell loss 
138,145,146
. 
 
DNA damage-induced aging 
Maintaining genome integrity is an important factor in the process of aging, and the use 
of transgenic mouse models with defects in genome maintenance is thus very important 
for understanding the molecular basis of DNA damage-induced aging in humans. The 
genomes of mice and humans are very similar and genome maintenance mechanisms 
are highly conserved. There is a wide variety of mouse mutants that are defective in 
genome maintenance, and many display common signs of segmental progeria as 
observed in human progeroid syndromes. One mouse model defective in genome 
maintenance and displaying a premature aging phenotype is the Ercc1 mutant mouse. 
Ercc1 forms a complex with the xeroderma pigmentosum group F protein (XPF) and 
acts as an endonuclease in the nucleotide excision repair (NER) pathway 
147
. In 
addition, it is also involved in inter-strand crosslink repair and double-strand break 
(DSB) repair 
148-152
. Ercc1 knockout (Ercc1
-/-
) mice develop a severe and accelerated, 
aging phenotype, including early cessation of growth, ataxia, and cachexia 
153-155
. 
Ercc1
-/-
 knockout animals die prematurely at an age of 3-8 weeks from liver and kidney 
abnormalities that are characterized by cellular age-related defects, including 
premature polyploidization and appearance of nuclear inclusions 
154
. These phenotypes 
generally develop in the second week of life and progress rapidly. Ercc1
∆/- 
mice, which 
have a knockout mutation in one allele of the Ercc1 gene and a less severe mutation in 
the other allele resulting in a truncated Ercc1 protein, which lacks the last 7 amino acids 
154
, have a milder phenotype compared to Ercc1
-/- 
mice and die at an age of 4-6 months. 
Ercc1
∆/- 
mice display many signs of accelerated aging, including motor neuron 
degeneration 
156
, changes in metabolism 
157
, and impaired synaptic plasticity and 
learning behavior 
158
. A human equivalent for the Ercc1 mouse mutant was discovered 
also in a patient with a mutation in the XPF gene, the product of which functions in a 
complex with Ercc1 
99
. This patient also suffered from a prematurely aged appearance, 
and exhibited progressive liver and kidney dysfunction, cachexia, hypertension, 
neuronal degeneration, and skin atrophy 
148
. In this thesis, Ercc1
∆/-
 mice have been 
used to characterize synaptic alterations in relation to DNA damage-induced brain 
aging. 
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AIM AND OUTLINE OF THIS THESIS 
The general aim of this thesis is to provide insight into the synaptic molecular 
mechanisms underlying aging and age-related cognitive decline by studying temporal 
dynamics of the hippocampal synaptic proteome in different mouse models of aging. 
Specifically, I have measured and analyzed synaptic proteome changes in relation to 
normal aging, Alzheimer’s disease and DNA damage-induced aging. The data 
presented in this thesis allow distinctions to be made between common synaptic 
pathways underlying aging and disease-specific pathways that contribute to 
pathological aging. This knowledge is of importance to develop new therapeutic 
treatments for age-related cognitive decline, a major area research area aiding future 
health care in our aging society. 
 
FIGURE 1.4. The different aging models used in this thesis and their respective ages used. Normal aging (WT), 
Alzheimer’s disease (APP-PS1 and 3xTg-AD) and DNA damage-induced aging (Ercc1). Grey vertical lines 
represent the timepoints of the different analyses. 
 
The aim of Chapter 2 was to elucidate the effects of aging on the proteomic 
composition of mouse hippocampal synaptosomes. Understanding the age-related 
changes in proteomic composition during normative aging sets a background against 
which it is possible to evaluate the effects of pathological disease states. Our findings 
suggest that both specific changes and increased variance in synaptic protein 
expression are associated with aging and may underlie reduced synaptic plasticity and 
impaired cognitive performance at old age. 
 
In Chapter 3 we investigated fundamental molecular mechanisms underlying synaptic 
dysfunction and cognitive decline in AD, and identified molecular targets for future 
disease treatment. Using an  APP
swe
,PS1
dE9
 (APP-PS1) transgenic AD mouse model we 
showed increased Aβ production, resulting from the introduction of two human disease 
related mutations in APP and PS1. We elucidated an important early role for ECM 
molecules in AD, presumably by regulating synaptic plasticity and causing aspects of 
early cognitive decline in AD. 
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Chapter 4 is elaborating on Chapter 3. In this chapter we have made use of a triple-
transgenic (3xTg-AD; APP
swe
,PS1
M146V
,tau
P301L
) mouse model for AD, which combines 
both plaques and NFTs in the same animal model, due to an additional tau mutation. 
We found important dysregulation of proteins involved in extracellular matrix as also 
shown in Chapter 3. In addition, we also found alterations in protein levels, such as 
changes in the glutamate receptors, which are likely due to the accumulation of tau in 
dendritic spines. 
 
In Chapter 5 we made use of the highly predictive accelerated aging pattern observed 
in Ercc1 mutant mice in order to robustly identify DNA damage-induced age-related 
changes in hippocampal synaptic protein composition that may be difficult to detect 
under normal aging conditions. Our data implicate different synaptic signaling 
pathways in age-related synaptic dysfunction, which may contribute to cognitive 
decline as seen in this model.  
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ABSTRACT 
With aging, we all experience a decrease in cognitive performance, which reduces our 
independence and thereby our quality of life. Healthy brain aging does not involve 
gross neuronal loss, but most likely involves subtle synaptic deficits that underlie age-
depencent cognitive decline. In this study, we investigated the temporal profile of 
mouse hippocampal synaptic proteome changes at 20, 40, 50, 60, 70, 80, 90 and 100 
weeks of age. The most significant alterations that we observed included a group of 
extracellular matrix proteins (e.g. Bcan, Ncan, Hapln1) that were progressively 
upregulated with age  In addition, several proteins involved in structural plasticity (e.g. 
Tubb3, Tubb4a, Tubb5, Tppp) and cell metabolism (i.e. Eno2, Gstp1, Prdx1) were also 
upregulated during aging. We also found that stochasticity in synaptic protein 
expression increased with age, in particular for proteins that are linked with 
neurodegenerative diseases (e.g. Cox5a, Ndufa5, Ndufb7, Atp5e). On the other hand, 
little change in variance, and thus high regulatory control, with aging was observed for 
proteins that perform basic functions in neuronal communication and synaptic 
neurotransmission (e.g. Sv2b, Stx1a, Stxb1, Syn1). Together, our findings suggest that 
both specific changes and increased variance in synaptic protein expression are 
associated with aging and may underlie reduced synaptic plasticity and impaired 
cognitive performance at old age. 
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INTRODUCTION 
With the quality of life in developed countries continuing to improve, so does the 
proportion of aged individuals in our population. Concomitantly, the prevalence of age-
related health problems is expected to rise concomitantly with our increasing lifespan. 
In particular, aged individuals have to cope with an age-related decline in memory 
function and cognitive performance, which may seriously affect their quality of life. A 
better understanding of the neurobiological mechanisms underlying age-related 
cognitive decline is crucial, to facilitate maintenance of cognitive health in the elderly, 
and to reveal potential causes of highly prevalent age-related sporadic forms of 
Alzheimer’s disease in which cognitive decline is severely impaired by yet unknown 
mechanisms. 
 Aging of the brain invariably leads to functional decline and impairments in 
cognitive performance and motor skills. Several studies suggested that normal brain 
aging is associated with subtle morphological and functional alterations in specific 
neuronal circuits, and does not include overall neurodegeneration in the brain 
159,160
. 
Diminished cognitive function with increasing age is likely due to synaptic dysfunction 
and ineffective neurotransmission 
161,162
. For instance, increasing evidence is in support 
of age-related alterations in hippocampal activity that co-occur with deficits in learning 
and memory in healthy aging humans 
163-165
. In addition, rodent models of healthy aging 
demonstrate strong correlations between impaired performance of aged rats in 
behavioral tests of hippocampus-dependent learning and memory on one hand, and 
disturbed hippocampal neuron ensemble activity on the other 
166-169
. 
Electrophysiological studies provide additional evidence that age-related disturbances 
in the hippocampus involve changes in the principle cellular features of learning and 
memory, i.e., synaptic long-term potentiation (LTP) and long-term depression (LTD) 
54,55,57,58
. Together, these observations suggest that age-related decline in hippocampal 
synaptic efficacy and plasticity likely plays a critical role in cognitive impairment. 
 Aging is also the primary risk factor for Alzheimer’s disease (AD), which 
clinically manifests as severe and accelerated age-dependent cognitive decline 
170
. 
Genetic causes of familiar early-onset AD all point to a key role in disease etiology for 
increased brain levels of the protein amyloid-β (Aβ) 106-110. However, familiar AD is rare, 
and it is likely that in most sporadic cases Aβ levels are increased as a result of other 
age-related brain changes. These may involve age-dependent alterations in the 
expression of specific genes or proteins. For instance reduced ApoE-dependent Aβ 
clearance is a significant risk factor for AD 
119-121
. Moreover, there are also indications 
that increased variance in gene or protein expression, and the resulting disruption of 
molecular network robustness, may be causal in the etiology of neurodegenerative 
diseases 
171
. Thus, identification of molecular mechanisms of normal brain aging may 
contribute to our understanding of cognitive decline under pathological conditions, in 
particular AD. 
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Although the exact mechanisms underlying brain aging remain to be fully 
determined, they likely include changes at the molecular, cellular, and neuronal network 
levels. In particular, alterations in the molecular composition and dynamics of 
hippocampal synapses could potentially reveal important aspects about the underlying 
mechanisms of brain aging. Age-related changes in global hippocampal gene and 
protein expression have been investigated previously 
49,83,172-174
, but were not geared to 
identify the specific synaptic molecular substrates of brain aging. Recent advances in 
proteomic technologies and bioinformatics analysis now provide the opportunity to 
specifically and quantitatively address hippocampal synaptic protein content in a 
reproducible manner. Global synaptic protein expression studies have identified some 
of the molecular changes in hippocampal synapses, but interpretation of these data is 
hampered by the limited numbers of proteins that were analyzed and/or the limited 
temporal resolution of the aging time series that was used 
175,176
. Here, we made use of 
iTRAQ technology and high-coverage mass-spectrometry to study the effects of aging 
on the proteomic composition of mouse hippocampal synaptosomes. Using this 
technology, we investigated the proteomes of aged mice at eight different ages, 20 
weeks, 40, 50, 60, 70, 80, 90 and 100 weeks. We identified a significant upregulation in 
time of proteins involved in the formation of extracellular matrix (ECM). In addition we 
found that stochasticity in synaptic protein expression increased with age, in particular 
for proteins that are linked with neurodegenerative diseases. Together, our findings 
suggest that both specific changes and increased variance in synaptic protein 
expression are associated with aging and may underlie reduced synaptic plasticity and 
impaired cognitive performance at old age. 
 
EXPERIMENTAL PROCEDURES 
Animals 
All animals in this study were C57BL/6J mice. C57Bl/6J breeders were received from 
Charles River (Lyon, France) and were bred in the animal facility of the VU University 
Amsterdam. All animal experiments were approved by the Animal Welfare Committee 
(DEC) of the VU University (protocol MCN 09-12). 
 
Synaptosome isolation and sample preparation 
Hippocampi were dissected, frozen, and stored at -80 °C until protein isolation. 
Synaptosomes were isolated from hippocampi at eight different ages, 20 weeks, 40 
weeks, 50 weeks, 60 weeks, 70 weeks, 80 weeks, 90 weeks and 100 weeks, as 
described previously 
177,178
 with minor modifications. In brief, hippocampi were 
homogenized in ice-cold 0.32 M sucrose buffer with 5 mM HEPES at pH 7.4 and 
protease inhibitor (Roche) and centrifuged at 1000 x g for 10 min at 4 °C to remove 
debris. Supernatant was loaded on top of a discontinuous sucrose gradient consisting 
of 0.85 M and 1.2 M sucrose. After ultracentrifugation at 110,000 x g for 2 h at 4 °C, the 
synaptosome fraction was collected at the interface of 0.85 M and 1.2 M sucrose, 
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resuspended and pelleted by ultracentrifugation at 80,000 x g for 30 min at 4 °C. After 
which the material was redissolved in 5 mM HEPES. Protein concentrations were 
determined using a Bradford assay (Bio-Rad, Hercules, CA, USA). For each sample, 50 
μg of protein was transferred to a fresh tube and dried in a SpeedVac overnight. 
 
Protein digestion and iTRAQ labeling  
Per sample, 50 μg synaptosome proteins were dissolved in 0.85% RapiGest (Waters 
Associates, Milford, MA, USA), alkylated with methyl methanethiosulfonate, and 
digested with trypsin (sequencing grade; Promega, Madison, WI, USA) as described 
178,179
. In each iTRAQ experiment samples were labeled respectively with iTRAQ 
reagents 113 = 20 weeks, 114 = 40 weeks, 115 = 50 weeks, 116 = 60 weeks, 117 = 70 
weeks, 118 = 80 weeks, 119 = 90 weeks, and 121 = 100 weeks. To accommodate eight 
independent protein samples for each time point, a total of eight 8-plex iTRAQ 
experiments was performed (8x8). 
  
Two-dimensional liquid chromatography (2DLC)  
The lyophilized iTRAQ labeled samples were separated in the first dimension by strong 
cation exchange column (2.1x150 mm polysulfoethyl A column, PolyLC), and the in 
second dimension on an analytical capillary reverse phase C18 column 
(150 mm x 100 m i.d. column) at 400 nL/min using the LC-Packing Ultimate system. 
The peptides were separated using a linear increase in concentration of acetonitrile 
from 4 to 28% in 75 minutes, to 36% in 7 minutes and finally to 72% in 2 minutes. The 
eluent was mixed with matrix (7 mg of re-crystallized -cyano-hydroxycinnaminic acid in 
1 ml 50% acetronitrile, 0.1% trifluoroacetic acid, 10 mM ammonium dicitrate) and 
delivered at a flow rate of 1.5 L/min and deposited onto an Applied Biosystems matrix-
assisted laser desorption ionization plated by means of a robot (Probot, Dionex) once 
every 15 sec for a total of 384 spots. 
  
MALDI-MS/MS 
Samples were analyzed on an ABI 5800 proteomics analyzer (Applied Biosystems, 
Forster City, CA). Peptide collision-induced dissociation was performed at 2 kV, the 
collision gas was air. MS/MS spectra were collected from 2000 laser shots. Peptides 
with signal-to-noise ratios over 50 at the MS mode were selected for MS/MS analysis, at 
a maximum of 30 MS/MS per spot. The precursor mass window was set to a relative 
resolution of 200. Peaklists were extracted from the instrument database using 
TS2Mascot software (MatrixScience). 
 
Protein identification 
Protein identification and quantification are described in detail in 
180
. To annotate 
spectra, Mascot (MatrixScience, version 2.3.01) searches were performed against the 
Swissprot database (20/10/2010) and against the larger but more redundant NCBI 
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database (20/10/2010). MS/MS spectra were searched with trypsin specificity and fixed 
iTRAQ modifications on lysine residues and N-termini of the peptides and methylthio 
modifications on cysteine residues. Oxidation on methionine residues was allowed as a 
variable modification. Mass tolerance was 150 ppm for precursor ions and 0.5 Da for 
fragment ions, while allowing a single site of miscleavage. The false discovery rate 
(FDR) for peptides identification was calculated using a randomized database. Protein 
redundancy in the result files was removed by clustering the precursor protein 
sequences at a threshold of 90% sequence similarity over 85% of the sequence length. 
Subsequently all peptides were matched against the protein clusters and only those 
peptides were included that mapped unique to one protein. Proteins were considered 
for quantification if at least two unique peptides had a confidence interval of ≥ 95%, and 
at least three peptides were identified in four replicate iTRAQ sets and at least one 
peptide in the four other sets. 
 
Protein quantification and identification of differentially expressed proteins 
iTRAQ areas (m/z 113-121) were extracted from raw spectra and corrected for isotopic 
overlap using GPS explorer. Peptides with iTRAQ signature peaks of less than 750 were 
not considered for quantification. To compensate for the possible variations in the 
starting amounts of the samples, the individual peak areas of each iTRAQ signature 
peak were log transformed to yield a normal distribution, and normalized to the mean 
peak area of every sample. Protein abundances in every experiment were determined 
by taking the average normalized standardized iTRAQ peak area of all unique peptides 
annotated to a protein. Finally, the standardized protein means were used to calculate 
the average abundance at each time point relative to week 20. To determine which 
proteins show significant differential expression, three types of statistical analysis were 
performed. First, the One-Class Time Course Analysis option implemented in the 
Significance Analysis of Microarrays (SAM) package 
181
 was used to determine 
significant regulation over time. In addition, the Two-Class Analysis option in SAM was 
used to determine significant regulation at individual time points. Two-class SAM 
analysis was used both as an unpaired analysis, and as a paired analysis in which the 8 
samples within iTRAQ sets were considered as paired with the 20 weeks time point as 
the base line. Paired analysis was performed to reduce false positives resulting from 
technical variation between iTRAQ sets, and resulted in more stringent selection of 
differentially regulated proteins than unpaired analysis. In all SAM analyses a threshold 
q-value of 10% was used to determine significant differential protein expression. The 
Time Course Analysis was used to determine the set of proteins for which there was 
strongest evidence for regulation over time. K-means clustering and Pearson correlation 
analysis were used to further analyze this set of proteins. The intersection of the paired 
and the unpaired Two-Class Analysis was used to determine the set of proteins for 
which there was evidence for regulation at one or more time points.  
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Functional protein group analysis 
All proteins were assigned to one of 17 functional synaptic protein groups as previously 
defined 
182,183
, and overrepresentation of regulated proteins within functional groups was 
determined using a Fisher’s exact test. Enrichment was only considered relevant when 
overrepresented functional groups contained at least 3 proteins. In addition, functional 
enrichment was determined using the DAVID functional annotation tool 
(http://david.abcc.ncifcrf.gov/) 
184,185
. The functional categories used were GO term 
related to Biological Process (BP), Cellular Component (CC), and Molecular Function 
(MF), as well as pathway annotations derived from KEGG. The entire set of detected 
proteins was used as the background set, and a Benjamini FDR <0.1 was considered 
significant. Enrichment was only considered relevant when enriched functional groups 
contained at least 5 proteins.  
  
Protein variance analysis 
For each detected protein, mean standardized peak areas and standard deviations 
(SD) of the mean standardized peak areas were calculated per time point for both the 
original dataset and subtracted data set (paired against the 20 week time point). 
Parametric one-way ANOVA and non-parametric Kruskal-Wallis 
186
 tests were used to 
determine whether the distribution of these sample means and SDs are dependent on 
time. Next, all SDs from all time points were collected and ranked, and the top 5% was 
selected and designated high variable proteins, whereas the bottom 5% was selected 
and designated low variable proteins. The intersection of the original and subtracted 
data was used to determine the set of proteins with either high or low variability. The 
distribution of high and low variable proteins over time points was determined, and 
functional enrichment analysis was performed using DAVID 
(http://david.abcc.ncifcrf.gov/) 
184,185
, using as a background the whole set of detected 
proteins and a significance threshold of Benjamini FDR <0.1. 
 
Immunoblotting 
Western blot analysis was performed on six synaptosome protein extracts (six biological 
replicates) per time point. For detection of extracellular matrix proteins, samples were 
treated with chondroitinase ABC (Sigma Aldrich, Zijndrecht, The Netherlands; 0.5 U/50 
mg protein) for 90 min at 37 °C. Of each sample, 2.5 µg protein was mixed with SDS 
sample buffer and heated to 90°C for 5 min. Proteins were separated on a CriterionTM 
TGX Stain-Free Precast Gel (4-16% Tris-Glycine; Bio-Rad) in a Criterion
TM
 Cell 
Electrophoresis System (Bio-Rad), and electroblotted onto PVDF membrane overnight 
at 4 °C. After blocking with 5% non-fat dry milk in TBS-T (TBS plus 0.5% Tween) for 1 h, 
blots were incubated with primary antibodies, followed by a horseradish peroxidase-
conjugated secondary antibody (Dako, Glostrup, Denmark; 1:10,000). The following 
antibodies were used: anti-Brevican (gift from Dr. C. Seidenbecher, Magdeburg, 
Germany; 1:2,000), anti-Hapln1 (Abcam; 1:1,000), anti-Neurocan (Sigma; 1:1,000). 
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Blots were incubated with ECL substrate (GE Healthcare, Pollards Wood, UK), scanned 
with a Odyssey Imager (LI-COR) and analyzed with Image Studio software (LI-COR, 
version 1.1.7) using background correction. To correct for differences in sample input, 
Criterion
TM
 TGX Stain-Free Precast Gel after SDS-page and PVDF membrane after 
electroblotting were visualized, and the densitometric values were used for 
normalization 
179,187. Significance was determined using a Student’s t-test (one-tailed, 
independent samples). 
 
RESULTS 
Proteomic analysis identifies 25 proteins that are significantly regulated over time 
To identify and quantify age-related changes in synaptic protein expression, we 
performed 8-plex iTRAQ proteomics of hippocampal synaptosomes isolated from 
C57BL/6 mice at 20, 40, 50, 60, 70, 80, 90 and 100 weeks of age. For each time point, 
eight independent biological replicate samples were measured. Each iTRAQ 
experiment contained samples from all eight time points, allowing comparison within 
and between age groups (Figure 2.1).  
 
FIGURE 2.1. Schematic representation of the 8-plex iTRAQ approach. In each 8-plex iTRAQ experiment, 
combined left and right hippocampi of mice from of eight different ages were pooled and labeled with one of the 
eight iTRAQ labels. After labeling the samples were pooled and subjected to MS/MS analysis for identification 
and quantification of proteins. In total, eight replicate 8-plex experiments were performed.  
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In total, 502 high confidence proteins were detected (CI ≥95%; number of quantifiable 
peptides >3 in at least 4 experiments, and >1 in four other experiments; Supplemental 
Table S2.1). In the text we will refer to proteins as ‘upregulated’ or ‘downregulated’, 
when their expression level is higher or lower respectively than at the 20 week age. To 
select differentially expressed proteins that are consistently up- or downregulated over 
time, we used the one-class time course analysis option in the Significance Analysis of 
Microarrays (SAM) package 
181
. Time course analysis revealed a total of 17 proteins 
significantly upregulated over time, and 8 proteins significantly downregulated over time 
(Figure 2.2A). K-means clustering was used to separate these 25 proteins into 4 
different expression clusters (Figure 2.2A). Clusters 1-3 contained proteins whose 
expression was increased or decreased already at early time points (40-50 weeks), and 
remained relatively constant over time thereafter. Only proteins in cluster 4 showed 
progressive upregulation over time until week 90. These proteins also showed the 
strongest correlation between expression and time, as evidenced by R correlation 
coefficients (Figure 2A). Interestingly, three out of the four proteins in this cluster 
represent protein constituents of the extracellular matrix (ECM; i.e., Hapln1, Ncan and 
Bcan) (Figure 2.2B). Western blotting confirmed the age-dependent upregulation of 
each of these three proteins (Figure 2.2C). Together, these findings suggest that the 
most significant and characteristic age-dependent alteration in the hippocampal 
synaptic proteome is a progressive increase in synaptic ECM levels. 
 
Proteomic analysis identifies 101 proteins that are significantly regulated at any time 
point 
Paired and unpaired two-class analyses in SAM were used to determine significant 
regulation at any time point. In the paired setup, the eight samples within each iTRAQ 
set were considered as paired, and were paired in respect to the 20 week age, which 
reduces false positives. The intersection of the paired and the unpaired analysis 
revealed 101 proteins being significantly differentially expressed at any time point 
(Figure 2.3A) (Supplemental Table S2.2). To allow robust functional characterization of 
these proteins, and to reduce the impact of potential false negatives at individual time 
points, we first combined differentially expressed proteins into three different age 
groups: early-aged (weeks 40 and 50), middle-aged (weeks 60, 70 and 80), and old-
aged (weeks 90 and 100). Whereas significantly upregulated proteins were present in 
all three age groups, a progressive increase was observed for significantly 
downregulated proteins with age (Figure 2.3B). For functional analysis, all differentially 
expressed proteins were categorized in 17 functional synaptic protein groups as 
previously defined 
182,183
, and regulated proteins at each age group were separately 
tested for overrepresentation of functional protein groups using a Fisher’s exact test 
(Figure 2.3C; Table 2.1). In early-aged mice, we observed overrepresentation of 
upregulated proteins involved in cell metabolism and structural plasticity (Figure 2.3C-
D). In middle-aged mice, overrepresentation was observed for proteins involved in cell  
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FIGURE 2.2.  Proteomic analysis identifies 25 proteins that are significantly regulated over time. A, K-means 
clustering revealed four different expression clusters. Clusters 1-3 contained proteins whose expression was 
increased or decreased already early during aging, and remained high or low over time. Only proteins in cluster 
4 showed progressive upregulation over time. These proteins also showed the strongest correlation between 
expression and age, as evidenced by R correlation coefficients. Average protein expression was calculated 
against 20 weeks. B, Temporal expression patterns of proteins in cluster 4. Three out of the four proteins in this 
cluster represent protein constituents of the ECM. Error bars represent SEM. C, Western blotting confirmed the 
age-dependent upregulation of each of these ECM proteins. * p<0.05, error bars represent SEM. 
  
C
h
a
p
t
e
r
 
2
 
35 
 
TABLE 2.1. Overrepresentation of functional protein classes per age-group. All quantified proteins were assigned 
to one of 17 functional synaptic protein groups. Significantly regulated proteins in each age-group (early-aged, 
middle-aged, old-aged) were separately tested for overrepresentation using a Fisher’s exact test. Numerators 
represent the total number of proteins detected, denominators represent the number of proteins belonging to the 
indicated functional class. 
Age group Functional group 
Present in all 
detected proteins 
Present in 
age-goup 
Fisher’s exact 
p-value 
     
Early-aged     
 Cell metabolism 503/33 30/8 0.0010 
 Structural plasticity 503/62 30/8 0.0315 
     
Middle-aged 
 
 
Cell adhesion/transsynaptic 
signaling 
 
 
503/28 
 
 
22/6 
 
 
0.0017 
 
 
adhesion (Figure 2.3C-D). There was no significant overrepresentation found for any 
functional group in old-aged mice.  
As a complementary approach, functional enrichment of differentially 
expressed proteins was determined using gene ontology (GO) and cellular pathway 
(KEGG) databases. Enrichment was determined separately for each age group (early-, 
middle-, and old-aged). Table 2.2 lists all overrepresented GO terms and KEGG 
pathways per age group, as well as the main direction of regulation for the proteins 
observed in each of these GO classes and KEGG pathways. Early-aged mice show an 
upregulation of several GO classes related to cytoskeletal proteins, in particular tubulins 
(i.e., Tubb3, Tubb4a, Tubb5, Tppp), and ECM (i.e., Ncan, Bcan, Hapln1). Middle-aged 
mice show both up- and downregulation of GO classes related to the cortical 
cytoskeleton (e.g., Acnt4, Nefl, Nefm), non-membrane bound organelles (e.g., Kif5c, 
Rps4x), and microtubule-based processes and movement (e.g., Tubb4, Tubb5, Kif5c). 
The most prominent functional enrichment observed in old-aged mice involved an 
upregulation of several GO classes related to the ECM. Thus, in addition to confirming 
our previous analysis in showing a strong age-dependent upregulation of the ECM, GO 
term and KEGG pathway overrepresentation analysis identified several other cellular 
functions that are affected by age.  
 
Variance in synaptic protein expression increases with age 
Increased variance in gene or protein expression might provide a possible causative 
explanation for neurodegenerative disorders 
171
. We therefore measured stochasticity in 
synaptic protein expression as a possible contributor to age-related synaptic  
dysfunction and cognitive decline. We calculated the standard deviations (SD) of the 
average standardized peak areas per protein per time point, and tested whether SD 
distribution changes with age. We observed a significant increase in SD variance with 
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FIGURE 2.3. Proteomic analysis identifies 101 proteins that are significantly regulated at any time point. A, SAM 
analysis revealed 101 proteins being significantly differentially expressed at any time point. B, These proteins 
were divided in age groups: early-aged, middle-aged, old-aged. Significantly upregulated proteins were almost 
equally present in all three age groups, whereas a progressive increase with age was observed for significantly 
downregulated proteins. C, All differentially expressed proteins were categorized in 17 functional synaptic 
protein groups as previously defined 
182,183
. Protein groups indicated in bold print were significantly enriched in 
that particular set of regulated proteins (p<0.05; see also Table 2.1). D, Individual protein expression profiles of 
significantly enriched functional protein groups. Red indicates proteins that are upregulated; blue indicates 
proteins that are downregulated. 
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TABLE 2.2. Functional enrichment of differentially expressed proteins. Significantly enriched (Benjamini FDR <0.1) 
GO and KEGG terms are indicated per age group, as well as the main direction of regulation of the proteins 
within each GO or KEGG class. 
Gene Ontology Young Middle Old 
GO:0031344~regulation of cell projection organization UP   
GO:0010975~regulation of neuron projection development UP   
GO:0030182~neuron differentiation UP   
GO:0030424~axon UP   
GO:0030534~adult behavior UP   
GO:0008344~adult locomotory behavior UP   
mmu00270:Cysteine and methionine metabolism UP   
GO:0005829~cytosol UP UP/DOWN  
GO:0034622~cellular macromolecular complex assembly UP     
GO:0043933~macromolecular complex subunit organization UP    
GO:0034621~cellular macromolecular complex subunit 
organization UP    
GO:0065003~macromolecular complex assembly UP    
GO:0070271~protein complex biogenesis UP    
GO:0043623~cellular protein complex assembly UP    
GO:0006461~protein complex assembly UP    
GO:0051258~protein polymerization UP     
GO:0015630~microtubule cytoskeleton UP     
GO:0000226~microtubule cytoskeleton organization UP    
GO:0007017~microtubule-based process  UP/DOWN   
GO:0007018~microtubule-based movement   UP/DOWN   
GO:0001871~pattern binding UP   UP 
GO:0030247~polysaccharide binding UP  UP 
GO:0005540~hyaluronic acid binding UP UP UP 
GO:0005539~glycosaminoglycan binding UP   UP 
GO:0007155~cell adhesion     UP 
GO:0022610~biological adhesion   UP 
GO:0007010~cytoskeleton organization UP UP/DOWN UP 
GO:0005576~extracellular region UP UP/DOWN   
GO:0031012~extracellular matrix UP UP/DOWN   
GO:0005578~proteinaceous extracellular matrix UP UP/DOWN UP 
GO:0044430~cytoskeletal part   UP/DOWN   
GO:0030863~cortical cytoskeleton  DOWN   
GO:0030864~cortical actin cytoskeleton   DOWN   
GO:0043228~non-membrane-bounded organelle   UP/DOWN   
GO:0043232~intracellular non-membrane-bounded organelle   UP/DOWN   
GO:0006457~protein folding  DOWN  
GO:0016790~thiolester hydrolase activity  DOWN  
mmu00480:Glutathione metabolism   UP   
mmu00980:Metabolism of xenobiotics by cytochrome P450  UP   
mmu00982:Drug metabolism  UP   
GO:0004364~glutathione transferase activity   UP 
GO:0016765~transferase activity, transferring alkyl or aryl 
(other than methyl) groups 
    UP 
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age (original data: one-way ANOVA test, p = 9.91x10
-16
; Kruskal-Wallis test, p = 2.2x10
-
16
; Figure 4A). Similar results were obtained with the subtracted dataset (data not 
shown); SD variance increased with age (one-way ANOVA test, p = 1.07
-11
; Kruskal- 
Wallis test, p = 9.99
-11
). Peptide based peak areas did not change with age (one-way 
ANOVA test, p = 0.134; Kruskal-Wallis test, p = 0.257, data not shown). Next, we 
ranked all the SD values, and we selected the 5% proteins with the lowest SD values, 
which we designated low variability proteins, as well as the 5% proteins with the highest 
SD values, which we named high variability proteins (Figure 2.4B). The intersection of 
the original and subtracted data sets  revealed 103 proteins with extreme SD values, 
either low variable or high variable, at different time points (Supplemental Table S2.3).  
 We next selected the low variability and high variability proteins that are 
specifically associated with the two oldest age classes (weeks 90 and 100) and 
performed a GO term and KEGG pathway functional enrichment analysis (Figure 2.4C). 
Low variability proteins are specifically associated with nucleocytoplasmic transport, 
establishment of protein localization, synaptic vesicle transport, cell junction, 
extracellular structure organization, and ATPase activity. High variability proteins, on the 
other hand, are involved in cellular respiration, and associated with Parkinson’s disease 
and Huntington’s disease pathways. Proteins within these disease pathways are mainly 
mitochondrial proteins, involved in mitochondrial complex I, NADH dehydrogenase, and 
mitochondrial complex IV, cytochrome C oxidase, as well as mitochondrial membrane 
proteins, F-type ATPases, and ATP synthases. In addition, the neurodegeneration-
related alpha-synuclein (Snca) protein was found to be highly variable. 
 
DISCUSSION 
Age is the primary risk factor for cognitive decline and age-related neurodegenerative 
disorders, such as AD. Age-related cognitive decline affects a significant proportion of 
the healthy aging population, but its causes remain to be determined. Here we 
investigated whether molecular changes at the synaptic level may underlie age-related 
cognitive deficits. We identified two types of proteomic alterations in hippocampal 
synapses that are correlated with age. Firstly, we identified synaptic proteins that 
significantly change in expression levels during aging. Secondly, we show that some 
proteins show increased stochasticity with aging, whereas as others are more stably 
expressed. A summary of these combined findings is provided in Figure 2.5. 
 The most significant age-dependent regulation of synaptic protein levels was 
observed for a small group of four proteins (cluster 4 in Figure 2.2A), all of which were 
progressively upregulated with increasing age. Three out of these four proteins are 
involved in the extracellular matrix (Ncan, Hapln1, Bcan), and their upregulation was 
confirmed with immunoblotting. ECM proteins are highly expressed in the brain and are 
produced by both neurons and glial cells. During postnatal maturation of neuronal 
circuits these ECM pack into netlike structures, termed perineuronal nets (PNN),  
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FIGURE 2.4. Variance in synaptic protein expression increases with age. A, Distributions of the standard 
deviations (SD) of the average standardized protein intensities (iTRAQ peak areas) per time point revealed a 
significant increase over time (original data). B, Distributions of average standardized protein intensities (iTRAQ 
peak areas) per time point revealed no dependence on time (original data). C, Distribution of all SD values from 
all time points indicating the highly-constrained proteins as the top 5% low variability proteins (yellow box), and 
lowly-constrained proteins as the top 5% high variability proteins (green box) (original data). D, Functional 
enrichment analysis for high variability and low variability proteins at old-age using GO terms and KEGG pathway 
databases. 
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localized around a subset of neurons. The main component of ECM in the brain is 
polysaccharide hyaluronic acid. It acts as a backbone to engage proteoglycans and 
other glycoproteins into ECM structures. These protein components of the hyaluronic-
based ECM are chondroitin sulfate proteoglycans (CSPGs; e.g., Ncan, Bcan and Vcan), 
tenascins (e.g., Tnc and Tnr), and so-called hyaluronan link proteins (e.g., Hapln1) 
188-
190
.  The developmental pattern of ECM formation corresponds with the ending of the 
critical periods in which synaptogenesis and synaptic refinement 
191
, myelination 
192,193
 
and the maturation of the nervous system 
194-196
 occur. The ECM, therefore, is thought to 
limit developmental plasticity in various cortical areas. In the developing visual cortex, 
for instance, the absence of ECM during the critical period is considered a critical factor 
that allows ocular dominance plasticity to occur 
197
. Consistent with this notion, 
degradation of the ECM in the adult visual cortex restores ocular dominance plasticity 
194
. ECM plasticity also underlies neuronal function in other brain regions than the 
cerebral cortex. In the basolateral amygdala, ECM formation marks the end of a critical 
period during which fear memories can be erased by extinction, and coincides with the 
ability to consolidate contextualized fear and extinction memories 
198
. Degradation of the 
ECM in adult animals enabled erasure of fear memories by extinction, suggesting that 
fear memories are actively protected from erasure by the ECM. 
Importantly, ECM proteins were also found to be associated with synapses, 
and were identified as important regulators of synaptic function 
199-201
. Synaptic ECM 
structures limit synaptic plasticity by restricting the lateral diffusion of extrasynaptic 
AMPA receptors in vitro 
202,203
. Synaptic activity induces the release of proteases that 
locally degrade ECM structures and thereby enhance AMPA receptor mobility and 
synaptic plasticity 
203
. Moreover, ECM-derived protein fragments that are thus 
generated bind to synaptic integrin receptors and regulate LTP in the hippocampus 
204-
206
. It is thus believed that the ECM is a critical regulator of synaptic efficacy and 
plasticity in the brain. Our finding that synaptic ECM proteins are progressively 
upregulated with aging may therefore be causally linked to gradual age-related 
cognitive impairments by limiting synaptic plasticity in the hippocampus.  
 In addition to the ECM, which showed the strongest temporal regulation with 
aging, other functional protein groups were regulated at specific time points. In early-
aged mice, we found an upregulation for proteins involved in structural plasticity, in 
particular cytoskeletal proteins such as the tubulins (Tubb3, Tubb4a, Tubb5, Tppp) and 
microtubule associated protein (Map6). Microtubules are critical for cellular function, 
and neurons require microtubule assembly for the growth and integrity of their axons 
and dendrites, 
207
 as well as for transport of molecular cargos between the cell body 
and remote synaptic sites 
208
.  Increased levels of tubulins could impair microtubule 
transport and thereby affect synaptic function. Deregulation of another microtubule-
associated protein, Tau, has for instance been linked to synaptic dysfunction and 
cognitive decline in Alzheimer’s disease and in frontotemporal lobe dementia 103,209-211. 
Early-aged mice also showed an upregulation of proteins involved in cell metabolism. 
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Interestingly, several of these proteins were found to have neuroprotective properties 
(Eno2) 
212
, to prevent neurodegeneration (Gstp1) 
213
, or to play a role in eliminating 
harmful peroxides generated during metabolism (Prdx1) 
214
. Upregulation of these 
proteins could thus protect neurons against the harmful consequences of aging. 
In old-aged mice, many proteins showed changes in expression with age, but 
we could not detect any significant enrichment of specific functional synaptic protein 
groups. Moreover, within functional protein groups, we often observed both up- and 
downregulation. These findings suggest that alterations in synaptic protein levels at old 
age might result from a more general non-specific dysregulation of proteins rather than 
the coordinated dysregulation of specific proteins. Obviously, less tight regulation of 
protein levels might result in a gradual decrease in the robustness of the protein 
networks underlying neuronal function and plasticity. We addressed this issue by 
measuring levels of stochasticity in synaptic protein expression at different time points 
during aging. Biological variation is known to play an important role in determining 
cellular and organismal phenotypes 
215,216
, and underlies a wide range of biological 
processes ranging from reduced penetrance 
217,218
, to evolutionary fitness 
219
. It was 
recently shown that variance in gene expression is increased in Parkinson’s disease 
patients and selectively affects cellular pathways that may contribute to the disease 
phenotype 
171
. Here, we found that stochasticity in protein expression increases with 
age, suggesting more phenotypic variance with aging. Importantly, the observed 
increase in variance is not the result of a decrease in protein abundance with aging, 
since the distributions of the standardized peak areas (i.e., protein levels) did not 
significantly change with age. Using functional enrichment analysis we found that 
proteins with low variability include proteins involved in synaptic vesicle transport and 
ATPase activity, in particular the Na,K-ATPases. Na,K-ATPase is a membrane-
embedded sodium pump that functions to maintain the asymmetric distribution of 
sodium and potassium across the plasma membrane 
220
. Sodium gradients form the 
foundation for synaptic transmission and neuronal excitation, and changes in the levels 
of Na,K-ATPases can cause long-term alterations in synaptic transmission 
221
. Together, 
these findings indicate high regulatory control with aging over mechanisms that play a 
basal role in neuronal function and synaptic neurotransmission. Using the same 
functional enrichment approach we found that highly variable proteins are specifically 
involved in energy production and are frequently associated with neurodegenerative 
diseases, in particular Parkinson’s disease and Huntington’s disease. Disease 
conditions may arise when an increase in variance changes the predictability of the 
network outcome, resulting in dysregulation of the preferred state 
171
. Interestingly, 
many complex diseases lack genetic variants associated with the disease 
217,218
, and in 
such cases variability in gene or protein expression might be a likely contributor to the 
development of diseases without obvious genetic heritability. Our data suggest that 
normal aging is associated with increased stochasticity in proteins levels and protein 
networks that are known to be involved in neurodegenerative diseases, and may thus 
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explain to some extent the highly prevalent sporadic forms of these diseases amongst 
aging individuals. 
 
 
 
 
FIGURE 2.5. Overview of protein expression and stochasticity changes with aging. Low variability proteins (yellow 
box), high variability proteins (green box), upregulated proteins (red box). 
 
SUPPLEMENTAL TABLES 
SUPPLEMENTAL TABLE 2.1. List of 502 quantified proteins. 
SUPPLEMENTAL TABLE 2.2. List of 101 differentially expressed proteins. 
SUPPLEMENTAL TABLE 2.3. List of 103 proteins with extreme variability. 
Supplemental Tables are provided in the online version. 
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ABSTRACT 
Alzheimer’s disease (AD) is characterized by early and progressive memory 
impairments and the gradual increase in amyloid plaques derived from overproduced 
beta amyloid in the brain. In this study we used an APP
swe
,PS1
dE9
 (APP-PS1) transgenic 
mouse model to elucidate fundamental molecular mechanisms underlying synaptic 
dysfunction and cognitive decline in AD. We performed a quantitative proteomics 
analysis of hippocampal synaptosome fractions obtained from transgenic and wildtype 
mice at different stages of disease development. We observed an early and significant 
upregulation of synaptic extracellular matrix (ECM) proteins in APP-PS1 mice at 3 
months of age, before the first appearance of amyloid plaques. Immunohistochemistry 
confirmed increased levels of ECM in the hippocampus of 3 months old APP-PS1 mice, 
in particular in the subiculum. Importantly, these early changes in ECM expression were 
paralleled by impairments in hippocampal spatial memory in APP-PS1 mice. In addition 
to the robust upregulation of ECM proteins, we observed a downregulation of proteins 
involved in exocytosis and endocytosis, suggesting a decrease in hippocampal 
neurotransmission and/or plasticity. Together, our findings suggest early synaptic 
deficits preceding plaque pathology in a well-established mouse model for AD, and 
indicate a potentially important role for ECM molecules in dysregulating hippocampal 
synaptic plasticity that might be causative to early cognitive decline in AD. 
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INTRODUCTION 
Alzheimer’s disease (AD) is a progressive age-dependent neurodegenerative disorder 
and the most common cause of dementia in the elderly. AD is characterized by global 
and progressive cognitive decline, causing impairments in memory processing, 
judgment and thinking, all of which eventually interfere with daily living. 
Neuropathological hallmarks of AD are the presence of diffuse and neuritic plaques, 
which are mainly composed of β-amyloid (Aβ) 39-42-amino-acid peptides formed after 
proteolytic cleavage of the β-amyloid precursor protein (APP) by β- and γ-secretases, 
and of neurofibrillary tangles which are intraneuronal aggregates of 
hyperphosphorylated tau protein 
222,223
. The currently prevailing hypothesis on the 
etiology of the disease is the amyloid cascade hypothesis, which states that 
overproduction of Aβ is a necessary prerequisite for the neuropathological and clinical 
changes observed in AD 
224,225
. Yet, early memory impairments in human AD patients 
are not temporally correlated with the formation of Aβ plaques in brain areas that are 
important for memory processing, such as the hippocampus. Tau pathology on the 
other hand may be a consequence of high Aβ levels in the brain 226 (see also Chapter 
4).  
Major progress in the understanding of the etiology of AD came from the 
identification of inherited disease-causing mutations. Mutations in APP and in presenilin-
1 (PS1 or PSEN1) and preselinin-2 (PS2 or PSEN2), the main components of the γ-
secretase complex, were found to cause autosomal dominant, early onset familial AD 
227
. All three genes are involved in Aβ production, and all identified mutations increase 
Aβ levels and promote the formation of extracellular plaques. However, mutations in 
APP or in the presenilins are infrequent causes of the disease, and >95% of all AD 
cases is of sporadic origin. The only gene found thus far to alter the susceptibility for AD 
is the apolipoprotein E (apoE) gene 
115
. Homozygous carriers of the ε4 allele of this 
gene have a 10-12 fold higher risk of developing late onset AD 
116
. Astrocytes are the 
primary source of apoE in the brain, and expression of apoE increases with age 
228,229
. 
In a recent study it was shown that increasing apoE expression in mouse models of AD 
enhances Aβ clearance from the brain, reduces plaque load, and restores cognitive 
function 
121
. Thus, the presently known genetic causes of both early and late onset AD 
both underscore the amyloid cascade hypothesis, likely leaving many of the causative 
factors open to explain. 
Less well-studied features of AD are changes in synaptic transmission and the 
loss of synaptic connections, in particular in forebrain regions and hippocampus that 
are involved in cognitive functions and memory 
101
. Synaptic dysfunction precedes 
neuronal degeneration 
128,129
, and is probably mediated by soluble oligomeric forms of 
β-amyloid that are toxic to synapses 130,131 and may reduce synaptic long-term 
potentiation (LTP) 
132
, the physiological correlate of learning and memory. Interestingly, 
memory deficits and cognitive decline observed in AD patients correlate better with the 
synaptic pathology than with the occurrence and presence of Aβ plaques 101,103,133,136,230. 
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This suggests that synaptic dysfunction is an important factor contributing to the early 
stages of cognitive decline in AD 
103,133-136
. Further insight into the molecular 
mechanisms of early synaptic dysfunction in AD may thus provide important clues as to 
how what causes cognitive decline in AD, and how it may eventually be treated. 
In order to elucidate fundamental molecular mechanisms underlying synaptic 
dysfunction and cognitive decline in AD, and to identify molecular targets for future 
disease treatment, we made use of an APP
swe
,PS1
dE9
 
137
 (APP-PS1) transgenic mouse 
model. Importantly, APP-PS1 mice show increased Aβ production resulting from the 
introduction of two human disease related mutations in APP and PS1, and mimic both 
the neuropathological and cognitive hallmarks of AD, including amyloid plaque 
formation, decreased memory performance and reduced synaptic plasticity 
137,141,142,144
. 
We performed a quantitative proteomics analysis of hippocampal synaptosome 
fractions obtained from APP-PS1 and wildtype animals at different stages of brain and 
disease development. Interestingly, most changes in synaptic protein expression were 
observed already at 3 months of age, long before the first plaques appeared. The most 
pronounced changes were observed for proteins belonging to the extracellular matrix 
(ECM), which all showed a significant increase in expression in APP-PS1 mice 
compared to wildtype controls. Furthermore, we confirmed hippocampal memory 
deficits in APP-PS1 mice at three months of age in a contextual fear memory test. 
Together, these findings suggest a novel and important role for ECM molecules in 
regulating synaptic plasticity, which might be causative to early cognitive decline in AD. 
 
EXPERIMENTAL PROCEDURES 
APP-PS1 mutant mice 
For details see The Jackson Laboratory [strain B6C3-Tg(APPswe, PSEN1-dE9)85Dbo/J; 
stock number 004462; http://jaxmice.jax.org/]. APP-PS1 transgenic mice express a 
chimeric mouse/human APP gene harboring the Swedish double mutation 
K595N/M596L (APPswe) and a human PS1 gene harboring the exon 9 deletion 
(PS1dE9), both under the control of the mouse prion protein promoter (MoPrP.Xho) 
137,231,232
. AD mice were maintained as hemizygous and crossed with WT C57BL/6. WT 
littermates served as controls for both AD mouse lines. 
 
Immunohistochemistry 
Immunohistochemistry was performed on brain sections at 3 months (P90), 6 months 
(P180), 9 months (P270), and 1 year (P365) of age. Brains were fixed by transcardial 
perfusion with 4% paraformaldehyde in phosphate buffered saline (n=4-6 pairs). 
Coronal cryosections (10 μm) were thaw-mounted on Superfrost Plus slides, dried for 1 
h at room temperature, and stored at -20 °C until use. Sections were fixed with fresh 4% 
paraformaldehyde in 0.1 M phosphate buffered saline (PBS), pH 7.0, for 10 min at room 
temperature. Sections were treated using 10 mM sodium citrate and 0.05% Tween 20 
(pH 6.0) for 20 minutes at 95 °C, blocked 10% normal donkey serum and 0.4% Triton X-
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100 in PBS, and were incubated overnight with 6E10 (Signet; 1:15,000) and GFAP 
(DAKO; 1:2,000). Antigens were visualized using Cy3 and DyLight 488 (Jackson 
ImmunoResearch Laboratories and Invitrogen; 1:400) incubated for 2 h at room 
temperature. Sections were washed and coverslipped in Vectashield including DAPI as 
a nuclear dye (Vector Laboratories). WFA and Tnr immunohistochemistry were 
performed on free-floating brain sections obtained from animals at 3 months of age. 
Sections were quenched (10% methanol, 0.3% H
2
O
2
 in PBS) for 30 minutes, blocked 
with 0.2% Triton X-100 and 5% fetal bovine serum in PBS, and were incubated 
overnight with fluorescent labeled WFA (Vector Laboratories; 1:400) and Tnr (P.Glia, 
Bonn, Germany; 1:400). Tnr was visualized using DyLight 488 (Invitrogen; 1:400) 
incubated for 2 h at room temperature. Sections were washed and coverslipped in 
Vectashield including DAPI as a nuclear dye (Vector Laboratories). 
 
Synaptosome isolation and sample preparation 
Hippocampi were dissected, frozen, and stored at -80 °C until protein isolation. 
Synaptosomes were isolated from hippocampi of APP-PS1 mice and wildtype 
littermates at four different ages, 1.5, 3, 6 and 12 months of age as described 
previously 
177,178
 with minor modifications. In brief, hippocampi were homogenized in 
ice-cold 0.32 M sucrose buffer with 5 mM HEPES at pH 7.4 and protease inhibitor 
(Roche) and centrifuged at 1000 x g for 10 min at 4 °C to remove debris. Supernatant 
was loaded on top of a discontinuous sucrose gradient consisting of 0.85 M and 1.2 M 
sucrose. After ultracentrifugation at 110,000 x g for 2 h at 4 °C, the synaptosome 
fraction was collected at the interface of 0.85 M and 1.2 M sucrose, resuspended and 
pelleted by ultracentrifugation at 80,000 x g for 30 min at 4 °C. After which the material 
was redissolved in 5 mM HEPES. Protein concentrations were determined using a 
Bradford assay (Bio-Rad, Hercules, CA, USA). For each sample, 50 μg of protein was 
transferred to a fresh tube and dried in a SpeedVac overnight. 
 
Protein digestion and iTRAQ labeling  
Per sample, 50 μg synaptosome proteins were dissolved in 0.85% RapiGest (Waters 
Associates, Milford, MA, USA), alkylated with methyl methanethiosulfonate, and 
digested with trypsin (sequencing grade; Promega, Madison, WI, USA) as described 
178,179
. In each iTRAQ experiment, four mutant samples were labeled respectively with 
iTRAQ reagents 113 (1.5 months), 114 (3 months), 115 (6 months), 116 (12 months), 
and four wildtype samples with iTRAQ reagents 117 (1.5 months), 118 (3 months), 119 
(6 months), and 121 (12 months). To accommodate multiple independent biological 
replicates for each experimental condition (i.e., 2 genotypes x 4 time points), a total of 
five 8-plex iTRAQ experiments were performed. 
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Two-dimensional liquid chromatography (2DLC)  
The lyophilized iTRAQ labeled samples were separated in the first dimension by strong 
cation exchange column (2.1x150 mm polysulfoethyl A column, PolyLC), and the in 
second dimension on an analytical capillary reverse phase C18 column 
(150 mm x 100 m i.d. column) at 400 nL/min using the LC-Packing Ultimate system. 
The peptides were separated using a linear increase in concentration of acetonitrile 
from 4 to 28% in 75 minutes, to 36% in 7 minutes and finally to 72% in 2 minutes. The 
eluent was mixed with matrix (7 mg of re-crystallized -cyano-hydroxycinnaminic acid in 
1 ml 50% acetronitrile, 0.1% trifluoroacetic acid, 10 mM ammonium dicitrate) and 
delivered at a flow rate of 1.5 L/min and deposited onto an Applied Biosystems matrix-
assisted laser desorption ionization plated by means of a robot (Probot, Dionex) once 
every 15 sec for a total of 384 spots. 
  
MALDI-MS/MS 
Samples were analyzed on an ABI 5800 proteomics analyzer (Applied Biosystems, 
Forster City, CA). Peptide collision-induced dissociation was performed at 2 kV, the 
collision gas was air. MS/MS spectra were collected from 2000 laser shots. Peptides 
with signal-to-noise ratios over 50 at the MS mode were selected for MS/MS analysis, at 
a maximum of 30 MS/MS per spot. The precursor mass window was set to a relative 
resolution of 200. Peaklists were extracted from the instrument database using 
TS2Mascot software (MatrixScience). 
 
Protein identification 
Protein identification and quantification are described in detail in 
180
. To annotate 
spectra, Mascot (MatrixScience, version 2.3.01) searches were performed against the 
Swissprot database (20/10/2010) and against the larger but more redundant NCBI 
database (20/10/2010). MS/MS spectra were searched with trypsin specificity and fixed 
iTRAQ modifications on lysine residues and N-termini of the peptides and methylthio 
modifications on cysteine residues. Oxidation on methionine residues was allowed as a 
variable modification. Mass tolerance was 150 ppm for precursor ions and 0.5 Da for 
fragment ions, while allowing a single site of miscleavage. The false discovery rate 
(FDR) for peptides identification was calculated using a randomized peptide database. 
Protein redundancy in the result files was removed by clustering the precursor protein 
sequences at a threshold of 90% sequence similarity over 85% of the sequence length. 
Subsequently all peptides were matched against the protein clusters and only those 
peptides were included that mapped unique to one protein. Proteins were considered 
for quantification if at least two unique peptides had a confidence interval of ≥95%, and 
at least three peptides were identified in three replicate iTRAQ sets and at least one 
peptide in the all other sets. 
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Quantification of differentially expressed proteins 
iTRAQ peak areas (m/z 113-121) were extracted from raw spectra and corrected for 
isotopic overlap using GPS explorer. Peptides with iTRAQ signature peaks of less than 
750 were not considered for quantification. To compensate for small differences in the 
starting amounts of the samples, the individual peak areas of each iTRAQ signature 
peak were log transformed to yield a normal distribution, and normalized to the mean 
peak area per sample. Protein abundance was determined by taking the average 
normalized standardized iTRAQ peak area of all unique peptides annotated to that 
protein. Finally, the standardized protein means (four mutant and four wildtype in each 
experiment) were used to calculate the average log-fold difference between WT and AD 
mice. To assess whether differences had occurred by chance or could be deemed 
significant, we calculated permutation-derived false discovery rates (FDR), using 
Significance Analysis of Microarrays (SAM) 
181
 as implemented in the Multi Experiment 
Viewer software (MeV, version 4.6.1) 
181,233
. SAM uses a data resampling-based method 
and creates randomized data distributions in order to estimate false positive rates 
181
, 
and can be successfully applied to proteomics data 
187,234-237
. Conventional t-test or fold 
change alone do not take into account the effect of multiple testing, and SAM is more 
adaptive to different biological experiments that may have asymmetrical distribution of 
differential protein expression profiles. The SAM q-values reflect for each protein the 
number of empirically determined false-positives at the significance level of the 
respective protein. The false discovery rate (FDR) levels in our results thus hold 
information about individual proteins, and should not be interpreted as a global FDR. 
Changes in protein expression are considered to be significant when the FDR is <10% 
and log-fold change >0.125. In addition, we have also provided the corresponding p-
value as determined by Student’s t-test. 
 
Functional protein group analysis 
For functional protein group analysis, two methods were used. First, all proteins were 
assigned to one of 17 functional synaptic protein groups as previously defined 
182,183
, 
and enrichment of functional groups in sets of regulated proteins was calculated 
relative to all detected proteins. Enrichment was only considered relevant when 
enriched functional groups contained at least 3 proteins, and when the fold enrichment 
was ≥1.1. Secondly, we used the Functional Classification Tool in the Database for 
Annotation, Visualization and Integrated Discovery (DAVID; 
http://david.abcc.ncifcrf.gov/) 
184,185
 to group proteins based on functional similarity and 
to determine enrichment of functional protein groups within the total set of differentially 
expressed proteins. Enrichment was determined using the total set of all detected 
proteins as the background set, and using the following settings: Similarity Term 
Overlap: 4; Similarity Threshold: 0.35; Initial Group Membership: 4; Final Group 
Membership: 4; Multiple Linkage Threshold: 0.50.  
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Immunoblotting 
Western blot analysis was performed on six independent synaptosome protein extracts. 
To facilitate detection of ECM proteins, protein pellets were treated with chondroitinase 
ABC (Sigma Aldrich, Zijndrecht, The Netherlands) at 0.5 U/50 mg protein for 90 min at 
37 °C. Of each sample, 10 µg protein was mixed with SDS sample buffer and heated to 
90 °C for 5 min. Proteins were separated on a CriterionTM TGX Stain-Free Precast Gel (4-
16% Tris-Glycine; Bio-Rad) in a Criterion
TM
 Cell Electrophoresis System (Bio-Rad), and 
electroblotted onto PVDF membrane overnight at 4 °C. After blocking with 5% non-fat 
dry milk in TBS-T (TBS plus 0.5% Tween) for 1 h, blots were incubated with primary 
antibodies, followed by a horseradish peroxidase-conjugated secondary antibody 
(Dako, Glostrup, Denmark; 1:10,000). The following antibodies were used: anti-ApoE 
(Chemicon, 1:1,000), anti-Aβ1-17 (Genscript; 1:500), anti-Brevican (gift from Dr. C. 
Seidenbecher, Magdeburg, Germany; 1:2,000), anti-Tenascin-R (P.Glia, Bonn, 
Germany; 1:2000), anti-Hapln1 (Abcam; 1:1,000), anti-Neurocan (Sigma; 1:1,000). Blots 
were incubated with ECL substrate (GE Healthcare, Pollards Wood, UK), scanned with 
a Odyssey Imager (LI-COR) and analyzed with Image Studio software (LI-COR, version 
1.1.7) using background correction. To correct for differences in sample input, 
Criterion
TM
 TGX Stain-Free Precast Gel after SDS-page and PVDF membrane after 
electroblotting were visualized, and the densitometric values were used for 
normalization 
179,187. Significance was determined using a Student’s t-test (one-tailed, 
independent samples). 
 
Contextual fear conditioning 
All experiments were carried out in a fear conditioning system (TSE Systems) as 
previously described 
238
. Training and testing was performed in a Plexiglas chamber 
with a stainless steel grid floor with constant illumination (100–500 lx) and background 
sound (white noise, 68 dB sound pressure level), situated in a gray box to shield it from 
the outside. The chamber was cleaned with 70% ethanol before each session. Training 
consisted of placing mice in the chamber for a period of 180 s, after which a 2 s foot 
shock (0.7 mA) was delivered through the grid floor. Mice were returned to their home 
cage 30 s after the end of the shock. The retrieval tests consisted of a 3 min re-
exposure to the context (conditioned stimulus) 24 h after acquisition. Baseline inactivity, 
exploration, distance traveled and freezing were assessed automatically. Freezing was 
defined as lack of any movement besides respiration and heart beat during 4 s intervals 
and is presented as a percentage of the total test time. APP-PS1 transgenic mice 
(n=11) and wildtype littermate controls (n=11) were tested at 3 months of age. 
Significance was determined using a one-tailed Student t-test. 
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RESULTS 
Identification of changes in hippocampal synaptic protein composition in APP-PS1 mice  
In order to identify age-dependent changes in the molecular composition of 
hippocampal synapses in APP-PS1 mice we performed 8-plex iTRAQ proteomics. 
Hippocampal synaptosomes were isolated from APP-PS1 mice and their wildtype 
littermates at 1.5 months, 3 months, 6 months and 12 months of age. We choose these 
time points in order to be able to distinguish early synaptic changes (1.5 and 3 months) 
that precede Aβ pathology, from late synaptic changes (6 and 12 months), which may 
be the consequence of Aβ pathology. The iTRAQ experiment was set-up as illustrated 
in Figure 3.1A, and included five independent biological replicates. A total of 376 
proteins were identified (Figure 3.1B; Supplemental Table S3.1). SAM analysis indicated 
that the levels of 104 proteins were significantly different between APP-PS1 mice and 
wildtype controls at one or more time points (FDR <10, log-fold change >0.125; Figure 
3.1B). Most differentially expressed proteins were detected at 3 months of age (86 
proteins) compared to the other ages (0 proteins at 1.5 months, 1 at 6 months and 33 at 
12 months; Figure 3.1C). Of these significantly regulated proteins, most proteins were 
downregulated, especially at 12 months of age, when almost all regulated proteins were 
downregulated (Figure 3.1C). Surprisingly, classical synaptic proteins such as PSD95 
(Dlg4), Bassoon (Bsn) and Piccolo (Pclo) were not significantly different between APP-
PS1 mice and wildtype controls, and also the major glutamate receptor subunits 
(GluR1, GluR2, Grin1, and Grin2b) were not significantly different, although they were all 
detectable. This suggests that more subtle synaptic alterations may underlie cognitive 
deficits in APP-PS1 mice. 
FIGURE 3.1. Identification of age-related changes in protein composition in 3xTg-AD AD mouse model. A, 
Schemtaic representation of the 8-plex iTRAQ approach. B, Proteomics analysis identified a total of 376 proteins. 
SAM analysis indicated that the levels that the levels of 104 proteins were significantly different (FDR < 10, log-
fold change >0.125) between AD mice and wildtype controls at one or more time points. C, Most proteins were 
significantly regulated at 3 and 12 months of age. 
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FIGURE 3.2. Increased expression of App/Aβ and ApoE in APP-PS1 mice. A, ApoE expression was only 
significantly upregulated at 12 months of age. B, This could be confirmed by immunoblotting. * FDR <10 (iTRAQ) 
or p <0.05. C, App expression was significantly increased at 3 and 6 months of age. D, the additional increase 
observed at 12 months was primarily due to an increase of the specific Aβ peptide and could be confirmed by 
immunolbotting. * FDR <10 (iTRAQ) or p <0.05. E, No plaques were observed at 3 months of age, whereas at 6 
months, all APP-PS1 mice had few hippocampal plaques and plaque load steadily increased up to 12 months. 
Parallel to the increase in plaque formation, there was a moderate increase in GFAP staining around all plaques 
at 12 months of age. 
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Increased expression of App/Aβ and ApoE in APP-PS1 mice 
The two most regulated proteins that were detected in hippocampal synaptosomes 
were App and ApoE, which showed a log-fold increase of 1.32 and 0.74 respectively in 
APP-PS1 mice compared with wildtype controls at 12 months of age. ApoE expression 
was only upregulated at 12 months of age (Figure 3.2A), which was confirmed by 
immunoblotting (Figure 3.2B). App expression was also significantly increased at 3 and 
6 months of age (Figure 3.2C). Interestingly, higher App expression in AD mice at 3 and 
6 months of age was observed for most App derived peptides, whereas the additional 
increase observed at 12 months was primarily due to an increase of the specific Aβ 
peptide LVFFAEDVGSNK (Supplemental Figure S3.1). The increase in Aβ levels at 12 
months was confirmed by immunoblotting using an anti-Aβ 1-17 specific antibody 
(Figure 3.2D). To correlate the observed increase in App/Aβ expression with 
pathological alterations in the brain, we next performed immunohistochemical stainings 
of hippocampal sections of APP-PS1 mice at different ages using an antibody (6E10) 
specific for Aβ. In accordance with earlier reports 137, no plaques were observed at 3 
months of age. At 6 months, APP-PS1 mice had few hippocampal plaques and plaque 
load steadily increased up to 12 months (Figure 3.2E). Parallel to the increase in plaque 
formation, there was a moderate increase in GFAP staining around all plaques at 12 
months of age. Together, our data show that APP-PS1 mice have increased levels of 
App expression and Aβ accumulation in or around synapses. Importantly, this increase 
is already significant at 3 months, before any Aβ plaques are observed. The robust 
increase in ApoE expression observed at 12 months of age may reflect increased Aβ 
clearance at hippocampal synaptic sites 
121
. 
 
 
TABLE 3.1. Functional classification using DAVID. Enrichment was determined using the total set of all detected 
proteins as the background set, and using the following settings: Similarity Term Overlap: 4; Similarity Threshold: 
0.35; Initial Group Membership: 4; Final Group Membership: 4; Multiple Linkage Threshold: 0.50. 
 
Functional class Group Gene name 
Enrichment 
score 
 
   Extracellular matrix 1 Ncan, Bcan, Hapln1, Cd200 0.815 
    Cell adhesion 2 Cd200, Ncam1, Icam5, Hnt 0.410 
    Excitability 3 Cacng8, Kcnab2, Cacnb4, Cacna2d3 0.395 
    G-protein 4 Gnaq, Gna11, Gnao1, Gnaz 0.343 
    Exocytosis 5 Rph3a, Syp, Stx1b, Syn2, Syn1 0.343 
    Energy metabolism 6 Ldha, Aldoc, Ldhb, Pkm2, Eno1 0.302 
    Mitochondrion 7 Sdha, Idh3a, Suclg1, Sdhb 0.217 
    Ion balance 8 Atp6v1e1, Atp6v1h, Atp1b1, Atp6v1a 0.063 
    Mitochondrion 
 
9 
 
Vdac1, Sfxn1, Samm50, Cox4i1, Phb 
 
0.023 
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FIGURE 3.3. Functional overrepresentation of significantly regulated proteins. A, Proteins were assigned to one of 
the 17 functional synaptic protein groups as previously defined 
182,183
. B, Overrepresentation of differentially 
expressed proteins within functional groups was determined by calculating the difference between proportions 
and the ratio of proportions. Overrepresentation was only considered relevant when overrepresented functional 
groups contained at least 3 proteins, and when the ratio of proportions was ≥1.1. C, Overrepresented groups at 3 
months of age were proteins involved in cell adhesion/transsynaptic signaling, endocytosis, excitability, 
exocytosis, and G-protein relay. Overrepresented groups at 12 months of age were proteins involved in cell 
adhesion/transsynaptic signaling, cell metabolism, exocytosis, and G-protein relay. 
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Functional overrepresentation analysis of significantly regulated proteins 
We next categorized all proteins in 17 functional synaptic protein groups as previously 
defined 
182,183
 (Figure 3.3A). Overrepresentation analysis was performed separately on 
regulated proteins at 3 and at 12 months of age. Enrichment of functional protein 
groups in these sets of regulated proteins was calculated relative to all detected 
proteins. At 3 months of age we observed an enrichment of proteins involved in cell 
adhesion/transsynaptic signaling, endocytosis, excitability, exocytosis, and G-protein 
relay (Figure 3.3A-B). At 12 months of age, enrichment was observed for proteins 
involved in cell adhesion/transsynaptic signaling, cell metabolism, exocytosis, and G-
protein relay (Figure 3.3A-B). The expression profiles of individual proteins in these 
functional protein classes are depicted in Figure 3.3C. In addition, we also performed 
functional classification analysis based on GO annotation using DAVID. Using the Gene 
Functional Classification tool in DAVID, nine different functional groups were detected 
as significantly enriched in APP-PS1 mice (Table 3.1). The highest enrichment scores 
were observed for proteins involved in cell adhesion, in particular the extracellular 
matrix (ECM). In addition, there was a significant enrichment for proteins involved in 
excitability, G-protein signaling, exocytosis, ion balance, and energy metabolism and 
mitochondrial respiration. 
 
 
 
FIGURE 3.4. Age-related changes in the extracellular matrix in APP-PS1 mice. A, There was an early (3 months) 
higher level of extracellular matrix proteins in young AD mice compared to wildtype controls, while expression 
levels returned to wildtype levels at older ages (12 months). B, This could be confirmed by immunoblotting.  
* FDR < 10 (iTRAQ) or p < 0.05. 
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FIGURE 3.5. Increased hippocampal staining of ECM in APP-PS1 mice at 3 months of age. A, Using 
immunohistochemistry we could determine increased immunofluorescence for WFA and Tnr in AD mice 
compared to their wildtype controls, indicating an increase of extracellular matrix proteins in these animals at 3 
months of age. (DAPI: blue; Tnr: red; WFA: green). B, Expression of WFA-positive neurons was particularly high 
in the subiculum and the adjacent tip of the CA1 region (DAPI: blue; WFA: green). 
Age-related changes in the extracellular matrix in APP-PS1 mice 
Combined functional enrichment analysis using synaptic protein annotation and GO 
annotation indicated a highly significant upregulation of ECM proteins in APP-PS1 mice 
compared to wildtype controls. Proteins in this group were neurocan (Ncan), tenascin-R 
(Tnr), hyaluronan and proteoglycan link protein 1 (Hapln1), and brevican (Bcan). 
Comparison of the time course expression profiles of these proteins revealed a gradual 
age-dependent upregulation in wiltype mice, which was accelerated in APP-PS1 mice, 
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resulting in relatively higher expression levels at 3 and 6 months of age (Figure 3.4A). 
Immunoblotting confirmed the upregulation of all four ECM proteins in APP-PS1 mice 
compared to wildtype controls at 3 months of age (Figure 3.4B). In addition, APP-PS1 
mice showed increased hippocampal staining using the ECM marker Wisteria 
floribunda agglutinin (WFA; Figure 3.5A). Specifically, we observed a strong increase in 
WFA-positive neurons in the subiculum and the adjacent tip of the CA1 region of the 
hippocampus. This increase in WFA staining was observed in three independent APP-
PS1 mice compared with three independent wildtype controls (Figure 3.5B). 
 
Reduced contextual fear memory in 3 months old APP-PS1 mice 
To investigate whether the early increase in synaptic ECM levels temporally correlate to 
early stages of memory decline in AD, we evaluated hippocampal spatial memory in 
APP-PS1 transgenic mice and wildtype controls at 3 months of age using a contextual 
fear memory task. Training consisted of placing mice in a test chamber for a fixed 
period of time, after which a foot shock was delivered through the grid floor. Mice were 
returned to their home cage after the shock had ended. Retrieval tests consisted of re-
exposure to the context (conditioned stimulus) at 24 h after acquisition (Figure 3.6A). 
We observed that wildtype and APP-PS1 mice exhibited similar baseline activity during 
the training trials before shock delivery, as assessed by the percentage of inactivity and 
exploration and the distance moved (Figure 3.6B). However, memory performance, as 
assessed by freezing behavior on re-exposure of mice to the context, was reduced in 
APP-PS1 mice compared with wildtype mice (Figure 3.6C). This effect almost reached 
statistical significance (p = 0.028). 
 
 
FIGURE 3.6. Reduced spatial memory in 3 months old APP-PS1 mice. Hippocampal-dependent memory in APP-
PS1 mice and their wildtype controls at 3 months of age using a contextual fear memory task. A, set up of 
contextual fear memory task. B, wildtype and APP-PS1 mice exhibited similar baseline activity during the training 
trials before the shock delivery. C, memory performance during retrieval session, as assessed by freezing 
behavior on re-exposure of mice to the context in which they were previously shocked, was reduced in APP-PS1 
mice compared with wildtype mice. * p < 0.05.  
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DISCUSSION 
APP-PS1 transgenic mice as a model for Alzheimer’s disease 
The earliest clinical manifestation of AD is a pure impairment of cognitive function. It is 
suggested that overproduction of Aβ in early AD causes subtle alterations in 
hippocampal synaptic efficacy that precede neuronal degeneration 
101
. In order to 
understand the role of Aβ in early hippocampal synaptic dysfunction and cognitive 
decline in AD we made use of an APP
swe
,PS1
dE9
 
137
 (APP-PS1) transgenic mouse model. 
We detected an early and progressive increase in App expression in hippocampal 
synapses of APP-PS1 mice, starting at 3 months of age. The increase in App expression 
at 12 months was primarily due increased levels of the Aβ, and may reflect increased 
hippocampal plaque load. In accordance, APP-PS1 mice showed no amyloid plaques 
at 3 months of age, whereas at 6 months, all APP-PS1 mice had few hippocampal 
plaques and plaque load steadily increased up to 12 months, as was described 
previously 
137
. Thus, APP-PS1 mice have increased levels of App expression and Aβ 
accumulation in or around synapses. Importantly, this increase in App expression is 
already significant at 3 months of age, before any Aβ plaques are observed, suggesting 
an early role for Aβ in synaptic dysfunction. In addition, the robust increase in ApoE 
expression observed at 12 months of age in APP-PS1 mice may reflect increased Aβ 
clearance at hippocampal synaptic sites. It has recently been shown that increasing 
ApoE expression in mouse models of AD enhances Aβ clearance from the brain, 
reduces plaque load, and restores cognitive function 
121
. 
 
Early proteomic changes preceding Aβ pathology 
Most significant alterations in hippocampal synaptic protein levels were observed at 3 
months of age, before plaque pathology occurs in APP-PS1 mice, confirming our 
hypothesis that early synaptic deregulation may underlie memory deficits in AD. 
Overrepresentation analysis identified a deregulation of proteins involved in cell 
adhesion/transsynaptic signaling as the most robust early alteration in APP-PS1 
hippocampal synaptosomes. In particular, we identified the main components of the 
ECM, i.e., neurocan (Ncan), tenascin-R (Tnr), hyaluronan and proteoglycan link protein 
1 (Hapln1), and brevican (Bcan), as early upregulated in APP-PS1 mice, which will be 
discussed below. 
 Overrepresentation among deregulated proteins was also observed for 
endocytosis and exocytosis related proteins, most of which showed a significant 
downregulation at 3 months in APP-PS1 mice. Downregulation of exocytosis proteins in 
particular was persistent with aging and was also observed at 12 months. The proteins 
affected are implicated in synaptic vesicle exocytosis and endocytosis, postsynaptic 
receptor aggregation, and activity-dependent synaptic maintenance. Their 
downregulation may decrease stimulus-induced neurotransmission and could 
potentially impact on learning and memory functions in the AD hippocampus. Several 
previous studies have reported that decreased expression of these proteins is 
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correlated with normal aging 
176,239
. For example, SNARE complex proteins (VAMP2, 
SNAP25, syntaxin 1), vesicle mobilizing proteins (synapsin 1, synapthophysin) and 
postsynaptic proteins (PSD95) are significantly decreased in hippocampal synapses of 
normal aged rats 
176
, indicating a loss of effective neurotransmission machinery. In 
addition, a decrease in synaptophysin immunoreactivity has been reported in the 
patients with mild cognitive impairment or very mild AD 
135
. Interestingly, in some APP 
transgenic mouse lines, the number of synaptophysin-positive presynaptic terminals are 
decreased compared to wildtype controls at the age of 2-3 months, well before any 
plaque formation 
240
. Thus, our findings, together with previously published data, 
suggest an early downregulation in of synaptic proteins involved in neurotransmission, 
which may relate to the impaired learning and memory functions AD. 
 
Late proteomic changes as possible consequence of Aβ pathology 
Late synaptic changes, at 6 and 12 months of age, could potentially be involved in Aβ 
pathology, either causally or consequentially. As mentioned before, the robust increase 
in ApoE expression in APP-PS1 mice observed at 12 months of age may reflect 
increased Aβ clearance at hippocampal synaptic sites. It was recently demonstrated 
that increasing ApoE expression in mouse models of AD enhances Aβ clearance from 
the brain, reduces plaque load, and restores cognitive function 
121
. Overrepresentation 
analysis also showed selective deregulation of proteins involved in G-protein relay. 
Several studies suggested an important role for G protein-coupled receptors (GPCRs) 
in the pathogenesis of AD and in multiple stages of the processing of App 
241,242
. The 
sequential cleavage of App by the α-, β-, and γ-secretases, for instance, was found to 
be regulated by GPCRs, and Aβ can directly or indirectly affect GPCR function 242. In 
addition, toxicity of Aβ may be a consequence of its interaction with the plasma 
membrane, which could potentially involve GPCRs 
242
. 
 The persistent downregulation of exocytosis proteins in APP-PS1 mice, in 
particular vesicle mobilizing proteins (synapsin 1, synapsin 2 and synapthophysin), may 
be related to clinical dementia, given the function of these proteins in synaptic 
transmission, including neurotransmitter exocytosis, vesicle trafficking, docking, and 
fusion to the synaptic plasma membrane 
243
. The degree of cognitive decline in patients 
with AD has been correlated with changes in the presynaptic vesicle protein 
synaptophysin in the hippocampus and the association cortices 
133,136,244
. In addition, 
downregulation of synaptophysin could also indicate a loss of presynaptic boutons as 
seen during later stages of AD. Previous studies have shown that as many as 45% of 
presynaptic boutons were lost in AD patients when compared to cognitively normal 
controls, especially in the neocortex and hippocampus, which may play a role in 
cognitive impairment in AD 
103,135
. Furthermore, loss of postsynaptic dendritic spines is 
also an important characteristic of AD. Overexpression of App has been shown to 
cause a reduction in spine density, and this was likely a result of secreted Aβ, as γ-
secretases inhibitors could block spine reduction 
245
. In contrast to the reduced 
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expression of presynaptic protein synaptophysin we do not find decreased expression 
of typical postsynaptic proteins. This indicates that the downregulation of exocytosis 
proteins in APP-PS1 mice is probably not due to synapse loss, but probably reflects 
more subtle deficits in the vesicle release machinery. 
 
Role of extracellular matrix and relation to cognitive impairment 
The most pronounced synaptic proteome changes were observed for proteins that 
belong to the ECM, which all showed an early significant increase in expression in APP-
PS1 mice compared to wildtype controls. Time course analysis revealed a gradual age-
dependent upregulation in wildtype mice, which was accelerated in APP-PS1 mice, 
resulting in relatively higher expression levels at 3 and 6 months of age and returning to 
wildtype levels at 12 months of age. A progressive age-dependent increase in ECM 
levels in hippocampal synaptosome preparations was independently observed in aging 
wildtype mice from the age of 12 months onwards (see Chapter 2). Our findings thus 
indicate that APP overexpression in APP-PS1 mice directly or indirectly accelerates 
age-dependent ECM formation in the hippocampus, and may contribute to the early 
stages of synaptic dysfunction and cognitive decline in AD. Developmental and activity-
dependent plasticity of the ECM are known to be important in the regulation of synaptic 
function. During postnatal maturation of neuronal circuits, for instance, a developmental 
increase in ECM content corresponds with the ending of the critical periods in which 
synaptogenesis and synaptic refinement 
191
, myelination 
192,193
 and the maturation of the 
nervous system 
194-196
 occur. In the adult brain, ECM components are known regulate 
synaptic plasticity in several ways 
194,198
. Importantly, we show that hippocampal 
memory deficits in APP-PS1 mice at 3 months of age are indeed correlated with the 
increased ECM levels observed in our iTRAQ experiments, suggesting that increased 
ECM expression limits hippocampal synaptic plasticity in early AD. 
Interestingly, it has also been found that binding of Aβ to the ECM is a critical 
step in the development AD. Although Aβ can readily self-aggregate to form amyloid 
fibrils in vitro, the binding of Aβ to the ECM enhances fibril formation in vivo 246-249. In this 
respect, increased ECM expression in APP-PS1 mice may be regarded as a protective 
mechanism to enhance Aβ aggregation and to protect neurons from Aβ toxicity, despite 
its negative consequences for synaptic plasticity and memory formation. Additional 
experiments should address the role of the ECM in AD and in concomitant age-related 
cognitive decline in detail. These experiments should include intervention studies at 
different ages in order to locally break down the ECM in the hippocampus, followed by 
behavioral testing of spatial memory, assessment of hippocampal synapse physiology 
and analysis of hippocampal plaque load. These studies could eventually lead to 
possible novel therapeutic treatment for age-related cognitive decline based on ECM-
related maintenance of hippocampal plasticity. 
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SUPPLEMENTAL FIGURE AND TABLE 
 
SUPPLEMENTAL FIGURE S3.1. Increased expression of the specific Aβ peptide at 12 months of age in APP-PS1 
mice. 
SUPPLEMENTAL TABLE S3.1. List of all quantified proteins APP-PS1. 
Supplemental Tables are provided in the online version.  
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ABSTRACT 
Alzheimer’s disease (AD) is characterized by deposits of amyloid-β (Aβ), and also by 
neurofibrillary tangles (NFTs) composed of aggregated tau protein. In contrast to Aβ 
deposition, tau aggregates are found in a range of neurodegenerative diseases, 
including frontotemporal dementia (FTLD) and Pick disease. Currently, there is a debate 
on the underlying cause of AD and the typical AD-related symptoms. Whereas Aβ 
deposition is a unique pathological hallmark of the disease, β-amyloidosis alone is not 
sufficient to produce the clinical symptoms of AD. On the other hand, neurofibrillary 
degeneration correlates better with the typical AD-like cognitive symptoms, but is not 
specific for AD. Tau mutations that are characteristic of FTLD are never observed in AD, 
and the precise role of tau in AD is still unknown.  
In this study we used of a triple-transgenic (3xTg-AD; APP
swe
,PS1
M146V
,tau
P301L
) 
mouse model, which combines both plaques and NFTs in the same animal model and 
is widely used in AD research. The introduction of a tau mutation that is normally only 
associated with FTLD, raises the question whether the pathological and clinical 
phenotype observed in these animals is really representative of human AD. We 
addressed this issue by performing comparative proteomics analysis of biochemically 
enriched hippocampal synaptosome fractions obtained from 3xTG-AD mice and 
wildtype controls. As expected, we observed many protein changes that were also 
identified in an APP-PS1 double transgenic AD mouse model that lacks the tau mutation 
(Chapter 3). These changes included an age-dependent increase in levels of proteins 
involved in the extracellular matrix, which appears to be a common characteristic of 
normal aging and AD. In addition, we also found alterations in protein levels that are 
specific for 3xTg-AD mice, such as changes in the levels of several glutamate 
receptors. We hypothesize that these changes are due to the accumulation of mutant 
tau in dendritic spines, and may thus represent synaptic adaptations in tauopathies in 
general, rather than in AD specifically. 
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INTRODUCTION 
In Alzheimer’s disease (AD), several proteins adopt potentially pathogenic 
conformations and accumulate in the brain. Based on the pathological definition of the 
disease, AD is characterized by deposits of amyloid-β (Aβ), and also by neurofibrillary 
tangles (NFTs) composed of aggregated tau protein 
222,223
. Tauopathy is also observed 
in a variety of other neurodegenerative diseases, including frontotemporal dementia 
and Pick disease 
210,211,250
. Currently, there is a strong debate on what are the precise 
causes of AD and the typical AD-related symptoms. Aβ deposition on one hand is a 
unique pathological hallmark of the disease and thus is likely to contribute to some 
disease-specific characteristics, however, β-amyloidosis alone does not produce the 
clinical symptoms of AD 
251
. On the other hand, neurofibrillary degeneration correlates 
better with the typical AD-like cognitive symptoms 
230
, however, is not specific for AD. 
 Tau is the major neuronal microtubule associated protein (MAP) 
252
.  It is 
encoded by a single gene on chromosome 17, but is expressed as several different 
isoforms that are generated by alternative splicing 
253
. Tau interacts with tubulin, 
promotes tubulin assembly into microtubules and helps to stabilize microtubular 
structure 
252,254
. Microtubules are critical for cellular function. This is especially true for 
neurons, since they require microtubule assembly for the growth and integrity of their 
axons and dendrites, 
207
 as well as for transport of molecular cargos between the cell 
body and remote synaptic sites 
208
. Tau thus plays an essential role in the regulation of 
microtubule dynamics in neurons; reduced tau levels may destabilize microtubules, 
whereas increased tau levels may cause excessive microtubule stabilization. In 
addition, tau is an important player in anterograde and retrograde axonal transport via 
kinesin and dynein complexes, respectively 
255
. Tau itself is regulated by extensive 
phosphorylation, and its phosphorylation state affects its binding to microtubules 
256
. 
Kinase-mediated phosphorylation inhibits microtubule binding, whereas phosphatase-
mediated dephosphorylation restores binding. Major understanding on the role of 
aberrant tau in neurodegenerative diseases arose from the discovery that mutations in 
the tau gene are associated with FTDP-17T (frontotemporal dementia with parkinsonism 
linked to chromosome 17), which is typically characterized by tau pathology 
254,257,258
.  
Initially, the identified mutations clustered in and around the regions encoding the 
microtubule-binding domains of tau, suggesting impaired tau binding to microtubules. 
These mutations provided clear evidence that alterations in tau alone can cause 
neurodegeneration, and suggest that aberrant tau might play a role in other tauopathies 
as well. However, tau mutations were never found to actually cause AD. 
The role of aberrant tau in AD is still under debate, and recent studies have 
shown that loss of tau function is an unlikely direct cause of neurodegeneration and 
neuronal dysfunction in AD 
259
. AD differs from most other tauopathies in the types of tau 
inclusions and in the brain regions that are most affected 
260
. Neurofibrillary 
degeneration in AD brains presents as intraneuronal NFTs, neuropil threads and as 
dystrophic neurites surrounding the Aβ core in plaques, and are made up primarily of 
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aggregated tau with abnormal posttranslational modifications, including increased 
phosphorylation and acetylation 
261-263
. The trigger for increased phosphorylation and 
aggregation of tau is also likely different in AD compared with other tauopathies. While 
FTLD for instance is caused by mutated tau, AD seems to involve pathogenic 
modifications of wildtype tau that are caused by upstream effects of Aβ and apoE4 226. 
Upon abnormal modification and pathogenic conformation, tau becomes enriched in 
dendritic spines where it interferes with neurotransmission 
209,259
. Aβ oligomers can 
directly promote postsynaptic enrichment of aberrant tau through a process that 
involves members of the microtubule affinity-regulating kinase (MAPK) family 
264
. Thus, 
AD is characterized by a unique interplay between tau and Aβ: conformational 
alterations of wildtype tau by increased Aβ levels may be a prerequisite for the 
development of AD and may in part explain the typical cognitive deficits observed in 
AD. 
Different transgenic mice expressing tau have been generated to provide 
disease models for AD 
143,210
. Although none of the available models is capable of 
recapitulating all the features of AD pathology, triple-transgenic (3xTg-AD; 
APP
swe
,PS1
M146V
,tau
P301L
) 
138
 mice now combine the principle neuropathological 
hallmarks of AD, including both plaques and NFTs, in the same animal model. 
Neurofibrillary pathology in these animals is due to the introduction of a tau mutation 
that is normally associated with FTLD, which raises the question whether the 
pathological and clinical phenotype observed in these animals is really representative 
of human AD. Here, we used 3xTg-AD mice to make a direct comparison with APP-PS1 
mice (Chapter 3) in terms of age-dependent changes in synaptic proteome 
composition. We performed proteomic analyses of synaptosome fractions using an 
isobaric tag for relative and absolute quantification (iTRAQ) followed by tandem mass 
spectrometry. As expected, we observed many similar protein changes as in the APP-
PS1 mouse model, including age-dependent deregulation of proteins involved in 
extracellular matrix and energy metabolism. In addition, we also found alterations in 
protein levels that are specific for 3xTg-AD mice, such as changes in the glutamate 
receptors, and that are likely due to the tau mutation.  
 
EXPERIMENTAL PROCEDURES 
3xTg-AD mutant mice 
3xTg-AD transgenic mice express the human APP gene (695 isoform) harboring the 
Swedish double mutation (K670N/M671L), a PS1 (M146V) knockin, and the human four-
repeat tau without amino terminal inserts (4R0N) harboring the P30IL mutation 
138
. 
Wildtype littermates served as controls for both AD mouse lines. 
 
Immunohistochemistry 
Immunohistochemistry was performed on brain sections at 3 months of age for Aβ, and 
21 months of age for tau. Brains were fixed by transcardial perfusion with 4% 
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paraformaldehyde in phosphate buffered saline (n=4-6 pairs). Coronal cryosections (10 
μm) were thaw-mounted on Superfrost Plus slides, dried for 1 h at room temperature, 
and stored at -20 °C until use. Sections were fixed with fresh 4% paraformaldehyde in 
0.1 M phosphate buffered saline (PBS), pH 7.0, for 10 min at room temperature. 
Sections were treated using 10 mM sodium citrate and 0.05% Tween 20 (pH 6.0) for 20 
minutes at 95 °C, blocked 10% normal donkey serum and 0.4% Triton X-100 in PBS, 
and were incubated overnight with 6E10 (Aβ) (Signet; 1:15,000), AT8 (Thermo 
Sciencific; 1:500) or TAU-5 (Invitrogen; 1:500). Antigens were visualized using Cy3 and 
DyLight 488 (Jackson ImmunoResearch Laboratories and Invitrogen; 1:400) incubated 
for 2 h at room temperature. Sections were washed and coversliped in Vectashield 
including DAPI as a nuclear dye (Vector Laboratories) and viewed with a Leica DMRE 
fluorescence microscope using a 20x objective. Images were recorded digitally with a 
Leica 350F 16-bit CCD-camera using Leica FW4000 imaging software. 
 
Synaptosome isolation and sample preparation 
Hippocampi were dissected, frozen, and stored at -80 °C until protein isolation. 
Synaptosomes were isolated from hippocampi of 3xTg-AD mice and wildtype 
littermates at four different ages, 1.5 months, 3 months, 6 months and 12 months, as 
described previously 
177,178
 with minor modifications. In brief, hippocampi were 
homogenized in ice-cold 0.32 M sucrose buffer with 5 mM HEPES at pH 7.4 and 
protease inhibitor (Roche) and centrifuged at 1000 x g for 10 min at 4 °C to remove 
debris. Supernatant was loaded on top of a discontinuous sucrose gradient consisting 
of 0.85 M and 1.2 M sucrose. After ultracentrifugation at 110,000 x g for 2 h at 4 °C, the 
synaptosome fraction was collected at the interface of 0.85 M and 1.2 M sucrose, 
resuspended and pelleted by ultracentrifugation at 80,000 x g for 30 min at 4 °C. After 
which the material was redissolved in 5 mM HEPES. Protein concentrations were 
determined using a Bradford assay (Bio-Rad, Hercules, CA, USA). For each sample, 50 
μg of protein was transferred to a fresh tube and dried in a SpeedVac overnight. 
 
Protein digestion and iTRAQ labeling  
Per sample, 50 μg synaptosome proteins were dissolved in 0.85% RapiGest (Waters 
Associates, Milford, MA, USA), alkylated with methyl methanethiosulfonate, and 
digested with trypsin (sequencing grade; Promega, Madison, WI, USA) as described 
178,179
. In each iTRAQ experiment, four mutant samples were labeled respectively with 
iTRAQ reagents 113=1.5 months, 114=3 months, 115=6 months, 116=12 months, and 
four wildtype samples with iTRAQ reagents 117=1.5 months, 118=3 months, 119=6 
months, and 121=12 months. To accommodate multiple independent pools of tissue of 
each experimental condition (1.5, 3, 6, and 12 months), a total of six 8-plex iTRAQ 
experiments were performed. 
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Two-dimensional liquid chromatography (2DLC)  
The lyophilized iTRAQ labeled samples were separated in the first dimension on a 
strong cation exchange column (2.1x150 mm polysulfoethyl A column, PolyLC), and in 
the second dimension on an analytical capillary reverse phase C18 column 
(150 mm x 100 m i.d. column) at 400 nL/min using the LC-Packing Ultimate system. 
The peptides were separated using a linear increase in concentration of acetonitrile 
from 4 to 28% in 75 minutes, to 36% in 7 minutes and finally to 72% in 2 minutes. The 
eluent was mixed with matrix (7 mg of re-crystallized -cyano-hydroxycinnaminic acid in 
1 ml 50% acetronitrile, 0.1% trifluoroacetic acid, 10 mM ammonium dicitrate) and 
delivered at a flow rate of 1.5 L/min and deposited onto an Applied Biosystems matrix-
assisted laser desorption ionization plated by means of a robot (Probot, Dionex) once 
every 15 sec for a total of 384 spots. 
  
MALDI-MS/MS 
Samples were analyzed on an ABI 5800 proteomics analyzer (Applied Biosystems, 
Forster City, CA). Peptide collision-induced dissociation was performed at 2 kV, the 
collision gas was air. MS/MS spectra were collected from 2000 laser shots. Peptides 
with signal-to-noise ratios over 50 at the MS mode were selected for MS/MS analysis, at 
a maximum of 30 MS/MS per spot. The precursor mass window was set to a relative 
resolution of 200. Peaklists were extracted from the instrument database using 
TS2Mascot software (MatrixScience). 
 
Protein identification 
Protein identification and quantification are described in detail in 
180
. To annotate 
spectra, Mascot (MatrixScience, version 2.3.01) searches were performed against the 
Swissprot database (20/10/2010) and against the larger but more redundant NCBI 
database (20/10/2010). MS/MS spectra were searched with trypsin specificity and fixed 
iTRAQ modifications on lysine residues and N-termini of the peptides and methylthio 
modifications on cysteine residues. Oxidation of methionine residues was allowed as a 
variable modification. Mass tolerance was 150 ppm for precursor ions and 0.5 Da for 
fragment ions, while allowing a single site of miscleavage. The false discovery rate 
(FDR) for peptides identification was calculated using a randomized peptide database. 
Protein redundancy in the result files was removed by clustering the precursor protein 
sequences at a threshold of 90% sequence similarity over 85% of the sequence length. 
Subsequently all peptides were matched against the protein clusters and only those 
peptides were included that mapped unique to one protein. Proteins were considered 
for quantification if at least two unique peptides had a confidence interval of ≥95%, and 
at least three peptides were identified in three replicate iTRAQ sets and at least one 
peptide in the all other sets. 
 
  
C
h
a
p
t
e
r
 
4
 
71 
 
Protein quantification and identification of differentially expressed proteins 
iTRAQ areas (m/z 113-121) were extracted from raw spectra and corrected for isotopic 
overlap using GPS explorer. Peptides with iTRAQ signature peaks of less than 1500 
were not considered for quantification. To compensate for the possible variations in the 
starting amounts of the samples, the individual peak areas of each iTRAQ signature 
peak were log transformed to yield a normal distribution, and normalized to the mean 
peak area of every sample. Protein abundances in every experiment were determined 
by taking the average normalized standardized iTRAQ peak area of all unique peptides 
annotated to a protein. Finally, the standardized protein means (four mutant and four 
wildtype in each experiment) were used to calculate the average difference between 
WT and mutant mice. To assess whether differences had occurred by chance or could 
be deemed significant, we calculated permutation-derived false discovery rates (FDR), 
using Significance Analysis of Microarrays (SAM) 
181
 as implemented in the Multi 
Experiment Viewer software (MeV, version 4.6.1) 
181,233
. SAM uses a data resampling-
based method and creates randomized data distributions in order to estimate false 
positive rates 
181
, and can be successfully applied to proteomics data 
187,234-237
. 
Conventional t-test or fold change alone do not take into account the effect of multiple 
testing, and SAM is more adaptive to different biological experiments that may have 
asymmetrical distribution of differential protein expression profiles. The SAM q-values 
reflect for each protein the number of empirically determined false-positives at the 
significance level of the respective protein. The false discovery rate (FDR) levels in our 
results thus hold information about individual proteins, and should not be interpreted as 
a global FDR. Changes in protein expression are considered to be significant when the 
FDR is <10% and log-fold change >0.125. In addition, we have also provided the 
corresponding p-value as determined by Student’s t-test. 
 
Functional protein group analysis 
For functional protein group analysis, we used the Functional Classification Tool in the 
Database for Annotation, Visualization and Integrated Discovery (DAVID; 
http://david.abcc.ncifcrf.gov/) 
184,185
 to group proteins based on functional similarity and 
to determine enrichment of functional protein groups within the total set of differentially 
expressed proteins. Enrichment was determined using the total set of all detected 
proteins as the background set, and using the following settings: Similarity Term 
Overlap: 4; Similarity Threshold: 0.35; Initial Group Membership: 4; Final Group 
Membership: 4; Multiple Linkage Threshold: 0.50. Finally, proteins were manually 
annotated according to their reported subcellular localization and protein function, 
based on Expasy information and on literature 
265,266
. In addition, for the correlation 
between the APP-PS1 and 3xTg-AD model functional enrichment was determined using 
the DAVID functional annotation tool (http://david.abcc.ncifcrf.gov/) 
184,185
. The functional 
categories used were GO term related to Biological Process (BP), Cellular Component 
(CC), and Molecular Function (MF), as well as pathway annotations derived from KEGG. 
 C
h
a
p
t
e
r
 
4
 
72 
 
The entire set of detected proteins was used as the background set, and a Benjamini 
FDR <0.1 was considered significant. Enrichment was only considered relevant when 
enriched functional groups contained at least 5 proteins (3xTG-AD data) or at least 3 
proteins (comparison of APP-PS1 and 3xTG-AD data). Correlation in temporal protein 
expression profiles in APP-PS1 and 3xTG-AD mice was determined by calculating 
Pearson correlation coefficient (R). 
 
Immunoblotting 
Western blot analysis was performed on six synaptosome protein extracts. To be able to 
identify extracellular matrix proteins, protein pellets were treated with chondroitinase 
ABC (Sigma Aldrich, Zwijndrecht, The Netherlands) at 0.5 U/50 mg protein for 90 min at 
37 °C. Of each sample, 2.5 µg protein was mixed with SDS sample buffer and heated to 
90 °C for 5 min. Proteins were separated on a CriterionTM TGX Stain-Free Precast Gel (4-
16% Tris-Glycine; Bio-Rad) in a Criterion
TM
 Cell Electrophoresis System (Bio-Rad), and 
electroblotted onto PVDF membrane overnight at 4 °C. After blocking with 5% non-fat 
dry milk in TBS-T (TBS plus 0.5% Tween) for 1 h, blots were incubated with primary 
antibodies, followed by a horseradish peroxidase-conjugated secondary antibody 
(Dako, Glostrup, Denmark; 1:10,000). The following antibodies were used: anti-Tau 
(Invitrogen, 1:1,000), anti-ApoE (Chemicon, 1:1,000), anti-GluR1 (Millipore; 1:1,000), 
anti-Grm3 (Millipore; 1:1,000), anti-Grin2a (NeuroMab, Davis, CA, USA; 1:1,000), anti-
Brevican (gift from Dr. C. Seidenbecher, Magdeburg, Germany; 1:2,000), anti-Hapln1 
(Abcam; 1:1,000), anti-Neurocan (Sigma; 1:1,000). Blots were incubated with ECL 
substrate (GE Healthcare, Pollards Wood, UK), scanned with a Odyssey Imager (LI-
COR) and analyzed with Image Studio software (LI-COR, version 1.1.7) using 
background correction. To correct for differences in sample input, Criterion
TM
 TGX 
Stain-Free Precast Gel after SDS-page and PVDF membrane after electroblotting were 
visualized, and the densitometry values were used for normalization 
179,187
. Significance 
was determined using a Student’s t-test (one-tailed, independent samples). 
 
RESULTS 
Characterization of 3xTg-AD mice 
In order to determine to what extent 3xTg-AD mice model AD, we investigated age-
dependent changes in the expression and/or accumulation of Aβ, apolipoprotein E 
(ApoE) and Tau. Intraneuronal Aβ immunoreactivity was one of the earliest 
neuropathological manifestations in the 3xTg-AD mice, and was apparent in the 
hippocampus from the age of 3 months (Figure 4.1A). In contrast to earlier reports 
138,267
, and in contrast to single-transgenic (APP only) 
143
 and double-transgenic 
(APP/PS1) mouse models for AD 
137
 (see also Chapter 3), accumulation of extracellular 
Aβ deposits was not detected at all, not even in 12 month old mice. Using 
immunoblotting, we did not observe an increase in Aβ levels in hippocampal 
synaptosome preparations from 3xTG-AD mice compared to wildtype littermates at 12  
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months of age (Fig 4.1C). ApoE expression, which was strongly induced in 
hippocampal synaptosomes in double-transgenic AD mice (Chapter 3), was not 
changed in the 3xTg-AD at 12 months of age (Figure 4.1D). Hyperphosphorylated tau 
pathology in the hippocampus was apparent from 18 months of age (Figure 4.1B), 
confirming the overexpression of mutant tau in the 3xTg-AD model. Importantly, using 
immunoblotting we could detect an increase in tau levels in hippocampal synaptosome 
preparations already at 3 months of age in 3xTg-AD mice compared to wildtype 
controls (Figure 4.1E). This indicates that tau possibly accumulates within synapses 
already before any tangle pathology occurs in the 3xTg-AD mice. 
 
FIGURE 4.1. Increased expression of intraneuronal Aβ and late-stage tau pathology. A, Intraneuronal Aβ 
immunoreactivity is apparent from the age of 3 months in the hippocampus of 3xTg-AD mice. B, 
Hyperphosphorylated tau pathology in the cortex was apparent from 18 months of age. C, No changes in Aβ 
levels in 3xTG-AD mice at 12 months of age. D, ApoE expression was also not tchanged in the 3xTg-AD mice. D, 
An increase in tau levels is detected already at 3 months of age in 3xTg-AD mice compared to wildtype controls. 
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Identification of age-related changes in protein composition in 3xTg-AD AD mouse 
model 
In order to identify age-dependent changes in the molecular composition of the 
hippocampal synapses in the 3xTg-AD model we performed 8-plex iTRAQ proteomics 
of hippocampal synaptosomes isolated from 3xTg-AD mice and their wildtype 
littermates at 1.5 months, 3 months, 6 months and 12 months of age. We choose these 
time points in order to be able to distinguish early synaptic changes (1.5 and 3 months) 
from late synaptic changes (6 and 12 months). Each 8-plex iTRAQ was set up as 
illustrated in Figure 4.2A. We used 6 independent sets of mice per age per genotype in 
order to adequately replicate our findings. We identified a total of 490 proteins (Figure 
4.2B) (Supplemental Table S4.1). SAM analysis indicated that the levels that the levels 
of 211 proteins were significantly different (FDR <10, log-fold change >0.125) between 
AD mice and wildtype controls at one or more time points (Figure 4.2B). Of these, most 
significant differentially expressed proteins were detected at 3 months (198 proteins) 
compared to the other ages (Figure 4.2C). In addition, few proteins were differentially 
expressed at 1.5 months (17 proteins) and 6 months (46 proteins) of age, and no 
proteins were differentially expressed at 12 months of age (Figure 4.2C). 
 
 
 
FIGURE 4.2. Identification of age-related changes in protein composition in the 3xTg-AD mouse model. A, 
Schematic representation of the 8-plex iTRAQ approach. B, Proteomics analysis identified a total of 492 proteins. 
SAM analysis indicated that the levels of 212 proteins were significantly different (FDR < 10, log-fold change 
>0.125) between AD mice and wildtype controls at one or more time points. C, Most proteins were significantly 
regulated at 3 months of age. 
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Functional overrepresentation of significantly regulated proteins 
Next, we performed functional classification analysis based on GO annotation using 
DAVID. This method uses grouping of functional annotations based on their functional 
similarity, and this allows an enhanced biological interpretation of large datasets. We 
determined significant enrichment in two groups, i.e. proteins that with significantly 
increased levels (‘upregulated’) at 3 or 6 months of age, and proteins with significantly 
lower levels (‘downregulated’) at 3 or 6 months of age. Significant functional enrichment 
in the upregulated group was observed for mitochondrial proteins, glutamate receptors 
and extracellular matrix (ECM) proteins (Figure 4.3A). In the downregulated group we 
observed significant enrichment for proteins involved in cell metabolism, protein 
synthesis/folding/breakdown, and for several V-type ATPases (Figure 4.3B). Only the 
enrichment of mitochondrial proteins was persistent also at the 6 months time point; all 
other enriched proteins were only up- or downregulated at the 3 months time point. 
 
Mitochondrial proteins 
The most significant enrichment was observed for upregulated proteins involved in 
mitochondrial function. Upregulated proteins included complex I proteins (NADH 
dehydrogenases), complex II proteins (succinate dehydrogenases), complex III 
proteins (cytochrome C reductases), complex IV proteins (cytochrome C oxidases), and 
complex V proteins, (F-type ATPases). In addition, many mitochondrial carrier proteins, 
belonging to the solute carrier family 25 (Slc25) were found to be upregulated in 3xTg- 
AD mice. All mitochondrial proteins showed upregulation at both 3 and 6 months of age 
(Figure 4.3A). In contrast, some complex V proteins, i.e., the V-type proton ATPases, 
showed a significant downregulation in 3xTg-AD mice compared to wildtype controls, in 
particular at 3 months of age (Figure 4.3B). V-type ATPases are involved in 
mitochondrial respiration, but they are also important for the generation of proton 
gradients in synaptic vesicles. Upregulation of the Na,K-ATPase Atp1b2 and 
downregulation of of the V-type ATPase Atp6v1c1 were confirmed by immunoblotting 
(Figure 4.4C). 
 
Glutamate receptors 
3xTg-AD also showed a significant upregulation of several glutamate receptor subunits. 
In particular, AMPA receptor subunit Gria1, NMDA receptor subunits Grin1 and Grin2a, 
and the metabotropic glutamate receptor Grm3 were all upregulated at 3 months of age  
(Figure 4.3A). The upregulation of Gria1, Grin2a and Grm3 was confirmed by 
immunoblotting (Figure 4.4A).  
 
The extracellular matrix 
ECM proteins that were significantly enriched in the upregulated protein group included 
versican (Vcan), neurocan (Ncan), hyaluronan and proteoglycan link protein 1 (Hapln1), 
and brevican (Bcan) (Figure 4.3A). The expression profiles of these proteins were 
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similar to those described for APP-PS1 double transgenic mice (see Chapter 3), 
although less pronounced. Compared to wildtype littermates, ECM proteins showed the 
highest upregulation at 3 months of age. Immunoblotting confirmed the upregulation of 
Bcan and Hapln1 (Figure 4.4B). 
 
 
FIGURE 4.3. Functional overrepresentation of significantly regulated proteins. For functional protein group 
analysis, we used the Functional Classification Tool in the Database for Annotation, Visualization and Integrated 
Discovery (DAVID; http://david.abcc.ncifcrf.gov/) 
184,185
 to group proteins based on functional similarity and to 
determine enrichment of functional protein groups within the total set of differentially expressed proteins. 
Enrichment was determined using the total set of all detected proteins as the background set, and using the 
following settings: Similarity Term Overlap: 4; Similarity Threshold: 0.35; Initial Group Membership: 4; Final Group 
Membership: 4; Multiple Linkage Threshold: 0.50. A, Proteins were assigned to one of 17 functional synaptic 
protein groups as previously defined 
182,183
. B, Overrepresentation of regulated proteins within functional groups 
was determined by calculating the difference between proportions and the ratio of proportions. 
Overrepresentation was only considered relevant when overrepresented functional groups contained at least 3 
proteins, and when the ratio of proportions was ≥1.1. C, Expression patterns of overrepresented groups cell 
metabolism, ion balance, neurotransmitter metabolism, intracellular signaling, LGIC signaling and mitochondria. 
Red indicates proteins that are upregulated, blue indicates proteins that are downregulated. 
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Cell metabolism and protein synthesis 
Downregulated proteins were most significantly enriched for proteins involved in cell 
metabolism and protein synthesis (Figure 4.3B). Metabolic proteins were all involved in 
glycolysis and ATP production, indicating a disturbed energy metabolism in 3xTg-AD 
mice. The protein synthesis group included many chaperones and heat-shock proteins. 
 
Comparative analysis of synaptic proteome changes in APP-PS1 and 3xTg-AD mice 
We next determined the overlap of significantly regulated proteins in the APP-PS1 
mouse model (Chapter 3) and 3xTg-AD mouse model. We selected and compared all 
proteins that were significantly upregulated at any time point, and all proteins that were 
significantly downregulated at any time point. Only 11 proteins were significantly 
upregulated in both models (Figure 4.5A), and 25 proteins were significantly 
downregulated in both models (Figure 4.5B). There were more significantly regulated 
proteins that were specific to either model. In particular, 81 proteins were significantly  
FIGURE 4.4. Validation of iTRAQ results by quantitative immunoblotting. A, For proteins in the functional group 
glutamate receptors, we confirmed the upregulation of GluR1, Grm3, and Grin2a. B, Of proteins in the functional 
group extracellular matrix, we confirmed the upregulation Bcan and Hapln1. C, Of proteins in the functional 
group mitochondria, we confirmed the regulation of Atp1b2 and Atp6v1c1* FDR <10 (iTRAQ) or p <0.05 
(immunoblot). 
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FIGURE 4.5. Comparative analysis of synaptic proteome changes in APP-PS1 and 3xTg-AD mice. A, Venn 
diagram of significantly upregulated proteins in APP-PS1 and 3xTg-AD mice. Proteins depicted in square box 
represent overlay proteins. B, Venn diagram of significantly downregulated proteins in APP-PS1 and 3xTg-AD 
mice. Proteins depicted in square box represent overlay proteins. C, Functional enrichment analysis of 12 
proteins that were significantly upregulated in both mouse models, and of 25 proteins that were significantly 
downregulated in both mouse models. Overrepresentation analysis was performed using GO terms and KEGG 
pathways in DAVID. 
 
upregulated in 3xTG-AD mice only, suggesting extensive tau-dependent synaptic 
alterations in these mice. Up- and downregulated proteins were separately tested for 
overrepresentation by performing a GO term and KEGG pathway functional enrichment 
analysis (Figure 4.5C). Proteins that were upregulated in both models were primarily 
enriched for ECM components (Bcan, Ncan, and Hapln1). In addition, the temporal 
expression patterns of these proteins in APP-PS1 and in 3xTg-AD mice were highly 
correlated (Bcan, R=0.74; Ncan, R=0.98; and Hapln1, R=0.96). Downregulated proteins 
were primarily involved in catabolic and metabolic proteins and in glycolosis (Ldha, 
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Ldhb, and Eno1). Again, the temporal expression profiles of these proteins were highly 
correlated (Ldha R=0.77; Ldhb R=0.78; Eno1 R=0.97). Proteins that were exclusively 
upregulated in APP-PS1 mice were enriched for G-protein coupled receptors, and 
downregulated proteins in APP-PS1 mice are involved in exocytosis (data not shown). 
Proteins that were exclusively upregulated in 3xTg-AD mice were enriched for 
mitochondrial proteins, and downregulated proteins in 3xTG-AD mice are involved in 
intracellular signal transduction (data not shown). 
 
DISCUSSION 
3xTg-AD mice as a model for Alzheimer’s disease or tauopathies 
AD is typically characterized by two distinct neuropathological lesions: diffuse and 
neuritic plaques, mainly composed of Aβ, and neurofibrillary tangles composed of 
aggregates of hyperphosphorylated tau protein 
101
, respectively. The role of these 
lesions in the pathology of AD is still under debate, and it is believed that not plaques, 
but neurofibrillary tangles are the closest correlate of cognitive decline in AD patients 
103,268,269
. Normal aged individuals often have as much Aβ plaque burden in the brain as 
typical AD patients, but lack neurfibrillary tangles surrounding these plaques 
251,268-271
. 
On the other hand, neurofibrillary degeneration in the absence of plaques is seen in 
several tauopathies, which are all characterized by dementia 
210,211,250
, but do not 
classify as AD. To study the possible role of tau pathology in AD we made use of 3xTg-
AD model, which expresses the human APP
SWE
 gene, a PS1
M146V
 knockin, and in 
addition the human tau gene harboring the P30IL mutation 
138
. Hyperphosphorylated tau 
pathology in the hippocampus was only apparent at very old age, from 18 months of 
age. However, we could detect increased tau levels in synaptosome fractions at already 
3 months of age in 3xTg-AD mice using immunoblotting. This indicates that tau possibly 
accumulates within synapses already before any tangle pathology occurs in the 3xTg-
AD mice. This accumulation of tau in synapses could be caused by changes in the 
phosphorylation state of tau, which disrupts tau-microtubule interactions and might free 
tau to diffuse into spines 
272,273
. In addition, it has been reported that tau-induced 
degeneration results in the accumulation of filamentous (F) actin, leading to direct 
interactions between the two proteins 
274
 and providing another potential mechanism for 
hyperphosphorylated tau to accumulate in dendritic spines. Alternatively, studies have 
found that dynamic microtubules can invade dendritic spines to influence spine 
plasticity 
275-277
. These invading microtubules could potentially translocate tau into 
spines. 
Tau pathology in the 3xTg-AD model is due to the introduction of a tau 
mutation that is normally only associated with FTLD, which raises the question whether 
the pathological and clinical phenotype observed in these animals is really 
representative of AD. In contrast with earlier studies 
138,267
, we did not find any Aβ 
deposits at any age in these animals, nor could we detect increased Aβ levels using 
immunoblotting of synaptosome fractions of 3xTg-AD mice, which was one of the most 
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prominent molecular alterations in APP-PS1 double transgenic mice (see Chapter 3). 
Interestingly, a recent study by Winton et al. 2011 
278
 confirmed that intraneuronal Aβ 
immunoreactivity in 3xTg-AD mice does not reflect the presence of cleaved Aβ 
peptides, but rather Aβ sequences within APP, which is in line with our findings. 
Moreover, these authors also showed that the 3xTg-AD mice exhibit severe impairments 
in axonal transport 
279,280
, and they suggest that the accumulation of intraneuronal APP 
may represent an organelle transport defect caused by the FTDP-17 tau mutation 
278
. 
The absence of Aβ pathology in 3xTg-AD mice questions the suitability of this model for 
AD research. It might well be argued that the observed tau pathology at later ages, in 
combination with the early increase in synaptic tau levels, makes these mice a better 
model to study cognitive deficits in other tauopathies. Comparative analysis of synaptic 
proteome changes in 3xTG-AD and APP-PS1 mice might help resolving this issue. 
 
Tau-induced synaptic deficits in 3xTg-AD mice 
Quantitative proteomics of hippocampal synapses of 3xTg-AD mice and wildtype 
littermates revealed that most changes in synaptic proteins levels occur at 3 and 6 
months of age. Increased levels of tau were detected from 3 months of age in 
synaptosome preparations of 3xTg-AD mice, which might indicate that the toxic effects 
of tau accumulation in synapses could contribute to the early synaptic molecular 
alterations observed. Changes in hippocampal synaptic plasticity in 3xTg-AD mice was 
only observed from 6 months of age 
138
. Changes in synaptic protein levels at 3 months 
of age thus precede any significant physiological deficits, and may therefore reflect tau-
dependent early causative mechanisms in age-related cognitive decline. Identification 
of these early synaptic deficits that are associated with tau-mediated pathologies and 
precede significant neurodegeneration is critical for understanding pathophysiological 
mechanisms. We observed a strong enrichment of high levels of mitochondrial proteins 
in our dataset. Increasing evidence highlights a connection between AD and other 
taupoathies on one hand, and mitochondrial dysfunction together with a dysregulation 
of energy metabolism and oxidative stress on the other hand 
78,79,281-283
. Alterations of 
mitochondrial efficiency and function are mostly related to changes in concentration 
and efficiency of the respiratory chain complexes. Most studies until now suggested a 
downregulation of mitochondrial proteins in AD 
284-286
. However, we found increased 
levels of mitochondrial proteins, which could indicate compensatory mechanisms in 
response to mild mitochondrial impairment. The upregulation of mitochondrial proteins 
is possibly due to the absence of Aβ pathology. Recent studies have shown that 
structural changes caused by Aβ result in increased mitochondrial fragmentation, 
mitochondrial dysfunction and synaptic damage 
284
. In contrast to most mitochondrial 
proteins, mitochondrial complex V V-type proton ATPases, which are also important for 
the generation of synaptic vesicle proton gradients, showed a significant 
downregulation in 3xTg-AD mice. This might indicate an impairment of presynaptic 
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vesicle transmitter filling, providing a link between tau accumulation in synapses to early 
synaptic dysfunction (see also below).  
 Interestingly we observed an early upregulation, already at 3 months of age, of 
several ECM proteins in 3xTg-AD mice compared to wildtype controls. This early 
upregulation was previously described in normal aging mice (Chapter 2), and in the 
APP-PS1 model (Chapter 3), suggesting an important role for the ECM during aging 
and age-related disorders in general. The developmental pattern of ECM formation in 
cortical areas corresponds with the ending of the critical periods in which 
synaptogenesis and synaptic refinement 
191
, myelination 
192,193
 and the maturation of the 
nervous system 
194-196
 occur, and is thought to limit developmental plasticity in various 
cortical areas 
194,197,198
. Importantly, ECM proteins were also found to be associated with 
synapses and regulate synaptic plasticity. Activity-dependent release of proteases 
causes a local degradation of synaptic ECM structures and thereby enhances AMPA 
receptor mobility and synaptic plasticity 
203
. Moreover, ECM-derived protein fragments 
that are thus generated bind to synaptic integrin receptors and regulate LTP in the 
hippocampus 
204-206
. In analogy, the increase in hippocampal synaptic ECM that we 
observed may therefore limit plasticity and could underlie the changes in synaptic 
plasticity seen at older ages. 
 Specific changes that were observed in the synaptic proteome of 3xTg-AD 
mice included an upregulation of glutamate receptors relative to wildtype controls at 3 
months of age. It has recently been suggested that early tau-related deficits develop as 
a result of synaptic abnormalities caused by the accumulation of hyperphosphorylated 
tau within intact dendritic spines, where it disrupts synaptic function by impairing 
glutamate receptor trafficking or synaptic anchoring 
209
. Importantly, this glutamate 
receptor trafficking deficit was not observed in mice overexpressing wildtype tau. 
Hoover et al. 2010 postulate that once tau is mislocalized to the spines, it impairs 
glutamatergic synaptic transmission by reducing the number of functional AMPA and 
NMDA receptors on the surface of the neuronal membrane through impaired anchoring 
of the glutamate receptors to the PSD complex, decreased exocytosis of receptors, or 
increased endocytosis of receptors. We find higher levels of glutamate receptors, which 
is in contrast with these findings. However, we used synaptosomal fractions containing 
both membrane bound and intrasynaptic glutamate receptors. Our findings thus 
suggest an upregulation of the total glutamate receptor pool due to the expression of 
mutant tau, but additional experiments are required to determine whether specifically 
membrane receptor levels are affected. It is possible that due to reduced postsynaptic 
targeting or anchoring, glutamate receptors accumulate in the postsynapse, causing an 
increase in total receptor levels. Together with the potential neurotransmitter vesicle 
release deficits discussed above, these findings may explain the age-related synaptic 
dysfunction observed in 3xTG-AD mice, including LTP deficits, which are apparent 
before any plaque and tangle pathology 
138
. 
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Relevance of APP-PS1 and 3xTg-AD model to Alzheimer’s disease 
Direct comparison of our 3xTG-AD data with the APP-PS1 data described in Chapter 3 
confirmed that most synaptic protein changes that we observed in 3xTG-AD mice were 
specific for this mouse model, and were not observed in APP-PS1 mice. In particular, a 
large group of 131 proteins was dysregulated in 3xTG-AD mice only. The fact that 
3xTG-AD mice lack Aβ pathology, and in addition express mutant tau, makes it very 
likely that these specific changes are due to the expression of mutant tau only. In 
particular, the downregulation of several glutamate receptor subunits may result from 
tau-dependent dendritic trafficking deficits in 3xTG-AD mice. We hypothesize that 
unique protein changes in 3xTG-AD mice reflect synaptic mechanisms that are 
important for other tauopathies, but not AD. Conversely, 53 proteins were found to be 
deregulated in APP-PS1 mice only, and may thus be associated with Aβ pathology (see 
Chapter 3). It is interesting to note that there also is a considerable overlap of 
deregulated proteins, 12 up- and 25 downregulated, which may reflect common 
mechanisms of aging. Most notably, we observed a common and age-dependent 
upregulation of ECM proteins, not only in 3xTG-AD and APP-PS1 mice, but also in 
normal aging wildtype mice (see Chapter 2). Increased levels of ECM at hippocampal 
synaptic sites are thus associated with both normal and pathological aging, and may 
represent a common mechanism of age-related synaptic dysfunction and cognitive 
decline. 
 
SUPPLEMENTAL TABLE 
SUPPLEMENTAL TABLE S4.1. List of all quantified proteins 3xTg-AD. 
Supplemental Tables are provided in the online version. 
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ABSTRACT 
Cognitive decline is one of the earliest hallmarks of both normal and pathological brain 
aging. Here we used Ercc1 mutant mice, which are impaired in multiple DNA repair 
systems and consequently show accelerated aging and progressive memory deficits, to 
identify changes in the levels of hippocampal synaptic proteins that potentially underlie 
these age-dependent deficits. Aged Ercc1 mutant mice show normal gross 
hippocampal dendritic morphology and synapse numbers, and Ercc1 mutant 
hippocampal neurons displayed normal outgrowth and synapse formation in vitro. 
However, using isobaric tag for relative and absolute quantification (iTRAQ) of 
hippocampal synaptic proteins at two different ages, postnatal days 28 and 112, we 
observed a progressive decrease in synaptic ionotropic glutamate receptor levels, and 
increased levels of G-proteins and of cell adhesion proteins. These together may cause 
long-term changes in synapse function. In addition, we observed a downregulation of 
mitochondrial proteins and concomitant upregulation of Na,K-ATPase subunits which 
might compensate for reduced mitochondrial activity. Thus, our findings show that 
under conditions of apparent intact neuronal connectivity, levels of specific synaptic 
proteins are already affected during the early stages of DNA damage-induced aging, 
which might contribute to age-dependent cognitive decline. 
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INTRODUCTION  
Impaired memory function is one of the earliest cognitive signs of both normal and 
pathological brain aging. This decline can be partly explained by early changes in 
synaptic transmission and/or plasticity, especially in brain areas related to learning and 
memory, such as the hippocampus . Neuronal and synaptic dysfunction precede age-
related synapse loss and neuronal degeneration, and occur long before, or even in the 
absence of, cell death in humans 
287
 as well as in animals 
159,160,288
. Moreover, in aged 
animals subtle changes in synaptic function appear to contribute to alterations in 
plasticity 
162
. How synaptic dysfunction disrupts neuronal network dynamics of aged 
neurons and ultimately leads to behavioral deficits and cognitive decline is still 
unknown. Molecular and functional analysis of aging synapses may therefore provide 
important clues as to how age-related cognitive decline is triggered, and how it may 
eventually be treated. 
DNA damage plays an important role in aging 
289
. Unrepaired DNA damage 
triggers a complex DNA damage response and may give rise to epigenetic changes 
82
, 
gene silencing, and specific changes in gene expression 
61,83
. In addition, persistent 
DNA injury may interfere with transcription and/or replication, triggering cell dysfunction, 
cell death or permanent cell cycle arrest. These processes are considered to be 
important causative factors in aging. This is reflected in rare inherited disorders named 
segmental progeroid syndromes, in which genome maintenance is compromised and 
many features of aging are accelerated 
85-87
. Natural aging is however highly variable in 
its onset and progression, and genetically modified mice in which DNA damage is 
induced or DNA repair is impaired are therefore attractive models to study the biology 
of aging 
290
. Here, we use Ercc1 mutant mice, which have a defective DNA repair 
mechanism and, as a consequence of unrepaired DNA damage, have a progeroid 
phenotype. Ercc1 forms a complex with the xeroderma pigmentosum group F protein 
(XPF) and acts as nuclease in the nucleotide excision repair (NER) pathway 
147
. In 
addition, it is also involved in inter-strand crosslink repair and double-strand break 
(DSB) repair 
148-152
. Ercc1 knockout (Ercc1
-/-
) mice develop a severe and accelerated, 
aging phenotype, including early cessation of growth, ataxia, and cachexia, and die 
prematurely at an age of 3-8 weeks 
153-155
. Ercc1
∆/- 
mice on the other hand have a 
knockout mutation in one allele of the Ercc1 gene and a premature stop codon in the 
other allele, resulting in a truncated Ercc1 protein, which lacks the last 7 amino acids 
154
. Therefore, Ercc1
∆/- 
mice have a milder phenotype compared to Ercc1
-/- 
mice and die 
at an age of 4-6 months. They display many signs of accelerated aging, including motor 
neuron degeneration 
156
, changes in metabolism 
157
, and age-dependent impairments in 
synaptic plasticity and learning behavior 
291
. 
Here we took advantage of the highly predictive accelerated aging pattern 
observed in Ercc1 mutant mice in order to robustly identify DNA damage-induced age-
related changes in hippocampal synaptic protein composition that may be difficult to 
detect under normal aging conditions. After having established that Ercc1 mutant mice 
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have no apparent features of affected hippocampal neuronal connectivity, including 
synapse numbers, we used direct approaches to quantitatively address the synaptic 
proteome. Specifically, we assessed biochemically enriched synaptosome fractions 
and performed proteomic analyses using an isobaric tag for relative and absolute 
quantfication (iTRAQ) followed by tandem mass spectrometry. This approach identified 
proteins whose levels are altered in 4 and 16 week-old Ercc1 mutant mice, and are 
discussed into the context of age-related cognitive decline. 
 
EXPERIMENTAL PROCEDURES 
ERCC1 mutant mice 
The generation of Ercc1
-/-
 and Ercc1
∆/-
 alleles has been previously described 
154
. 
Ercc1
Δ/–
 mice were obtained by crossing Ercc1
+/–
 with Ercc1
Δ/+ 
mice of C57Bl6J and 
FVB backgrounds, respectively, and vice versa, to yield Ercc1
Δ/–
 with an F1 
C57Bl6J/FVB hybrid background. Ercc1
-/-
 mice were obtained by crossing Ercc1
+/–
 with 
Ercc1
+/–
 mice of C57Bl6J and FVB backgrounds to yield Ercc1
-/-
 with an F1 
C57Bl6J/FVB hybrid background. Wildtype littermates were used as controls. Breeding 
was performed in accordance with the Principles of Laboratory Animal Care (NIH 
publication no. 86-23) and with the guidelines approved by the Erasmus University 
Animal Care Committee. All animal experiments were approved by the Animal Users 
Care Committee of the VU University Amsterdam (protocol MCN 08-06). 
 
Primary hippocampal cultures 
Hippocampi were dissected from E18 Ercc1
-/-
, Ercc1
∆/-
, and wildtype embryos and 
collected in Hanks balanced salts solution (HBSS; Sigma-Aldrich, St. Louis, MO), 
buffered with 7 mM HEPES (Invitrogen, Carlsbad, CA, USA). Hippocampi were 
incubated for 30 minutes in HBBS containing 0.25% trypsin (Invitrogen) at 37 °C. After 
washing, neurons were triturated using fire-polished Pasteur pipettes, counted and 
plated in Neurobasal medium supplemented with 2% B-27, 1.8% HEPES, 1% glutamax, 
1% Pen Strep (all from Invitrogen) and 0.2% 14.3 mM β-mercapto-ethanol. Cells were 
plated in 96-wells plates (Cellstar, Greiner Bio-One, Frickenhausen, Germany) that were 
previously coated with poly-D-lysine (Sigma-Aldrich) and 5% heat-inactivated horse 
serum (Invitrogen). Neurons were plated at a seeding density of 830 cells/mm
2
 and 
cultured at 37 °C/5% CO
2
 for up to 15 days. Half of the medium was replaced with fresh 
medium every week.  
 
Immunofluorescence and high-content screening 
Neurons were fixed for 12 minutes using 4% paraformaldehyde and 4% saccharose in 
PBS (pH 7.4), washed with PBS, permeabilized with 0.25% Triton X-100 in PBS for 4 
minutes and blocked for 1 h in 1% BSA in PBS. Neurons were stained with chicken anti-
MAP2 (Abcam, Cambridge, UK; 1:5,000), and anti-Synapsin I (Millipore, Billerica, MA, 
USA; 1:1,000) overnight at 4°C. Antigens were visualized using Alexa Fluor 488 and 568 
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(Invitrogen; 1:400) incubated for 2 h at room temperature. Neurite outgrowth and 
synapse formation were quantified using a Cellomics ArrayScan HCS Reader and the 
Cellomics Neuronal Profiling 3.5 bioapplication (Thermo Scientific, Pittsburgh, PA, USA). 
In these experiments, Ercc1
-/-
 (n = 6) and wildtype (n = 6) neurons were used, and per 
experiment 400-1,200 cells were analyzed and neuron counts, neurite lengths and 
synapse numbers were determined. Significance was calculated using univariate 
analyses of variance (ANOVA). 
 
Immunohistochemistry 
Mice were intracardially perfused with ice-cold paraformaldehyde (4% PFA in PBS, pH 
7.4). Brains were removed, postfixed, embedded in paraffin, and microtome-sectioned 
at 6 µm. and were stained with anti-MAP2 (Millipore; 1:2,000). As secondary antibody 
Dylight 549 (Jackson ImmunoResearch, West Grove, PA, USA; 1:400) was used. 
Confocal microscopy was performed using a Carl Zeiss LSM 510 (Zeiss, Germany) at 
40x magnification. 
 
Golgi-Cox staining 
Ercc1
∆/-
 (n = 3) and wildtype (n = 3) mice were intracardially perfused with ice-cold 
paraformaldehyde (4% in PBS, pH 7.4). Brains were removed, post-fixed and Golgi-Cox 
staining was performed using the FD Rapid GolgiStain Kit (FD NeuroTechnologies, 
Ellicott City, MD, USA). After staining, brains were microtome-sectioned at 100 µm. 
Neurons were photographed using a Carl Zeiss LSM 510 meta laser scanner at 63x 
magnification and Z-stacks were generated using Carl Zeiss LSM Image Browser 4.2 
software. Z-stacks were used in ImageJ 1.44g software (NIH, Bethesda, MD, USA) for 
synapse counting and dendrite length measurements. To keep the counting procedure 
consistent, we only counted spines of which the spine heads clearly protruded laterally 
from the dendritic shafts. Spine densities were calculated by dividing the total number 
of spines by the total dendritic length. 
 
Synaptosome isolation and sample preparation 
Hippocampi were dissected, frozen, and stored at -80 °C until protein isolation. 
Synaptosomes were isolated from hippocampi of Ercc1
Δ/–
 mice and wildtype littermates 
at two different ages, 4 weeks (P28) and 16 weeks (P112), as described previously 
177,178
 with minor modifications. Eight animals were used per genotype per time point. In 
order to obtain sufficient amounts of protein, hippocampi of two mice were pooled, 
resulting in four biological replicates per genotype per time point (n = 4 per genotype, 
per time point). In brief, pooled samples were homogenized in ice-cold 0.32 M sucrose 
buffer with 5 mM HEPES at pH 7.4 and protease inhibitor (Roche) and centrifuged at 
1000 x g for 10 min at 4 °C to remove debris. Supernatant was loaded on top of a 
discontinuous sucrose gradient consisting of 0.85 M and 1.2 M sucrose. After 
ultracentrifugation at 110,000 x g for 2 h at 4 °C, the synaptosome fraction was 
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collected at the interface of 0.85 M and 1.2 M sucrose, resuspended and pelleted by 
ultracentrifugation at 80,000 x g for 30 min at 4 °C, after which the material was 
redissolved in 5 mM HEPES. Protein concentrations were determined using a Bradford 
assay (Bio-Rad, Hercules, CA, USA). For each sample, 75 μg of protein was transferred 
to a fresh tube and dried in a SpeedVac overnight. 
 
Protein digestion and iTRAQ labeling  
Per sample, 75 μg synaptosome proteins were dissolved in 0.85% RapiGest (Waters 
Associates, Milford, MA, USA), alkylated with methyl methanethiosulfonate, and 
digested with trypsin (sequencing grade; Promega, Madison, WI, USA) as described 
178,179
. In each iTRAQ experiment, four wildtype samples were labeled respectively with 
iTRAQ reagents 113-116, and four Ercc1
Δ/–
 samples with iTRAQ reagents 117-119 and 
121. To accommodate four biological replicates in each experiment (P28 and P112), a 
total of two 8-plex iTRAQ experiments was performed (Supplemental Figure S5.2). 
  
Two-dimensional liquid chromatography (2DLC)  
The lyophilized iTRAQ labeled samples were separated in the first dimension by strong 
cation exchange column (2.1x150 mm polysulfoethyl A column, PolyLC), and the in 
second dimension on an analytical capillary reverse phase C18 column 
(150 mm x 100 m i.d. column) at 400 nL/min using the LC-Packing Ultimate system. 
The peptides were separated using a linear increase in concentration of acetonitrile 
from 4 to 28% in 75 minutes, to 36% in 7 minutes and finally to 72% in 2 minutes. The 
eluent was mixed with matrix (7 mg of re-crystallized -cyano-hydroxycinnaminic acid in 
1 ml 50% acetronitrile, 0.1% trifluoroacetic acid, 10 mM ammonium dicitrate) and 
delivered at a flow rate of 1.5 L/min and deposited onto an Applied Biosystems matrix-
assisted laser desorption ionization plated by means of a robot (Probot, Dionex) once 
every 15 sec for a total of 384 spots. 
  
MALDI-MS/MS 
Samples were analyzed on an ABI 4800 proteomics analyzer (Applied Biosystems, 
Forster City, CA). Peptide collision-induced dissociation was performed at 2 kV, the 
collision gas was air. MS/MS spectra were collected from 2500 laser shots. Peptides 
with signal-to-noise ratios over 50 at the MS mode were selected for MS/MS analysis, at 
a maximum of 30 MS/MS per spot. The precursor mass window was set to a relative 
resolution of 200. Peaklists were extracted from the instrument database using 
TS2Mascot software (MatrixScience). 
 
Protein identification 
Protein identification and quantification are described in detail in 
180
. To annotate 
spectra, Mascot (MatrixScience) searches were performed against the Swissprot 
database (release January 2009; 16,028 mouse entries) and against the larger but more 
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redundant NCBI database (release January 2009; 140,210 mouse entries) using the 
GPS Explorer software (version 3.6, Applied Biosystems). MS/MS spectra were 
searched with trypsin specificity and fixed iTRAQ modifications on lysine residues and 
N-termini of the peptides and methylthio modifications on cysteine residues. Oxidation 
on methionine residues was allowed as a variable modification. Mass tolerance was 
150 ppm for precursor ions and 0.5 Da for fragment ions, while allowing a single site of 
miscleavage. The false discovery rate (FDR) for peptides identification was calculated 
using a randomized database (P28: 0.028 and 0.025; P112: 0.027 and 0.027 for NCBI 
and SwissProt respectively). Protein redundancy in the result files was removed by 
clustering the precursor protein sequences at a threshold of 90% sequence similarity 
over 85% of the sequence length. Subsequently all peptides were matched against the 
protein clusters and only those peptides were included that mapped unique to one 
protein. Proteins were considered for quantification if at least three unique peptide had 
a confidence interval of ≥95%, and at least three peptides were identified in both 
experiments (P28 and P112; stringent selection criteria), or at least three peptides were 
identified in one experiment and at least one peptide in the other (relaxed selection 
criteria). 
 
Protein quantification and identification of differentially expressed proteins 
iTRAQ areas (m/z 113-121) were extracted from raw spectra and corrected for isotopic 
overlap using GPS explorer. Peptides with iTRAQ signature peaks of less than 1500 
were not considered for quantification. To compensate for the possible variations in the 
starting amounts of the samples, the individual peak areas of each iTRAQ signature 
peak were log transformed to yield a normal distribution, and normalized to the mean 
peak area of every sample. Protein abundances in every experiment were determined 
by taking the average normalized standardized iTRAQ peak area of all unique peptides 
annotated to a protein. Finally, the standardized protein means (four mutant and four 
wildtype in each experiment) were used to calculate the average difference between 
WT and mutant mice. To assess whether differences had occurred by chance or could 
be deemed significant, we calculated permutation-derived false discovery rates (FDR), 
using Significance Analysis of Microarrays (SAM) 
181
 as implemented in the Multi 
Experiment Viewer software (MeV, version 4.6.1) 
181,233
. SAM uses a data resampling-
based method and creates randomized data distributions in order to estimate false 
positive rates 
181
, and can be successfully applied to proteomics data 
187,234-237
. 
Conventional t-test or fold change alone do not take into account the effect of multiple 
testing, and SAM is more adaptive to different biological experiments that may have 
asymmetrical distribution of differential protein expression profiles. The SAM q-values 
reflect for each protein the number of empirically determined false-positives at the 
significance level of the respective protein. The false discovery rate (FDR) levels in our 
results thus hold information about individual proteins, and should not be interpreted as 
a global FDR. Changes in protein expression are considered to be significant when the 
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FDR is <10%. In addition, we have also provided the corresponding p-value as 
determined by Student’s t-test. 
 
Functional protein group analysis 
All quantified proteins assigned to one of 17 functional synaptic protein groups as 
previously defined 
182,183
. Up- and downregulated proteins at each time point (P28 and 
P112) were separately tested for overrepresentation of functional protein groups using a 
Fisher’s exact test. 
 
Immunoblotting 
Western blot analysis was performed on six independent synaptosome protein extracts, 
i.e., the four samples that were used in the iTRAQ experiment plus two independent 
samples derived from two animals each. Of each sample, 2.5 µg protein was mixed with 
SDS sample buffer and heated to 90 °C for 5 min. Proteins were separated on a 
Criterion
TM
 XT Precast Gel (4-12% Bis-Tris; Bio-Rad) in a Criterion
TM
 Cell Electrophoresis 
System (Bio-Rad), and electroblotted onto PVDF membrane overnight at 4 °C. After 
blocking with 5% non-fat dry milk in TBS-T (TBS plus 0.5% Tween) for 1 h, blots were 
incubated with primary antibodies, followed by an alkaline phosphatase-conjugated 
secondary antibody (Dako, Glostrup, Denmark; 1:10,000). The following antibodies 
were used: anti-PSD95 (NeuroMab, Davis, CA, USA; 1:5,000), anti-UQCRC2 (Abcam; 
1:500), anti-GAP43 (GenScript, New Jersey, NJ, USA; 1:2,000), anti-NCAM (Hybrdoma 
Bank, Iowa City, IA, USA; 1:2,000), anti-ATP1B2 (GenScript; 1:2,000), anti-CamKIIa 
(GenScript; 1:1,000) and anti-GluA1 (GenScript; 1:1,000). Blots were incubated with 
ECF substrate (GE Healthcare, Pollards Wood, UK), scanned with a FLA 5000 
instrument (Fujifilm) and analyzed with Quantity One software (Bio-Rad) using 
background correction. To correct for differences in sample input, half of the same gel 
was stained with Coomassie blue and scanned, and the densitometric values were 
used for normalization 
179,187. Significance was determined using a Student’s t-test (1-
tailed, independent samples). 
 
RESULTS 
Ercc1
-/-
 hippocampal neurons display normal outgrowth and synapse formation in 
vitroErcc1 mutant mice are normal at birth, but they soon develop a severe and 
accelerated aging phenotype. To investigate whether neurons in the central nervous 
system are normal at birth, and are not functionally impaired due to their inability to 
repair DNA during embryonic development, we isolated E18 primary hippocampal 
neurons from Ercc1
-/-
 mice, and tested whether these neurons are capable of normal 
dendrite outgrowth and synapse formation in vitro compared to wildtype neurons. 
Neurons were cultured, fixed at DIV6, DIV9, DIV12, and DIV15, and co-stained with a 
nuclear marker (Hoechst), a dendritic marker (MAP2) and a presynaptic vesicle marker 
(VAMP) (Figure 5.1A). Dendrite outgrowth and synapse formation were quantified using  
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FIGURE 5.1. Ercc1
-/-
 hippocampal neurons display normal outgrowth and synapse formation in vitro. A, E18 
primary hippocampal neurons of Ercc1
-/-
 (KO) mice and wildtype (WT) littermates were fixed at DIV6, DIV9, DIV12 
and DIV15 and co-stained with a nuclear marker (Hoechst), a dendritic marker (MAP2) and a presynaptic vesicle 
marker (VAMP). B, Total cell numbers were stable over time. Dendrite length and the number of synapses per 
dendrite increased over time, indicating maturation of the neuronal network. No differences in network 
development were observed between Ercc1
-/-
 mice and wildtype littermates. 
 
automated high-content microscopy. No significant differences in dendrite outgrowth 
and synapse formation were observed between Ercc1
-/-
 and wildtype neurons (Figure 
5.1B), indicating that neuronal network development of Ercc1
-/-
 neurons proceeds 
normally in vitro. Moreover, the number of neurons remained the same over time, 
indicating that the Ercc1
-/-
 repair defect did not cause increased cell death under 
normal conditions. These findings show that Ercc1 mutant hippocampal neurons have 
no apparent developmental impairments that might account for the age-related deficits 
observed postnatally. Interestingly, when treating these primary hippocampal cultures 
with rotenone, to chemically induce oxidative stress through inhibition of mitochondrial 
electron transport 
292
, we observed a significant reduction in synaptic densities 
compared to wildtype neurons (data not shown). This could indicate increased 
mitochondrial dysfunction and susceptibility to oxidative stress in Ercc1
-/-
 neurons. 
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FIGURE 5.2. Ercc1
∆/-
 mice have normal hippocampal synapse numbers at 16 weeks of age. A, MAP2 
immunohistochemistry on hippocampal sections revealed no differences between Ercc1
∆/-
 mice and wildtype 
control mice in the distribution or the staining intensity of the dendritic marker MAP2. B, Representative images of 
Golgi-Cox-stained sections of the hippocampal CA1 region. Spines were counted as synapses when spine 
heads were clearly visible outside the dendritic shaft region (arrowheads indicates examples valid spine 
profiles). C, Quantification of dendritic spine densities in the CA1, CA3 and dentate gyrus (DG) regions of the 
hippocampus shows no differences between Ercc1
∆/- 
mice and wildtype littermates. N-numbers represent the 
numbers of dendrites included in the spine counts. 
 
Ercc1
∆/-
 mice have normal hippocampal synapse densities at 16 weeks of age 
To determine whether synapse numbers are affected in Ercc1 mutant mice in vivo, we 
performed immunohistochemistry on hippocampal sections of Ercc1
∆/-
 and wildtype 
mice at P112. We used Ercc1
∆/-
 mice in these and in all following experiments, as they 
allow a temporal window of 16 weeks to study age-related synaptic changes, whereas 
Ercc1
-/-
 mice die at an age of 4 weeks on average. No differences were observed 
between hippocampal sections of Ercc1
∆/-
 mice and wildtype control mice in the 
distribution or in the staining intensity of the dendritic marker MAP2 (Figure 5.2A); both 
the dendritic layers and the cell body layers have a normal gross morphological 
appearance. In addition, we performed Golgi-Cox staining and quantified synapses in 
all regions of the hippocampus of Ercc1
∆/-
 mice and of wildtype controls. No differences 
were observed in the density of dendritic spines in any region of the hippocampus 
(Figure 5.2B and 5.2C). Together, these findings show that hippocampal synapse 
numbers are normal in 16 week-old Ercc1
∆/-
 mice, and are consistent with earlier reports 
showing that hippocampal morphology and cell numbers are normal in aged Ercc1
∆/-
 
mice 
291
.  
 
 
  
C
h
a
p
t
e
r
 
5
 
95 
 
 
FIGURE 5.3. Ercc1
∆/-
 mice show age-dependent changes in the proteomic composition of hippocampal synapses. 
A, Bar graphs showing the number of significantly up- (red bars) and downregulated (blue bars) proteins at P28 
and P112 (mutant relative to wildtype; FDR <10). Dark red and blue bars indicate protein numbers under 
stringent protein selection criteria; pale red and blue bars indicate protein numbers under relaxed protein 
selection criteria (see text for details). B, Using relaxed protein selection criteria, a total of 439 proteins were 
detected, which could be assigned to 17 different functional protein groups. C, Up- and downregulated proteins 
at either P28 (left panel) or P112 (right panel) were differentially enriched for several functional protein groups. 
Red and blue bars indicate the number of up- and downregulated proteins per functional group (dark red/blue, 
stringent protein selection criteria; pale red/blue, relaxed protein selection criteria). Functional protein group 
names indicated in bold are significantly enriched in the corresponding protein cluster using a Fisher’s exact test 
(see also Table 5.1). 
 
Ercc1
∆/-
 mice show age-related changes in hippocampal synapse protein composition 
After having established normal growth, synapse formation, synapse numbers and 
connectivity of hippocampal neurons, both in vitro and in vivo, we continued to 
investigate age-dependent changes in the molecular composition of the hippocampal 
synapses. Specifically, we performed 8-plex iTRAQ proteomics of hippocampal 
synaptosomes isolated from Ercc1
∆/-
 and wildtype littermates at 4 weeks (P28) and 16 
weeks (P112) of age (Supplemental Figure S5.2) in order to identify whether quantitative 
changes in the proteome of hippocampal synapses may provide an explanation for the 
age-related behavioral deficits in Ercc1
∆/-
 mice 
291
. We confirmed the isolation of 
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synaptosomes by showing enrichment of the synaptic protein marker PSD-95 
(Supplemental Figure S5.1). For each time point, four independent Ercc1
∆/-
 samples 
were compared with four independent wildtype samples. These four samples thus 
provide biological replicates, and allow us to adequately test the reproducibility of our 
findings. We identified a total of 288 proteins with at least three peptides with a 
confidence interval >95%, and which were quantifiable by at least three peptides at 
each time point (Supplemental Table S5.1). SAM analysis indicated that the levels of 
175 proteins were significantly different  from wildtype controls at one or both time 
points (FDR <10) (Figure 5.3A; Supplemental Table S5.2). Most significant differentially 
expressed proteins were detected at P112 (148 proteins), whereas much less proteins 
showed differential expression at P28 (77 proteins). Fifty proteins showed significant 
differential expression at both time points. Thus, impaired DNA repair impacts heavily 
on the quantitative composition of the hippocampal synapses. 
 
FIGURE 5.4. Validation of iTRAQ results by quantitative immunoblotting. A, For proteins that were significantly 
regulated at P28, we confirmed the upregulation of neuromodulin (Gap43), neural cell adhesion molecule 1 
(Ncam1) and Na,K-ATPase subunit beta-2 (Atp1b2), and the downregulation of calcium/calmodulin-dependent 
protein kinase II subunit alpha (Camk2a). B, For proteins that were significantly regulated at P112, we confirmed 
the upregulation of Gap43, and the downregulation of cytochrome b-c1 complex subunit 2 (Uqcrc2), AMPA-
selective glutamate receptor subunit 1 (GluA1), and Camk2a. * FDR <10 (iTRAQ) or p <0.05 (immunoblot). 
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To confirm the iTRAQ results, we next performed quantitative immunoblotting 
(n = 6 per genotype) for a representative set of significant differentially expressed 
proteins (Figure 5.4). For proteins that were significantly regulated at P28 we confirmed 
the upregulation of neuromodulin (Gap43), neural cell adhesion molecule 1 (Ncam1) 
and Na,K-ATPase subunit beta-2 (Atp1b2), and the downregulation of 
calcium/calmodulin-dependent protein kinase II subunit alpha (Camk2a) (Figure 5.4A). 
For proteins that were significantly regulated at P112 we confirmed the upregulation of 
Gap43, and the downregulation of cytochrome b-c1 complex subunit 2 (Uqcrc2), 
AMPA-selective glutamate receptor subunit 1 (GluA1), and Camk2a (Figure 5.4B). 
These findings demonstrate that there is a perfect correlation between protein 
expression as measured by iTRAQ quantitative proteomics and by quantitative 
immunoblotting. In most cases, the changes in protein levels assessed by 
immunoblotting exceed the changes observed by iTRAQ, a phenomenon that was 
previously described in several other studies 
179,235
. 
 
Functional characterization of hippocampal proteome changes in Ercc1
∆/-
 mice 
To permit a large-scale functional interpretation of the overall changes in synaptic 
protein expression in Ercc1 mutant mice, we also selected and quantified proteins 
using less stringent criteria. Instead of only including proteins with three or more 
quantifiable peptides at each time point, we now included all proteins with three or more 
quantifiable peptides at one time point, and at least one quantifiable peptide at the 
other time point. By doing so, we reduce the risk of selectively discarding proteins that 
are less abundant at one time point, resulting in fewer detectable peptides at that time 
point. Using the relaxed protein selection criteria, a 52% increase in the total number of 
identifiable proteins was observed (439 compared to 288 using stringent selection; 
Supplemental Table S5.3). SAM analysis showed that the expression levels of 216 
proteins were significantly different from wildtype controls at one or both time points 
(FDR <10) (Figure 5.3A; Table 5.1; Supplemental Table S5.4), which is 23% more than 
with stringent selection criteria. This modest increase in the number of differentially 
expressed proteins, together with the relatively strong increase in the number of 
detectable proteins, significantly increases the statistical power to detect changes in 
the overall expression of functional groups of proteins 
235
. 
We next categorized all proteins in 17 functional synaptic protein groups as 
previously defined 
182,183
 (Figure 5.3B), and used a Fisher’s exact test to determine 
which protein functions are significantly enriched within each of four protein clusters, 
i.e., proteins that are upregulated at P28, proteins that are downregulated at P28, 
proteins that are upregulated at P112, and proteins that are downregulated at P112 
(Figure 5.3C; Table 5.2). The most significant enrichment was observed for 
mitochondrial proteins in downregulated protein clusters, both at P28 and at P112, with 
protein numbers increasing from 17 at P28 to 56 at P112. In addition, three protein 
functions were significantly enriched in upregulated proteins at P28, i.e., ion balance,   
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TABLE 5.1. List of interesting proteins that are significantly regulated in hippocampal synapses of Ercc1
∆/-
 mice. 
Proteins that belong to the functional protein groups G-protein relay,  ion balance, cell adhesion, and LGIC 
signaling that are significantly regulated at one or both time points (relaxed protein selection criteria) are 
indicated, together with their levels of regulation and significance. 
ID  
Gene 
symbol 
Log-fold 
change 
P28 
KO:WT 
Log-fold 
change 
P112 
KO:WT 
SAM 
FDR % 
P28 
SAM 
FDR % 
P112 
t-test 
P28 
t-test 
P112 
        
G-protein relay 
      
GBG2_MOUSE Gng2 0.49 0.16 0.0 18.1 0.003 0.157 
GNAO_MOUSE Gnao1 0.42 0.49 0.0 0.0 0.012 0.002 
GBG7_MOUSE Gng7 0.31 0.23 2.0 8.8 0.042 0.129 
GNAZ_MOUSE Gnaz 0.27 0.18 0.0 8.8 0.003 0.077 
GNAS2_MOUSE Gnas 0.20 0.21 0.0 1.8 0.002 0.014 
GNA11_MOUSE Gna11 0.20 0.05 5.5 42.2 0.060 0.579 
GBB1_MOUSE Gnb1 0.20 0.15 5.5 6.9 0.058 0.023 
GNAI2_MOUSE Gnai2 0.10 0.32 39.2 0.0 0.267 0.014 
GNA13_MOUSE Gna13 0.14 0.22 20.4 4.5 0.182 0.049 
GNAI3_MOUSE Gnai3 0.12 0.21 13.3 2.4 0.054 0.024 
  
      Ion balance/transport 
      gi148707687 Atp2b4 0.61 0.13 0.0 22.8 0.002 0.151 
AT1B1_MOUSE Atp1b1 0.50 0.36 0.0 1.3 0.012 0.040 
CXA1_MOUSE Gja1 0.38 0.60 4.4 0.0 0.117 0.000 
NAC1_MOUSE Slc8a1 0.35 0.07 0.0 36.3 0.037 0.358 
AT1B2_MOUSE Atp1b2 0.33 0.19 1.7 25.5 0.067 0.296 
AT1A1_MOUSE Atp1a1 0.29 0.24 3.2 1.3 0.060 0.013 
S12A5_MOUSE Slc12a5 0.25 0.19 6.2 2.4 0.115 0.015 
AT1A3_MOUSE Atp1a3 0.23 0.37 5.5 1.1 0.090 0.027 
S4A10_MOUSE Slc4a10 0.21 0.06 4.1 33.8 0.045 0.168 
VPP1_MOUSE Atp6v0a1 0.16 -0.02 7.2 39.4 0.041 0.770 
  
      Cell adhesion/transsynaptic signaling 
     NCAM1_MOUSE Ncam1 0.53 0.49 0.0 0.0 0.002 0.002 
L1CAM_MOUSE L1cam 0.45 0.33 0.0 1.4 0.001 0.032 
CNTN1_MOUSE Cntn1 0.37 0.32 0.0 0.0 0.007 0.016 
GPM6A_MOUSE Gpm6a  0.37 0.21 1.9 15.5 0.061 0.202 
CD166_MOUSE Alcam 0.36 0.39 0.0 0.0 0.001 0.018 
NTRI_MOUSE Ntm 0.33 0.14 0.0 24.9 0.036 0.218 
GPM6B_MOUSE Gpm6b 0.30 0.12 2.4 29.0 0.032 0.274 
OX2G_MOUSE Cd200 0.28 0.27 0.0 1.4 0.001 0.016 
OMGP_MOUSE Omg 0.22 0.25 3.0 1.3 0.033 0.020 
TENR_MOUSE Tnr 0.22 0.22 8.1 3.0 0.128 0.039 
NFASC_MOUSE Nfasc 0.15 0.19 8.2 1.3 0.053 0.003 
IGSF8_MOUSE Igsf8 0.15 0.23 4.1 1.1 0.005 0.005 
NRX1A_MOUSE Nrxn1 0.12 -0.12 6.2 14.2 0.005 0.201 
gi148694008 Nptn 0.09 -0.15 46.9 6.5 0.455 0.055 
  
      LGIC signaling 
      GRIA2_MOUSE Gria2 0.03 -0.14 52.9 8.3 0.644 0.074 
NMDE2_MOUSE Grin2b 0.07 -0.22 46.9 1.7 0.337 0.014 
NMDZ1_MOUSE Grin1 -0.05 -0.26 37.3 0.8 0.558 0.012 
GRIA1_MOUSE Gria1 -0.08 -0.26 33.3 1.7 0.436 0.028 
NMDE1_MOUSE Grin2a 0.08 -0.27 46.9 0.0 0.419 0.000 
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cell adhesion and G-protein relay. The latter two were also significantly enriched in 
upregulated proteins at P112. Finally, we observed a significant enrichment of proteins 
involved in ligand-gated ion channel (LGIC) signaling in downregulated proteins at 
P112. In particular, subunits of AMPA- and NMDA-type glutamate receptors were 
significantly downregulated at this time point. It is noteworthy that we observed a 
concomitant downregulation of several glutamate receptor-scaffolding proteins (protein 
clustering), and of several downstream intracellular signaling proteins. Although these 
last two functional groups were not significantly enriched, they do confirm that 
glutamate receptor signaling is indeed decreased at P112, but not yet at P28. Individual 
protein members of the above mentioned functional groups (except mitochondrial 
protein) are listed in Figure 5.5, together with their levels of regulation at each time 
point. Taken together, our data show a significant and age-dependent deregulation of 
distinct synaptic protein signaling pathways during DNA damage-induced aging. 
 
 
 
TABLE 5.2. Significantly enriched functional protein classes within protein expression clusters. All quantified 
proteins were assigned to one of 17 functional synaptic protein groups. Up- and downregulated proteins at each 
time point (P28 and P112) were separately tested for overrepresentation of functional protein groups using a 
Fisher’s exact test. Numerators represent the total number of proteins detected, denominators represent the 
number of proteins belonging to the indicated functional class. 
  Functional group 
Present in all 
detected proteins 
Present in 
cluster 
Fisher's exact p-
value 
     P28 up 
    
 
Cell adhesion 439/23 68/13 0.0003 
 
G-protein relay 439/11 68/7 0.0054 
 
Ion balance 439/26 68/10 0.0184 
     P28 down 
    
 
Mitochondria 439/114 24/17 <0.0001 
     P112 up 
    
 
Cell adhesion 439/23 72/9 0.0312 
 
G-protein relay 439/11 72/8 0.0022 
     P112 down 
    
 
Mitochondria 439/114 103/56 <0.0001 
  LGIC signaling 439/6 103/5 0.0397 
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FIGURE 5.5. List of proteins that are significantly regulated in hippocampal synapses of Ercc1
∆/-
 mice. Proteins 
that belong to the functional protein groups cell adhesion (A), ion balance (B), G-protein relay (C), LGIC 
signaling (D), protein clustering (E) and intracellular signaling (F), and that are significantly regulated at one or 
both time points (relaxed protein selection criteria) are indicated, together with their levels of regulation. Red 
indicates proteins that are upregulated, blue indicates proteins that are downregulated (mutant relative to 
wildtype). 
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DISCUSSION 
Ercc1 mutant mice as a model for DNA damage induced age-related synaptic 
dysfunction 
DNA damage plays an important role in aging 
289
. Accumulation of DNA damage is 
associated with the age-dependent decline in vital functions 
4,84,89
, and defects in 
genome maintenance are associated with accelerated aging in humans 
85-87
. Thus, DNA 
is an important target of aging, and maintenance of genome integrity is a major anti-
aging mechanism. Increasing evidence suggests that accumulation of DNA damage 
and subsequent genotoxic stress are also involved in aging of the brain 
90-92
, and that 
the inability of neurons to appropriately handle DNA damage may be causative in the 
etiology of neurodegenerative disorders 
93-95,293
. As a model for accelerated brain aging 
we use Ercc1 mutant mice. Ercc1 mutant mice are indistinguishable from wildtype 
littermates at birth. However, they soon develop a severe and accelerated, aging 
phenotype 
148,153-155
, including progressive age-related neuropathological changes in 
the brain, the spinal cord, and at neuromuscular junctions 
156
. In a recent study, it was 
shown that hippocampal neurons in Ercc1
∆/-
 mice show an age-dependent increase in 
the expression of several genotoxic markers, i.e., p53 and ATF3, compared with 
wildtype littermates, while very few neurons actually experienced cell death 
291
. The 
authors conclude that between P28 and P112, neurons in the hippocampus of Ercc1
∆/-
 
mice become increasingly compromised due to genotoxic stress, but do not die. Here 
we further substantiate these findings by showing that besides being healthy, cultured 
Ercc1 mutant hippocampal neurons are capable of normal dendrite growth and 
synapse formation. Moreover, we did not observe differences in the gross dendritic 
morphology of the hippocampus or in the density of hippocampal dendritic spines 
between Ercc1
∆/-
 mice and wildtype littermates at P112. In literature, there is still 
controversy whether synapse loss actually contributes to early cognitive signs of aging 
294
. In the Ercc1 mutant mouse model, however, hippocampal synapse loss does not 
seem to be an important factor, allowing us to identify molecular changes at synapses 
that precede, or may even occur in the absence of, overt synapse loss. 
 
Robust and dynamic changes in synaptic proteome composition of Ercc1 mutant mice 
Quantitative proteomics revealed that the hippocampal synaptic proteome of Ercc1
∆/-
 
mice is very different from that of wildtype littermates. Depending on whether stringent 
or relaxed protein inclusion criteria were applied, 49-61% of all detected proteins 
showed significantly changed levels. These findings indicate that defective DNA repair 
as a result of the Ercc1 mutation has a relatively large impact on synaptic protein 
composition. 
Many changes in synaptic protein levels are age-specific, and we observed 
little overlap in significantly deregulated proteins at the two different time points that we 
investigated. Most changes in synaptic protein levels were observed at P112. This 
corresponds with the age at which Ercc1
∆/-
 mice start to show reduced hippocampal 
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long-term potentiation as well as clear deficits in spatial learning and memory 
291
. 
Changes in synaptic protein levels at P112 may thus directly underlie physiological and 
behavioral alterations that are linked to age-related cognitive decline. At P28, on the 
other hand, no alterations in hippocampal synaptic plasticity and learning behavior are 
yet apparent 
291
. Still, many synaptic proteins show significant changes in abundance at 
P28, and these changes are often specific for this early time point. It is tempting to 
speculate that these changes precede any significant physiological or behavioral 
deficits, and that they thus may reflect early causative mechanisms in age-related 
cognitive decline (see below). 
 
Early proteomic changes in Ercc1 mutant synapses: causative factors for cognitive 
decline? 
Synaptic proteins that are early affected in Ercc1 mutant mice may play a causal role in 
the cognitive impairment observed later. Overrepresentation analysis of protein clusters 
that are either up- or downregulated at P28 revealed an enrichment of four distinct 
functional protein groups. Mitochondrial proteins were significantly enriched in 
downregulated proteins at P28. Mitochondrial dysfunction and the progressive decline 
in mitochondrial gene expression are conserved features of aging 
66,67
. Moreover, age-
related or toxin-induced mitochondrial dysfunction underlies neurodegenerative 
disorders, and it has been proposed that ROS-mediated mitochondrial defects may 
accumulate during, and contribute to, disease progression 
285
. Finally, there is a causal 
and self-reinforcing link between mitochondrial dysfunction, ROS production and DNA 
damage 
295
, which may explain the lower synaptic expression of mitochondrial proteins 
in Ercc1 mutant mice. Although based on our proteomics data we cannot distinguish 
between differences in mitochondrial protein levels and overall mitochondrial 
abundance, our findings do confirm an important role for synaptic mitochondria during 
the early stages of brain aging.  
Amongst upregulated proteins at P28, we observed a significant enrichment of 
proteins associated with ion balance. In particular, we found all subunits of the Na,K-
ATPase complex to be more abundant in Ercc1 mutant mice. Na,K-ATPase is a 
membrane-embedded sodium pump that functions to maintain the asymmetric 
distribution of sodium and potassium across the plasma membrane 
220
. Sodium 
gradients form the foundation for synaptic transmission and neuronal excitation, and 
changes in the levels of Na,K-ATPases can cause long-term alterations in synaptic 
transmission 
221
. Na,K-ATPases are also the primary energy consumers in the brain, 
utilizing half of the brains ATP content. Na,K-ATPase will therefore be affected by 
decreased concentrations of ATP, caused by mitochondrial dysfunction, and the higher 
levels of Na,K-ATPases that we observed might be a compensatory mechanism to 
counteract the consequences of ATP depletion. We also found a significant enrichment 
of proteins involved in G-protein relay and in cell adhesion, both associated with 
upregulated proteins at P28. G-proteins are central relay factors between the activation 
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of plasma membrane receptors by extracellular ligands, and the cellular responses that 
these ligands induce. In a recent large-scale gene linkage study, synaptic G-proteins 
were demonstrated to be significantly associated with cognitive ability (IQ) 
182
. In 
addition, several G-protein pathways have been implicated in the pathology of 
Alzheimer’s disease 241. Thus, early deregulation of synaptic G-proteins may well be an 
important contributing factor to age-dependent cognitive decline. Cell adhesion 
molecules may serve to facilitate both the organization and adhesion of the synapse. 
Dysfunction of cell adhesion molecules can lead to abnormalities in cell migration and 
synaptic plasticity, and are found to be causal to cognitive impairments observed in for 
instance autism 
296,297
 and schizophrenia 
298,299
. Whether early deregulation of these 
molecules also underlies age-dependent cognitive decline needs to be determined. 
 
Late proteomic changes in Ercc1 mutant synapses: pathways for permanent cognitive 
dysfunction? 
Late affected synaptic proteins are more likely to be involved in the actual physiological 
changes underlying synaptic dysfunction and cognitive decline. Similar as for P28, we 
observed a significant enrichment of mitochondrial proteins amongst downregulated 
proteins at P112, and of proteins involved in G-protein relay and in cell adhesion 
amongst upregulated proteins at P112, indicating that these represent sustained 
synaptic proteome changes in Ercc1 mutant mice. A significant and age-specific 
enrichment was observed for proteins involved in LGIC signaling amongst 
downregulated proteins at P112. Interestingly, all five proteins in this functional group 
are ionotropic glutamate receptors, including the two major AMPA-type receptor 
subunits Gria1 and Gria2, which mediate fast excitatory transmission at hippocampal 
synapses, and the major NMDA-type receptor subunits Grin1, Grin2a and Grin2b, 
which mediate calcium influx required for long-term changes in synaptic strength and 
are key to hippocampal learning and memory 
300
. Interestingly, a concomitant 
downregulation of several proteins involved in protein clustering and intracellular 
signaling was observed. Although these functional protein groups were not significantly 
enriched using a Fisher’s exact test, their individual protein members all show a 
significant downregulation in Ercc1 mutant synapses at P112 specifically. 
Downregulated clustering proteins include Dlg2 (PSD-93), Dlg3 (SAP102), Dlg4 (Psd-
95), Dlgap3 and Shank3, which are postsynaptic density proteins involved in the 
scaffolding of AMPA- and NMDA-type glutamate receptors 
301
. Reduced abundance of 
these proteins in Ercc1 mutant synapses at P112 thus reflects the inability of these 
synapses to correctly organize postsynaptic glutamate receptor signaling. 
Downregulated intracellular signaling proteins include three subunits of the 
calcium/calmodulin-dependent protein kinase type II complex (Camk2a, Camk2b and 
Camk2g), both subunits of the calcium-dependent protein phosphatase calcineurin 
(Ppp3ca and Ppp3r1), and the calcium-binding protein Hpca (hippocalcin). These 
proteins all mediated calcium-dependent signaling downstream of NMDA receptors 
302
, 
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and thus reflect reduced plasticity signaling in Ercc1 mutant hippocampal 
glutamatergic synapses at P112. Importantly, Camk2 activation is regarded a master-
switch for in the induction of synaptic plasticity underlying learning and memory 
303
. 
Reduced expression of synaptic glutamate receptors and of synaptic 
glutamate receptor scaffolding and signaling components in Ercc1
∆/-
 mice at P112 may 
well explain the deficits in hippocampal synaptic plasticity and learning behavior 
observed at this age 
291
. These late changes in synaptic protein levels may however 
result from earlier changes, and establishing such causal relationships is important for 
defining molecular targets that may be used to pharmacologically treat and prevent 
cognitive decline. In this respect it is interesting to note that Na,K-ATPase deregulation, 
as we observed at P28, is causally linked with glutamate receptor surface expression 
221
. Na,K-ATPases are enriched at synapses and are co-localized and associated with 
ligand-gated ion channels such as AMPA receptors. Na,K-ATPase dysfunction induces 
a rapid reduction in AMPA receptor surface expression as well as total protein 
abundance, leading to a long-lasting depression of synaptic transmission 
221
. As such 
Na,K-ATPase and mitochondrial dysfunction may well precede, and possibly cause, the 
observed glutamatergic signaling deficits. 
 
CONCLUSIONS 
A model for synaptic dysfunction and age-related cognitive decline 
and thus reflect reduced plasticity signaling in Ercc1 mutant hippocampal 
glutamatergic synapses at P112. Importantly, Camk2 activation is regarded a master-
switch for in the induction of synaptic plasticity underlying learning and memory 
303
. 
Reduced expression of synaptic glutamate receptors and of synaptic 
glutamate receptor scaffolding and signaling components in Ercc1
∆/-
 mice at P112 may 
well explain the deficits in hippocampal synaptic plasticity and learning behavior 
observed at this age 
291
. These late changes in synaptic protein levels may however 
result from earlier changes, and establishing such causal relationships is important for 
defining molecular targets that may be used to pharmacologically treat and prevent 
cognitive decline. In this respect it is interesting to note that Na,K-ATPase deregulation, 
as we observed at P28, is causally linked with glutamate receptor surface expression 
221
. Na,K-ATPases are enriched at synapses and are co-localized and associated with 
ligand-gated ion channels such as AMPA receptors. Na,K-ATPase dysfunction induces 
a rapid reduction in AMPA receptor surface expression as well as total protein 
abundance, leading to a long-lasting depression of synaptic transmission 
221
. As such 
Na,K-ATPase and mitochondrial dysfunction may well precede, and possibly cause, the 
observed glutamatergic signaling deficits. 
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FIGURE 5.6. Synaptic proteins and cognitive decline: a hypothetical model. Based on our findings we propose the 
following model to explain DNA damage-induced aging and cognitive decline. Compromised DNA damage 
repair as in Ercc1 mutants causes mitochondrial dysfunction. This then leads to increased levels of reactive 
oxygen species (ROS), which in turn causes further DNA damage and mitochondrial dysfunction. This self-
reinforcing cycle of detrimental decline is central to normal and pathological aging 
295
. Reduced mitochondrial 
activity or abundance also results in lowered concentrations of ATP, which in turn affects Na,K-ATPase function. 
The up-regulation of Na,K-ATPases that we observed could be a compensatory mechanism to counteract the 
effect of ATP depletion. Dysfunction of Na,K-ATPases is known to induce a rapid reduction in synaptic AMPA 
receptor surface expression and AMPA receptor  protein abundance, leading to a long-lasting changes in 
synaptic function 
221
. In addition to Na,K-ATPases, we found an early upregulation of proteins associated with G-
protein relay and cell adhesion. Together, these early changes may lead to synaptic dysfunction and cognitive 
decline later in life. 
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SUPPLEMENTAL FIGURES AND TABLES 
 
SUPPLEMENTAL FIGURE S5.1. Enrichment of PSD-95 in hippocampal synaptosomes. 
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SUPPLEMENTAL FIGURE S5.2. Schematic representation of the 8-plex iTRAQ approach. 
SUPPLEMENTAL TABLE S5.1. List of all quantified proteins using stringent protein inclusion criteria. All 
quantified proteins detected with stringent protein inclusion criteria: at least three unique peptides with a 
C.I. ≥ 95% and at least three peptides in all experiments identified. 
SUPPLEMENTAL TABLE S5.2. List of significantly changed proteins using stringent protein inclusion criteria. 
All significantly changed proteins detected with stringent protein inclusion criteria: at least three unique 
peptides with a C.I. ≥ 95%, at least three peptides in all experiments identified, and significant (FDR < 
10%) at at least one time point. 
SUPPLEMENTAL TABLE S5.3. List of all quantified proteins using relaxed protein inclusion criteria. All 
quantified proteins detected with relaxed protein inclusion criteria: at least three unique peptides with a 
C.I. ≥ 95% and at least three peptides at one time point, and at least one quantifiable peptide at the other 
time point.  
SUPPLEMENTAL TABLE S5.4. List of significantly changed proteins using relaxed protein inclusion criteria. All 
significantly changed proteins detected with relaxed protein inclusion criteria: at least three unique 
peptides with a C.I. ≥ 95% and at least three peptides at one time point, and at least one quantifiable 
peptide at the other time point, and significant (FDR < 10%) at at least one time point.  
SUPPLEMENTAL TABLE S5.5. Peptide identification and iTRAQ quantification information of set 1. 
SUPPLEMENTAL TABLE S5.6. Peptide identification and iTRAQ quantification information of set 2.  
Supplemental Tables are provided in the online version. 
  
 
 
  
 
 
 
6 
General discussion 
 
 C
h
a
p
t
e
r
 
6
 
110 
 
Synaptic protein changes during normal aging, accelerated aging and Alzheimer’s 
disease: what do they tell about age-dependent cognitive decline? 
 
BACKGROUND 
Age-related cognitive decline, a common problem of aging, which manifests in multiple 
brain dysfunctions, including perceptual speed, inductive reasoning, and perhaps most 
importantly and disabling, hippocampus-dependent spatial learning and memory 
24
. 
Impairment in any or all of these functions considerably reduces the quality of life for 
aging individuals, and severely decreases their independence. A substantial fraction of 
the population over 60 years of age is affected by varying degrees of cognitive decline, 
and as the lifespan of individuals in our population increases, the prevalence of age-
related health conditions is expected to rise concomitantly. Therefore, understanding, 
preventing and treating cognitive decline will become of great importance.  
 Over the last two decades our knowledge of the molecular basis of brain 
function in health and disease has grown exponentially. Notably, recent advances in 
proteomic technologies and the implementation of these in neuroscience research, has 
provided deeper insight into the molecular components of cognitive function. In this 
thesis, I used a neuroproteomics approach to characterize brain region-specific 
changes that contribute to neuronal dysfunction and cognitive impairment with different 
conditions of aging, ranging from normal aging, to DNA damage- induced accelerated 
aging and neurodegenerative diseases, such as Alzheimer’s disease (AD). Our studies 
focused on the hippocampus, which is an important brain structure implicated in 
context-dependent learning and memory and is profoundly affected by aging. 
Moreover, we specifically studied proteomic changes in hippocampal synapses, since 
these are the subcellular compartments that are believed to contain the molecular 
components that are crucial to the execution of cognitive functions. 
 In the studies presented in this thesis, we identified many changes in the 
hippocampal synaptic proteome associated with normal aging, AD and DNA damage-
induced accelerated aging. We postulated several age-dependent molecular 
mechanisms and pathways, and we have outlined how these may contribute to different 
aspects of aging. In this general discussion I will present an overall interpretation of the 
major proteomic alterations that we observed in the four different aging models. The 
proteins and pathways identified in the different models will be discussed in the context 
of their potential involvement in cognitive decline during normal and pathological aging, 
with the aim to define the most important synaptic processes that are either common for 
aging in general or specific for pathological aging, in particular AD. 
 
HIPPOCAMPAL FUNCTION WITH AGING 
The hippocampus is the most important mediator of context-dependent learning and 
memory. The hippocampus is impaired in healthy aging subjects who experience 
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cognitive decline and even further impaired in patients who suffer from AD 
24
. Impaired 
hippocampal function, in particular memory loss, leads to reduced independence, 
mobility, and activity, and severely reduces health status and quality of life. The 
hippocampus exhibits complex anatomical and physiological changes during aging 
that might contribute to cognitive decline 
45,46,48-51,304,305
. Cellular processes that are 
dysregulated in the aging hippocampus and affect hippocampal function include 
changes in energy metabolism, oxidative stress, and intracellular trafficking of proteins 
and organelles. At the most basic level, cognitive function is a manifestation of neuronal 
activity and synaptic signaling in brain circuitry. For the hippocampus, it is known that 
synaptic dysfunction, as measured by changes in neurochemical organization, 
morphology and electrophysiology (e.g. LTP and LTD), is associated with aging and 
cognitive decline 
306-308
. These changes may be related to alterations in synapse 
morphology, decreased neurotransmitter synthesis and release, decreased receptor 
signaling, and changes in neuronal protein and gene expression 
162,309,310
. In addition, 
aging and age-related cognitive decline are associated with loss of synapses, which 
could impact on hippocampal network properties, and thereby alter plasticity at the 
network level 
53,162,311
. However, the molecular processes underlying age-dependent 
hippocampal synaptic changes are largely unknown, and a full understanding of 
hippocampal proteome dynamics with aging and concomitant age-related cognitive 
decline is important to find targets for the development of cognition-promoting therapies 
to prevent or reverse cognitive decline, especially for neurodegenerative disorders, 
such as AD. 
 
THE HIPPOCAMPAL PROTEOME 
In recent years, much progress has been made in the field of mass spectrometry-based 
proteomics. The use of neuroproteomics allowed to study the effect of aging directly at 
the protein level, and to include the effects of posttranscriptional events, such as 
translational regulation or altered protein degradation. Because it is difficult to obtain 
and analyze human (or other primate) brain material, rodent models are most commonly 
used in neuroscience research. The clear similarities between humans and rodents, at 
the molecular and cellular levels, as well as the availability of many mouse models 
modeling different human diseases, make rodents attractive objects of study in the 
neurosciences. The first neuroproteomic studies focused on the whole brain rodent 
proteome 
312
. Later, specific examination of the hippocampus provided more 
information about the molecular underpinnings of the formation and retrieval of memory 
312
. The mainly high abundant proteins identified in these studies were comparable to 
human studies and showed mainly cytosolic proteins and mitochondrial enzymes, 
which comprised about 50% of all identified proteins 
313-316
. To increase the detection of 
low abundant proteins, proteomics is often combined with subcellular fractionation, 
which allows for enrichment and thus improved detection of synaptic proteins 
317
. In this 
thesis, we showed that proteomics on hippocampal synaptosomal preparations allows 
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detection and quantification of various synaptic proteins in a wide range of 
abundancies, including subuntis of the glutamate receptors (e.g. Grin2a, Grin2b, Gria1, 
Gria2, Gria3), synaptic signaling molecules (e.g. CaMKII, protein kinase C, BASP), and 
proteins associated with the extracellular matrix (e.g. Tenascin-R, Brevican, Neurocan, 
Hyaluronan and proteoglycan link protein 1). Thus, proteomic approaches are very 
useful in neuroscience research, and the ability to quantitatively characterize the 
hippocampal synaptic proteome is a powerful tool for investigating differential protein 
expression with aging and age-related cognitive decline.  
 
THE HIPPOCAMPAL SYNAPTIC PROTEOME WITH AGING 
Several proteomic screens were conducted in the past to obtain insight into molecular 
processes of brain aging. In 2008, Yang et al. 
316
 profiled the proteome of whole mouse 
brain from animals of 4 days (neonate), 3 months (young adult), 6 months (mature 
adult), 12 months (middle age) and 15 months (senile) old. They identified, among 
others, a downregulation with age of proteins involved in the ubiquitin-proteasome 
system (e.g. vasolin-containing protein, proteasome subunits alpha-type 3 and 6, 
ubiquitin carboxyl-terminal esterase L3) and in biological transport (e.g. dynamin 1, 
ampyphysin, transferrin, calbindin 1). In addition, they found an upregulation with age of 
enzymes involved that mediate energy metabolism and oxidative stress (e.g. Ckmt1, 
TpI1). They also observed specific patterns of regulation across the lifespan, including 
biphasic patterns of proteins showing increased expression in adulthood but decreased 
expression with aging (e.g. amphiphysin, dynamin, voltage-dependent anion channel 
1). However, due to the use of whole brain tissue, many low abundant proteins were not 
detected.  
 To asses hippocampus-specific alterations with increasing age, Weinreb et al. 
2007 
173
 performed proteomic analysis on hippocampi of young (8 months) and old (27 
months) rats. Old rats showed differential expression of proteins involved in oxidative 
stress (e.g. peroxiredoxin, cytochrome c oxidase). Furthermore, the neurofilament light 
chain protein, associated with several neurodegenerative processes, was upregulated, 
and binding/chaperone proteins were increased in old versus young rats possibly 
reflecting the cytoskeletal changes during aging. Several proteins that were identified in 
this study were previously linked to hippocampus-dependent learning and memory and 
increased oxidative stress 
318-321
, suggesting a possible role for these proteins in age-
related cognitive decline due to hippocampal aging. The effects of aging on the protein 
composition of hippocampal synapses have also been described. For instance, 
VanGuilder et al. 
176
 studied the proteome of hippocampal synaptosomes of young-adult 
(3 months), adult (12 months), and aged (26 months) rats. Bioinformatics analysis of 
differentially expressed proteins with increasing age identified a significant effect of 
aging on a network of neurotransmission-regulating proteins (e.g. dynamin 1, HPCA, 
PSD95, SNAP25, syntaxin 1, synapsin 1, synapsin 2, synaptophysin, and VAMP2). 
Together, these studies suggest that many proteins, including many synaptic proteins, 
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undergo age-related alterations in expression. Proteins affected are implicated in 
synaptic vesicle endocytosis and exocytosis, postsynaptic receptor aggregation and 
activity-dependent synaptic maintenance. Altered synaptic protein expression may 
decrease stimulus-dependent neurotransmission and vesicle replenishment, and 
synaptic plasticity, all of which are necessary for learning and the formation and 
perseverance of memory.  
 All studies described above examined the effects of aging with limited 
temporal resolution, in particular lacking time points of ages of one year and above, and 
are hampered by the limited numbers of proteins that were analyzed. In this thesis, we 
provided multiple high temporal resolution studies of normal aging, as well as age-
related changes in two AD mouse models (APP-PS1 and 3xTg-AD) and an Ercc1 model 
for DNA damaged-induced accelerated aging, using state-of-the-art mass 
spectrometry-based proteomics techniques. Moreover, in all these studies we used the 
same biochemical preparation, i.e., the hippocampal synaptosome. This allowed us to 
study synaptic proteome changes in a large temporal window, and to make a direct 
comparison between these models in order to distinguish synaptic pathways involved in 
healthy aging and cognitive decline from disease-specific changes that may underlie 
pathological cognitive deficits. 
 
PATHWAYS OF THE AGING SYNAPSE 
Mitochondria 
Earlier studies have shown that mitochondrial dysfunction plays an important role in 
aging and age-related neurodegenerative diseases, such as AD 
66,67,322,323
. Alterations in 
mitochondrial efficiency and function are mostly related to changes in the concentration 
and efficiency of protein complexes in the respiratory chain. This respiratory chain is 
located in the inner mitochondrial membrane and consists of five enzyme complexes. 
Complexes II and III of the respiratory chain are almost unaffected with aging. However, 
complexes I and IV have significantly decreased enzymatic activity with increasing age 
324-327
. In addition, it is known that mitochondrial mutations (mtDNA) accumulate with age 
90-92
, and the inability of neurons to appropriately handle DNA damage may be 
causative in the etiology of neurodegenerative disorders 
93-95,293
. In line with these 
studies, all four animal models used in my thesis showed dysregulation of a substantial 
number of mitochondrial proteins. 
Overall, we observed a decrease in mitochondrial protein abundance in Ercc1 
mutant mice, whereas in all other models many mitochondrial proteins were increased 
in expression. This decrease in Ercc1 mutant mice equally involved complex I, III, IV, 
and V proteins, suggesting a general effect on synaptic mitochondrial activity and/or 
abundance. This could be a consequence of accumulated DNA damage due to the 
Ercc1 mutation, since it is well known that there is a causal and self-reinforcing link 
between mitochondrial dysfunction and DNA damage 
295
. We conclude that the 
mitochondrial alterations observed in Ercc1 mutant mice are unique for DNA damage-
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induced accelerated aging, and may not represent the typical synaptic mitochondrial 
deficits that characterize normal aging or AD. 
In normal aging mice and AD mice we observed an upregulation of many 
mitochondrial proteins. The specific patterns of regulation were not the same for the 
different mitochondrial complexes in the different mouse models, suggesting that 
specific mitochondrial functions are affected rather than total mitochondrial activity or 
abundance. In normal aging mice, complex II, III and IV proteins were the least 
affected, and the strongest increase was observed for complex I proteins. In 3xTg-AD 
mice, and to a lesser extent also in APP-PS1 mice, we observed an increase in the 
expression of mitochondrial complex III (cytochrome C reductase) and complex IV 
(cytochrome C oxidase) proteins in particular. It is known that cytochrome C reductase 
can trigger apoptosis when it is released into the cytosol 
328
, and our findings thus might 
indicate increased apoptosis in AD mice compared to normal aging mice. Cytochrome 
c oxidase dysfunction on the other hand is known to increase ROS production, reduce 
energy stores, and disturb energy metabolism 
329
, processes that are all known to play a 
role in the etiology of AD. Finally, some complex V (ATP synthase) proteins were found 
to be upregulated in 3xTG-AD mice, and to a lesser extent also in APP-PS1 mice, 
whereas others were downregulated. In particular, multiple subunits of the F-type 
ATPase complex were upregulated, whereas multiple subunits of the V-type ATPase 
complex were downregulated. These findings could indicate very specific deregulatory 
effects on mitochondria in AD mouse models. However, it should be noted that V-type 
ATPase are also important for receptor-mediated endocytosis and synaptic vesicle 
proton gradient generation, and their opposite regulation compared to most other 
mitochondrial proteins might thus also reflect specific deficits in synaptic transmission 
rather than mitochondrial dysfunction (see also below). Taken together, our findings 
seem to indicate an important role for mitochondria in the aging synapse. However, 
additional experiments are required to determine if our observations primarily reflect 
changes in mitochondrial abundance, or whether and to what extent specific 
mitochondrial alterations play a role in age-dependent synaptic dysfunction. 
 
Neurotransmitter release 
Impaired hippocampal activity is a well-characterized phenomenon of aging in humans, 
and coincides with deficits of learning and memory. Impaired synaptic plasticity (LTP 
and LTD) and deficits in synaptic transmission underlie these problems. Several 
neuroproteomic studies have shown that there is decreased expression of proteins 
involved in neurotransmitter release with increasing age 
176,239
. Many of these 
dysregulated proteins, including SNAP25, syntaxin 1, synaptophysin, synapsin 1, 
amphiphysin, and syntaxin-binding protein 1, are directly involved in exocytosis. For 
example, SNAP25, syntaxin 1, and VAMP2 interact to form the SNARE complex that is 
critical for vesicle docking and fusion. Although these proteins were not significantly 
regulated in normal aging mice in our study, they all showed an overall trend towards 
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downregulation with age, with the exception of SNAP25. Proteins involved in exocytosis 
do however show a significantly lower expression in APP-PS1 mice compared with 
wildtype controls. The downregulation of exocytosis proteins in APP-PS1 mice was 
persistent during aging, which could also indicate loss of synaptic boutons as seen 
during AD. Previous studies have shown that as many as 45% of presynaptic boutons 
were lost in AD patients when compared to cognitively normal controls. In contrast, we 
did not find a downregulation of typical postsynaptic proteins, suggesting that the 
downregulation of exocytosis proteins in APP-PS1 mice is probably not due to synapse 
loss, but probably reflects more subtle deficits in the vesicle release machinery. It 
should be noted however that we did not observe dysregulation of other synaptic 
proteins (e.g. PSD95, Piccolo, Bassoon, and various glutamate receptors) in APP-PS1 
mice, indicating that the downregulation of exocytosis proteins in these mice likely 
reflects a specific deficit in neurotransmitter release. Interestingly, exocytosis proteins 
were upregulated in Ercc1 mutant mice, indicating again that DNA damage-induce 
accelerated aging is different from normal aging or AD, and may involve compensatory 
mechanisms that easily maintained over the relatively short lifespan of these mice 
compared with the other aging models. 
 
Vesicle endocytosis 
In all aging models we observed decreased expression of proteins involved in vesicle 
recycling and endocytosis (e.g. clathrin light chain b, clathrin coat assembly protein 
AP180, clathrin heavy chain 1, ampiphysin, dynamin 1) in hippocampal synapses. The 
downregulation of these proteins is more severe in APP-PS1, 3xTG-AD and Ercc1 mice 
than in normal aging mice. These findings suggest that reduced endocytosis is a 
common phenomenon in aging that is enhanced under pathological conditions. Due to 
the combined pre- and postsynaptic nature of our biochemical preparations, i.e. 
synaptosomes, we cannot tell if presynaptic transmitter vesicle recycling or 
postsynaptic receptor recycling is affected, but both could in principle explain some 
aspects of age-related cognitive decline.  
 
Glutamate receptors 
Glutamate receptors are responsible for glutamate-mediated postsynaptic excitation of 
neurons as well as for the induction of plasticity (LTP and LTD), and thus are crucial for 
neural communication, for learning, memory formation and cognitive performance. We 
therefore expected glutamate receptors dysregulation to be one of the potential 
mechanisms underlying age-dependent cognitive decline. In all our experiments, 
iononotropic glutamate receptor subunits were readily detected, including both AMPA-
type receptor subunits (i.e. Gria1, Gria2 and Gria3), which mediate fast excitatory 
transmission at hippocampal synapses, and NMDA-type receptor subunits (i.e. Grin1, 
Grin2a and Grin2b), which mediate calcium influx required for long-term changes in 
synaptic strength and are key to hippocampal learning and memory 
300
. Interestingly, 
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glutamate receptors levels in hippocampal synaptosome preparations did not change 
during normal aging, neither were they significantly altered in APP-PS1 mice. These 
findings suggest that relative glutamate receptor content at hippocampal synapses 
does not change with age or due to AD pathogenic mechanisms as in the APP-PS1 
model. However, glutamate receptors were downregulated in Ercc1 mutant mice, and 
upregulated in 3xTG-AD mice. The downregulation observed in Ercc1 mice is possibly 
caused by an early synaptic deregulation of Na,K-ATPase that was also observed in 
this model, and which is known to induce a reduction in AMPA receptor surface 
expression 
221
. The upregulation of glutamate receptors in 3xTg-AD mice on the other 
hand may be due to tau pathology in these animals. It has recently been shown that 
synaptic abnormalities can be caused by the accumulation of hyperphosphorylated tau 
within intact dendritic spines, where it disrupts synaptic function by impairing glutamate 
receptor trafficking or synaptic anchoring 
209
. Our findings in these animal models thus 
suggest that hippocampal synaptic glutamate receptors are not general targets in 
aging or age-related disorders. They can however play very specific roles in different 
models of aging due to other upstream changes that may cause glutamate receptor 
dysregulation. 
 
G-proteins 
In a recent large-scale gene linkage study, synaptic G-proteins were demonstrated to 
be significantly associated with cognitive ability (IQ) 
182
. In addition, several G-protein 
pathways have been implicated in the pathology of AD 
241
. The α-, β- and γ-secretases, 
which are required for APP cleavage and generation of amyloid-β, are regulated by G-
protein coupled receptors, and amyloid-β can in turn directly or indirectly affect G-
protein coupled receptor function. Thus, dysregulation of synaptic G-proteins may well 
be an important contributing factor to age-dependent cognitive decline, both under 
normal and pathological conditions of aging. Most dysregulated G-proteins were 
observed in the Ercc1 model, where they showed an overall higher expression 
compared to wildtype mice. To a lesser extent G-proteins were also significantly 
upregulated in APP-PS1 mice, in particular at late age (12 months), after Aβ pathology 
has occurred. This might implicate that dysregulation of G-proteins is causally linked to 
Aβ pathology in late stages of AD. Taken together, our findings suggest that higher 
expression of G-proteins is associated with age-related disorders. 
 
Extracellular matrix 
One of the most prominent findings in our studies is the significant upregulation of 
extracellular matrix (ECM) proteins in normal aging mice, as well is in APP-PS1 and 
3xTG-AD mice relative to their wildtype controls. The ECM is a complex network of 
macromolecules including glycoproteins, polysaccharides and proteoglycans. 
Chondroitin-sulphate proteoglycans (CSPGs; e.g. aggrecan, versican, neurocan and 
brevican) and secreted glycoproteins (e.g. tenascin-C and tenascin-R) form aggregates 
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with hyaluronan and are considered to be major components of the ECM in the adult 
brain 
330-332
. During postnatal maturation of neuronal circuits, the ECM packs into net-like 
structures named perineuronal nets around a subclass of neurons. In addition, ECM 
components are associated with synaptic complexes and were identified as important 
contributors to synaptic function 
199-201
. ECM-derived cell surface structures were found 
to restrict the lateral diffusion of extrasynaptic AMPA receptors 
202,203
, and local activity-
dependent degradation of the ECM results in the production of ECM ligands that via 
synaptic integrin receptors affect LTP in the hippocampus 
204-206
. Several studies have 
demonstrated a role for the ECM in developmental plasticity in the visual cortex 
194,333
, 
and hippocampus-dependent learning 
334
 and fear conditioning 
198
, demonstrating the 
importance of the ECM in various forms of plasticity. 
 We observed a robust and age-dependent upregulation of several ECM 
proteins, including brevican, neurocan and hyaluronan and proteoglycan link protein 1, 
in hippocampal synaptosome fractions of wildtype mice. Moreover, these same 
proteins, and also tenascin-R, showed significantly increased expression at 3 and 6 
months of age in APP-PS1 and 3xTG-AD mice, after which they returned to wildtype 
levels again at 12 months of age. These findings show that hippocampal synaptic ECM 
levels increase with age, and that this increase is enhanced in young AD mouse, before 
the onset of typical AD brain pathology. As mentioned before, ECM-derived cell surface 
structures restrict lateral diffusion of extrasynaptic AMPA receptors 
202,203
. Perisynaptic 
ECM affects synaptic depression during high-frequency stimulation, presumably by 
restricting the exchange of desensitized receptors for naive functional ones from 
extrasynaptic sites 
203
. Immature neurons also show a higher mobility of GluR1- and 
GluR2-containing receptors compared with mature neurons, and removal of the ECM 
restored to a large degree juvenile receptor mobility, suggesting that increased ECM 
levels account for a decrease in lateral receptor mobility and synaptic plasticity with 
age 
203
. The ECM thus represents a common target in aging and a potential source of 
early synaptic deficits and cognitive decline in normal aged individuals and in AD. 
 
FUTURE PERSPECTIVES 
The work described in this thesis provides a detailed comparison of hippocampal 
synaptic proteome changes during aging and age-related disorders. We show that 
brain aging involves dysregulation of mitochondria, oxidative stress, synaptic signaling, 
synaptic plasticity, and proteins involved in the ECM (Figure 6.1). Comparing the four 
mouse models of aging (normal aging, Alzheimer’s disease, Alzheimer’s disease with 
tau pathology and DNA damage-induced aging), we observed both common and 
model-specific synaptic alterations. It is believed that cognitive decline does not 
necessarily represent a more aged phenotype, but rather is associated with specific 
(neuropathological) changes that occur in addition to age-related adaptations. 
However, we identified two important synaptic alterations that are common to all aging 
models and may thus reflect general mechanisms of age-dependent cognitive decline. 
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Firstly, we noticed an overall downregulation of proteins involved in endocytosis and 
exocytosis in all models, and secondly, we observed an upregulation of ECM proteins in 
normal aging mice and in the two Alzheimer’s disease mouse models. Future work 
should address the possible causal relationships between these alterations and age-
dependent cognitive decline, and more importantly, whether intervention with which 
processes can rescue or prevent cognitive deficits in humans. 
 
 
 
FIGURE 6.1. Overview of all synaptic proteome changes in the different aging models. Blue indicates 
downregulated, red indicates upregulated.  
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Nederlandse samenvatting 
Nederland vergrijst. In 2011 telden we ruim 2,6 miljoen mensen boven de leeftijd van 65 
jaar, waarvan zelfs bijna 650.000 boven de leeftijd van 85 jaar. Dit aantal zal naar 
verwachting de komende jaren alleen maar blijven stijgen. Deze vergrijzing van onze 
maatschappij zorgt ervoor dat we steeds meer te maken krijgen met de ongemakken 
van veroudering. Behalve de lichamelijke beperkingen die veroudering met zich 
meebrengt is er vooral ook de mentale achteruitgang die steeds belangrijker wordt. 
Naarmate we ouder worden zijn er vaak kleine dingen die we vergeten, zoals 
bijvoorbeeld waar we de autosleutels ook al weer hadden neergelegd. Bij veel oudere 
mensen blijft het gelukkig bij deze kleine ongemakken, maar bij sommigen kan het 
vergeten ernstige vormen aannemen. Deze ernstige geheugenstoornissen noemen we 
dementie en dit wordt veroorzaakt door een verstoring van de informatieverwerking in 
de hersenen. De bekendste vorm van dementie is de ziekte van Alzheimer. Ongeveer 1 
op de 100 mensen boven de leeftijd van 70 jaar lijdt aan de ziekte van Alzheimer, en dit 
is zelfs 1 op 3 mensen boven de leeftijd van 85 jaar. Op dit moment bestaan er nog 
geen effectieve behandelmethoden en daarom is onderzoek naar de veranderingen in 
de hersenen die ten grondslag liggen aan veroudering en de verouderingsgerelateerde 
ziekten, zoals de ziekte van Alzheimer, van essentieel belang. 
 
De hersenen van de mens bestaan uit miljarden zenuwcellen, neuronen genoemd. 
Deze zenuwcellen bestaan uit een cellichaam met daaraan verschillende uitlopers die 
we dendrieten en axonen noemen. Een zenuwcel ontvangt informatie van andere 
zenuwcellen via de dendrieten, en geeft dit signaal door via het axon. De contactpunten 
tussen axonen en dendrieten noemen we synapsen. Deze bestaan uit een presynaptich 
(axonaal) en een postsynaptisch (dendritisch) gedeelte met daartussen een ruimte 
(synaptische spleet) waar door middel van signaalstoffen (neurotransmitters) signalen 
worden doorgegeven. De sterkte van de signaaldoorgifte (de hoeveelheid 
neurotransmitter die wordt afgegeven of de gevoeligheid waarmee de neurotransmitter 
wordt waargenomen) kan veranderd worden wanneer er veranderingen in de omgeving 
optreden. Dit proces noemen we synaptische plasticiteit, en is erg belangrijk voor 
bijvoorbeeld leren en geheugen. Een belangrijk hersengebied waar synaptische 
plasticiteit optreed in relatie tot leren en geheugen is de hippocampus. Veel 
verschillende eiwitten in hippocampale synapsen zijn betrokken bij signaaldoorgifte en 
synaptische plasticiteit, en wanneer de compositie van deze eiwitten verstoord raakt 
kan dit leiden tot het minder goed doorgeven van signalen en uiteindelijk tot 
verminderde plasticiteit, leerproblemen en geheugenstoornissen.  
 
Om meer inzicht te krijgen in de processen die ten grondslag liggen aan de 
veroudering van de hersenen en de daaraan gerelateerde cognitieve achteruitgang 
heb ik in mijn proefschrift de moleculaire veranderingen bestudeerd in hippocampale 
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synapsen in verschillende diermodellen voor normale veroudering en voor verschillende 
verouderingsziektes. 
 
RESULTATEN 
In hoofdstuk 2 beschrijf ik veranderingen in synapsen zoals ik die heb gevonden tijdens 
normale veroudering. Door middel van het bestuderen van processen die optreden 
tijdens veroudering kunnen eiwitten worden geïdentificeerd die een rol spelen bij 
normale leeftijdsafhankelijke cognitieve achteruitgang, en kan bovendien een goede 
achtergrond worden gedefiniëerd waartegen andere verouderingsmodellen kunnen 
worden afgezet. Op deze manier kan bekeken worden welke veranderingen altijd 
optreden en welke er alleen verstoord zijn tijdens een ziekteproces. De meest 
opvallende en significante observatie was een sterke leeftijdsafhankelijke toename in 
eiwitten die behoren tot de extracellulaire matrix (ECM). Daarnaast was er een toename 
in mitochondriale eiwitten, wat kan duiden op veranderingen in de synaptische 
energievoorzieningsprocessen. Tenslotte was er een significante toename in de 
variantie in synaptische eiwitexpressie in oudere dieren. Al deze veranderingen kunnen 
een onderliggende reden zijn van de verminderde synaptische plasticiteit en 
verslechterd cognitieve functioneren op hogere leeftijd. 
 
In hoofdstuk 3 en 4 heb ik gekeken naar veranderingen in hippocampale synapsen in 
twee verschillende Alzheimer muismodellen. Sinds de ontdekking van een aantal 
verschillende genmutaties die leiden tot zeldzame, erfelijke vormen van de ziekte van 
Alzheimer is er veel vooruitgang geboekt in het onderzoek naar het ontstaan van deze 
ziekte. Ik heb gebruik gemaakt van twee verschillende modellen die een combinatie 
van twee of drie van deze mutaties in zich hebben.  
 
In hoofdstuk 3 heb ik gebruik gemaakt van een APPswe,PS1dE9 (APP-PS1) transgeen 
muismodel voor de ziekte van Alzheimer, welke verhoogde niveaus van Aβ productie 
laat zien door de introductie van humane ziekte-gerelateerde mutaties in zowel APP als 
PS1. Hierdoor heb ik ontdekt dat dezelfde ECM eiwitten die een sterke 
leeftijdsafhankelijke toename vertoonden tijdens normale veroudering, versneld 
toenemen in APP-PS1 muizen, en dat dit gebeurd voordat deze muizen de specifieke 
Alzheimer geassocieerde pathologische veranderingen vertonen. Verder laat ik zien dat 
APP-PS1 muizen op het moment dat de ECM voor het eerst toeneemt tevens een 
verslechterd geheugen vertonen in een hippocampus-specifieke leertaak. Omdat 
bekend is dat ECM eiwitten synaptische plasticiteit reguleren is het dus mogelijk dat 
een toename ervan rond hippocampale synapsen deels verantwoordelijk is voor de 
vroege cognitieve achteruitgang die gezien wordt tijdens de ziekte van Alzheimer. 
Naast deze veranderingen in ECM eiwitten was er net als bij normale veroudering ook 
een duidelijke toename te zien in mitochondriale eiwitten. 
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In hoofdstuk 4 heb ik gebruik gemaakt van een triple-transgeen (3xTg-AD; 
APPswe,PS1M146V,tauP301L) muismodel voor de ziekte van Alzheimer. Dit model 
ontwikkeld net als het APP-PS1 muismodel Aβ plaques, maar pas op latere leeftijd. 
Daarnaast zijn er als gevolg van de tau mutatie tangles te zien die weliswaar typerend 
zijn voor de ziekte van Alzheimer, maar die in Alzheimer patiënten nooit door mutaties in 
tau worden veroorzaakt. In 3xTG-AD muizen heb ik net als in APP-PS1 dieren een 
toename van ECM eiwitten en mitochondriale eiwitten aangetroffen. De toename in ECM 
eiwitten was minder groot dan in APP-PS1 muizen, wat waarschijnlijk te maken heeft 
met de late Aβ pathologie in dit diermodel. Daarnaast heb ik veranderingen gevonden 
in de niveaus van veel andere eiwitten, zoals bijvoorbeeld de glutamaat receptoren. 
Deze veranderingen zijn mogelijk toe te schrijven aan de opstapeling van tau in de 
dendritische spines. 
 
Ten slotte heb ik in hoofdstuk 5 gebruik gemaakt van een snel verouderend muismodel. 
Tijdens ons hele leven staan we bloot aan schadelijke effecten van onze omgeving en 
producten in ons lichaam die ons DNA beschadigen. Deze beschadigingen in ons DNA 
worden normaal gesproken hersteld door DNA herstelmechanismes. Wanneer deze 
herstelmechanismes niet goed werken is er een opstapeling van DNA schade die leidt 
tot versnelde veroudering, zoals dit bijvoorbeeld te zien is in progeria patiënten. In dit 
hoofdstuk heb ik hippocampale synapsen onderzocht in een muismodel waarin een 
mutatie is aangebracht in één van de DNA herstelmechanismes. Deze zogenaamde 
Ercc1 muizen leven maximaal vier maanden, en dit gaf me de mogelijkheid om te kijken 
of versnelde veroudering van de hersenen als gevolg van DNA schade vergelijkbaar is 
met de verouderingsprocessen zoals die zich afspelen tijdens normale veroudering. 
Hoewel sommige synaptiche eiwitveranderingen in Ercc1 muizen overeen lijken te 
komen met die in de overige muismodellen, bijvoorbeeld eiwitten die betrokken zijn bij 
G eiwit-gemedieerde signaaltransductie en endocytose, zijn er ook veel groepen van 
eiwitten die geen of juist een tegengesteld regulatiepatroon vertonen. Mitochondriale 
eiwitniveaus bijvoorbeeld zijn in 16 weken oude Ercc1 muizen sterk afgenomen in 
hoeveelheid, terwijl ze in de andere muismodellen juist zijn toegenomen. Mogelijk komt 
versnelde veroudering als gevolg van DNA schade, en de daaraan gekoppelde 
cognitieve achteruitgang, deels overeen met normale verouderingsprocessen in het 
brein, maar kent het ook unieke onderliggende moleculair synaptische veranderingen.. 
 
CONCLUSIES 
Belangrijke moleculaire veranderingen die ik heb gevonden in de synaps tijdens 
veroudering zijn onder anderen veranderingen in de niveaus van mitochondriale 
eiwitten die betrokken zijn bij het handhaven van de energiehuishouding van 
zenuwcellen. Wanneer energiehuishouding vestoord is kan dit leiden tot de productie 
van schadelijke zuurstofradicalen, wat leidt tot oxidatieve stress. De bekende 
antioxidante werking van rode wijn, groene thee, groente en fruit gaat deze schadelijke 
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stoffen tegen en worden daarom vaak aangedragen als beschermers tegen de ziekte 
van Alzheimer. Daarnaast hebben we veel veranderingen gevonden in eiwitten die 
betrokken zijn bij het doorgeven van signalen van de ene zenuwcel naar de andere. Dit 
zijn vooral eiwitten die betrokken zijn bij het afgeven van neurotransmitters in de 
synaptische spleet, en bij het doorgeven van neurotransmittersignalen naar de 
volgende zenuwcel. Veranderingen in deze groepen eiwitten leiden tot minder goede 
communicatie tussen de zenuwcellen en mogelijk tot verminderde plasticiteit, en 
kunnen daardoor processen zoals leren en geheugen aandoen. 
 
De meest opvallende vindingen van dit proefschrift zijn de veranderingen tijdens 
normale veroudering en in Alzheimer muismodellen in een groep eiwitten die behoren 
tot de ECM. De ECM bestaat uit een aantal eiwitten die samen een complex vormen 
rondom synapsen. Op deze manier kunnen deze eiwitten de plasticiteit van synapsen 
beperken. Tijdens normale veroudering heb ik een toename in de niveaus van 
meerdere van deze ECM eiwitten gevonden, wat duidt op een leeftijdsafhankelijke 
afname in de plasticiteit van hippocampale synapses. Dit kan een reden zijn waarom wij 
als wij ouder worden vergeetachtiger worden. Nog belangrijker is dat ik in beide 
Alzheimer muismodellen al veel vroeger veel meer van deze eiwitten heb aangetroffen. 
Dit kan een aanwijzing zijn dat geheugenstoornissen bij de ziekte van Alzheimer, die 
veel vroeger en veel ernstiger optreden dan tijdens normale veroudering, deels 
veroorzaakt worden door dezelfde plasticiteits-remmende factoren die ook bij normale 
veroudering een rol spelen. Veranderingen in ECM eiwitten geven aanleiding om 
vervolgexperimenten te doen waarin onderzocht moet worden of het afbreken van de 
ECM, of het remmen van ECM opbouw, deze geheugenstoornissen ongedaan kunnen 
maken. In de toekomst zou dit kunnen leiden tot de ontwikkeling van nieuwe medicijnen 
die mogelijk de vroege geheugenproblemen die gepaard gaan met de ziekte van 
Alzheimer tegen zouden kunnen gaan. 
  
  
N
e
d
e
r
la
n
d
s
e
 
s
a
m
e
n
v
a
t
t
in
g
 
143 
 
 
 
 
  
  
144 
 
  
D
a
n
k
w
o
o
r
d
 
145 
 
Dankwoord 
Het is af! Een klein stukje levenswerk staat op papier… Als ik terug kijk op deze vier jaar 
heb ik, behalve heel veel geleerd, een ontzettend leuke tijd gehad. Ik had mij geen 
leukere afdeling en collega’s kunnen wensen om deze vier jaar door te brengen. 
Zonder al deze mensen was dit nooit zo’n mooi boekje geworden. 
Allereerst wil ik Guus en Ronald bedanken. 
Guus, bedankt voor al betrokkenheid al die jaren. Eerst als ‘mentor’ tijdens mijn 
zoektocht welke weg in te slaan na mijn studie, en later als promotor. Jouw 
enthousiasme en grote kennis van de neurobiolgie zijn een inspiratie. Naast het 
motiveren om nieuwe experimenten op te zetten, liet je mij ook altijd kritisch kijken naar 
welke volgende stappen te nemen. 
Ronald, ik had mij geen beter copromotor kunnen wensen. Jouw deur stond altijd open 
om even de nieuwste resultaten door te nemen, of om even snel wat te bespreken of te 
vragen. Ik heb veel bewondering voor jouw brede kennis en de manier waarop jij alles 
beredeneert en samen brengt.  
In addition, special thanks goes to my reading committee, Prof. Dr. Jan Hoeijmakers, 
Prof. Dr. Elly Hol, Prof. Dr. Antonio de Sol Mesa, Prof. Dr. Joost Verhaagen and Prof. Dr. 
Sabine Spijker. Thank you for your time and effort for reading and correcting my thesis. 
Sasja, bedankt dat jij mijn paranimf wilde zijn! We hebben elkaar tijdens onze studietijd 
bij Gyrinus leren kennen en onze tijd als “buuf & buuf” zal ik nooit vergeten! Dat jij mijn 
paranimf bent is een mooie afsluiting van onze tijd samen op de VU. 
Priyanka, there was no doubt in my mind that you should be my paranimf. You have 
made my PhD so much fun with all the craziness, creativeness and coffee walks! 
Nobody else understood our humour… Thanks for all the fun and friendship! 
My colleagues from the very first day, Little Nuts (Nutabi), PvB (Pieter), Patty (Patricia), 
Eva, Jochem, Barty (Bart) and Danny (awesomeness Danai). Thank you all for making 
going to work such a joy! Thank you for all the “science” talks, “frustration” talks, and 
Friday afternoon drinks!  
Ofcourse all my other colleagues, in particular Rolinka, Marion, Pim, Irinya, and Roel, for 
helping me with my experiments, and Yvonne, for all the nice coffee breaks. Of course 
all the others Andrea, Anya, Brigitte, Daniëlle, Harold, Jörg, Karen, Ka Wan, Leanne, 
Loek, Lody, Maarten, Mariëtte, Mark, Michel, Natasha, Nikhil, Ning, Ramesh, Remco, 
René, Riejanne, Ruud, Sabine, en Sigrid. 
 D
a
n
k
w
o
o
r
d
 
146 
 
Verder wil ik natuurlijk al mijn vrienden en (schoon)familie bedanken die allemaal op 
hun eigen manier een steentje hebben bijgedragen aan dit proefschrift. Het zijn er 
teveel om allemaal op te noemen, een aantal wil ik natuurlijk is het bijzonder bedanken: 
Eef, vriendinnetje vanaf het eerste uur. Ik ben blij dat we na al die jaren nog steeds zo’n 
hechte vriendschap hebben die in de loop der jaren is uitgebreid met Reinier, en nu 
zelfs kleine Sete erbij. Leuk dat we nu weer buren zijn! Bedankt voor je/jullie 
vriendschap door de jaren heen! 
Sabina en Nina, bedankt voor alle gezellige avondjes met z’n drieën, vooral toen ik net 
in de stad kwam wonen! Ondanks de afstand, die behalve de stadsgrenzen van 
Amsterdam nu ook de oceaan overgaat, is jullie vriendschap mij veel waard. 
Kai Mee en Suus, goede herinneringen heb ik aan onze stagetijd bij het NIN. We 
ontpopten ons tot ware labnerds. Leuk dat we daar zo’n goede vriendschap aan over 
hebben gehouden! En bedankt voor alle gezellige avondjes cocktails drinken! 
Esther, vanaf dag één op de VU zijn wij studiemaatjes. Samen naar alle colleges en 
later samen ons afstudeerfeestje. De etentjes met z’n vieren, samen met Rick en Jan, 
zijn altijd een feestje, en goed voor het luchten van onze harten over de frustraties van 
het promoveren. Bedankt hiervoor! 
Karin en Remy, ik heb jullie leren kennen als familie van Mark, maar al snel groeide dit 
uit tot een goede vriendschap! Ik vind het ontzettend leuk dat we nu zo dicht bij elkaar 
kwonen en kijk nu al uit naar al onze gezellige avondjes samen! 
De bootmensen! Wat hebben wij een leuke tijd daar met z’n allen gehad! Dit zijn téveel 
mensen om op te noemen, maar in het bijzonder Henk, Peter, Sabina, Anika, en Kevin. 
Een tijd om nooit te vergeten, bedankt! 
Fardy, wij gaan al lange tijd terug! Bedankt voor je vriendschap al die jaren! 
En dan natuurlijk de allerbelangrijkste mensen, mijn lieve ouders en zusje. Zonder jullie 
was dit nooit zo’n mooi boekje geworden. Papa en mama, jullie hebben mij altijd 
onvoorwaardelijke liefde en vertrouwen gegeven. Jullie onvoorwaardelijke steun in mijn 
(soms wat overhaastte) keuzes hebben mij gebracht waar ik nu ben. Jullie zijn mijn 
voorbeeld en ik ben bijzonder trots op jullie! Dreetje, naast mijn zusje ben je ook mijn 
beste vriendin. Een beter en liever zusje had ik mij niet kunnen wensen! Bedankt dat 
jullie er altijd voor mij zijn! 
Lieve Mark, last but not least! Dank je voor al je onvoorwaardelijk steun en liefde al die 
jaren lang. Ik kijk uit naar alle nieuwe dingen die er in ons leven staan te gebeuren. Met 
jou kan ik de hele wereld aan! Hvj ♥  
Marlene 
  
D
a
m
k
w
o
o
r
d
 
147 
 
  
148 
 
  
C
u
r
r
ic
u
lu
m
 
v
it
a
e
 
149 
 
Curriculum Vitae 
Marlene Johanna Végh werd geboren op 10 juni 1984 in Amsterdam. In 2002 behaalde 
zij haar VWO diploma aan het VeenLanden College in Mijdrecht. In datzelfde jaar 
begon zij haar studie Biomedische Wetenschappen aan de Vrije Universiteit in 
Amsterdam. Daar ontdekte zij al snel dat haar interesses in de neurowetenschappen 
lagen en daarom besloot zij de master Neuroscience aan de Vrije Universiteit te volgen. 
Tijdens deze master liep zij stages bij de afdeling Neuropsychiatric Disorders aan het 
Netherlands Institute for Neuroscience (NIN) onder de begeleiding van Prof. Dr. Dick 
Swaab, met als onderwerp: “Sexual dimorphisms of the hypothalamo pituitary adrenal 
axis in schizophrenia”.  Vervolgens schreef zij haar scriptie aan het Swammerdam 
Institute for Life Sciences (SILS) onder begeleiding van Prof. Dr. Paul Lucassen, met als 
onderwerp: “Is mom to blame? The effects of prenatal stress on hippocampal 
neurogenesis and the development of depression in later life”. Zij eindige haar studie 
met een stage bij de afdeling Moleculaire en Cellulaire Neurobiologie onder de 
begeleiding van Dr. Ronald van Kesteren, met als onderwerp: “Subcellular localization 
and function of Progranulin in human neurons“. Na het afronden van haar studie begon 
zij in februari 2008 aan haar promotieonderzoek onder de begeleiding van Prof. Dr. 
Guus Smit en Dr. Ronald van Kesteren. Hier deed zij onderzoek naar de cellulaire en 
moleculaire mechanismen onderliggende aan veroudering en het daarbij behorende 
cognitieve dysfunctioneren, door middel van het bestuderen van het synaptisch 
proteome van verschillende verouderingsmodellen. De resultaten van dit onderzoek zijn 
beschreven in dit proefschrift. Tijdens haar promotieonderzoek volgde zij ook vele 
cursussen buiten de muren van de universiteit, waaronder cursussen bij TIPharma en 
Financial Management for Non-financials aan Nyenrode. Hier ontdekte zij haar passie 
om de wetenschap en het bedrijsleven samen te brengen. Daarom is zij momenteel 
werkzaam als consultant bij een subsidieadviesbureau. 
 

